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Preface
Some chapters of this thesis have been published before. At the beginning of
such chapters, it is indicated which experiments were done by the author of this
thesis, which persons contributed to the publication, and in which journal the
work has been published.
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1. Introduction I: Tumour vs. normal
tissue – Differences at various levels
In Germany each year about 400,000 new cancers are diagnosed and about half as
many casualties are caused, making cancer Germany’s second frequent cause of
death. Tumourigenesis summarizes changes ranging from metabolic alterations
within cells to physiologic changes in tissues or organs. These changes can pro-
mote tumour growth on the one hand but are principally also recognizable by
the immune system and thus may provide a basis for the eradication of the
tumour. The notion that the immune system could protect the body from neo-
plastic growth dates back to Paul Ehrlich [1] and was revived decades later as
the ‘cancer immunosurveillance hypothesis’ [2, 3], which was at that time still
heavily debated. Today it is well accepted that there are in fact substantial in-
teractions between the immune system and tumour cells [4, 5] and that immune
cells can have an active role controlling the malignancy [6, 7]. However, the
amount of newly diagnosed tumours each year shows that in many cases tumours
obviously find ways to escape the immune system and its surveillance due to their
alterations in metabolism and physiology.
1.1. Differences from a physiological point of
view
After the initial events of carcinogenesis, neoplastic growth is limited to a very
restricted area if local physiological changes like angiogenesis can not be achieved.
Moreover, neoplastic growth is frequently accompanied by local changes of the
surrounding tissue resulting in the establishment of a complex tumour microen-
vironment.
1.1.1. Hypoxia and angiogenesis
Tumour tissues need their own supply with oxygen and nutrients for a growth
beyond 1 mm3 [8]. An insufficient oxygen supply can induce the expression of
several angiogenic key molecules in tumour tissues. For example, the expres-
sion of the vascular endothelial growth factor (VEGF), a key regulator for neo-
vascularization has been described as mediated by the expression of the hypoxia
inducible factor 1 (HIF-1) in various tumour entities such as renal cell carcinoma
(RCC) [9, 10]. However, even vascularized tumour areas differ distinctly in their
1
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blood vessel pattern from normal vasculature. Normal vasculature is organized
in a hierarchical manner, ensuring adequate nutrition and oxygen supply for all
cells. In contrast to that, tumour vessels are chaotic, dilated, torturous, and often
have a sluggish blood flow (reviewed in [11]). Thus, even the induction of angio-
genesis in tumours does not prevent the presence of certain hypoxic and necrotic
regions within the tumour. This was shown in several studies where a very het-
erogeneous O2 distribution in tumours with many regions under a constant pO2
insufficiency were detected (Table 1.1).
Table 1.1.: The partial oxygen pressure (pO2) was measured in mmHg using an ‘Eppen-
dorf’ electrode. pO2 values are given as median; values in brackets represent
the number of patients analysed. This table has been adapted from [12].
Tumour type pO2 tumour pO2 normal References
Head and neck cancer 14.6(65) 51.2(65) [13]
Lung cancer 7.5(17) 38.5(17) [12]
Pancreatic cancer 2.7(7) 51.6(7) [14]
Cervical cancer 5.0(8) 51.0(8) [15]
Prostate cancer 2.4(59) 30.0(59) [16]
Although hypoxia is generally an undesired state for the tumour, these areas
bear a source for tumour cells with increased malignant potential. Hypoxic cells
are not only hard to reach for oxygen but also for some chemotherapeutic agents
[17]. Areas lacking sufficient oxygen supply show an increased level of gene ex-
pression regarding angiogenesis [9]. Furthermore hypoxia selects for cells which
have lost sensitivity to p53 induced apoptosis and have an increased mutation rate
[18]. Additionally, hypoxic states induce genes as P-glycoprotein, a transmem-
brane transporter mediating multi drug resistance [19]. Summarizing, hypoxia in
tumours selects for cells with an increased malignant potential, including elevated
mutation levels and increased metastatic potential [16, 20].
1.1.2. Tumour microenvironment and inflammation
Dvorak suggested the methapher ‘tumours are wounds that do not heal’ to de-
scribe the state in which an established tumour exists [21]. This state of inflam-
mation is triggered by the constant disruption of homeostasis by proliferating
tumour cells. Furthermore, stromal elements can also undergo alterations, pro-
moting the inflammatory response and enhancing tumour growth e.g. by neovas-
cularisation [22]. In the attempt to re-establish homeostasis, inflammatory cells
as mast cells, granulocytes and macrophages are attracted (reviewed in [23] and
[24]). However, in some cases – namely these cases, where a tumour manages
to become established – these immune cells react in a way which promotes the
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tumour cell survival and replication: For example, VEGF can be released in a
neutrophil-dependent manner [25]. It has been shown that high levels of sev-
eral cytokines and chemokines as VEGF, TGF-β, IL-6 and IL-10 enhance the
immunosuppressive features of the tumour microenvironment [26]. In such an
cytokine milieu, dendritic cells (DCs) tend to mature into a immunosuppressive
phenotype expressing IDO [27] and co-inhibitory molecules such as B7-H1 [28].
These DCs induce arrest of the T cell cycle as well as T cell apoptosis and thus
favor immune tolerance of the tumour. This tolerance is furthermore enhanced
by the attraction of regulatory T cells to the tumour microenvironment respec-
tively the differentiation of T cells into a regulatory phenotype within the tumour
microenvironment [29].
1.2. Differences by losing key gene transcripts
and proteins
Neoplastic changes transforming benign cells into malignant tumor cells are caused
by alterations either in gene expression and/or protein levels. These changes can
range from the loss of protein function regarding several key molecules to the ad-
ditional expression of genes and proteins in the tumour – which will be discussed
in section 1.3.2.
1.2.1. Inactivation of tumour suppressor genes
One of the most prominent examples of a tumour suppressor gene is p53, a major
player involved in the regulation of cell cycle. A mutation of p53 occurs in about
50% of all human tumours [30]. The hotspot mutations (248R and 273R) in
human p53 fail to bind the DNA consensus sequence, and thus lead to the loss
of tumour suppressing activity of p53 [31].
An other example of a tumour suppressor, frequently mutated in tumours
– especially in renal cell carcinoma – is the von Hippel-Lindau gene product
(pVHL). pVHL is part of a ubiquitin ligase complex, targeting the hypoxia-
inducible factor (HIF) for ubiquitinylation, provided oxygen is available [32].
Inactivation of pVHL leads to excessive VEGF production [33] due to constitutive
HIF-1 [34] and HIF-2 [35] activation.
1.2.2. TAP deletion
The transporter associated with antigen processing 1 and 2 (TAP1/2) is crucial
for efficient transport of peptides from the cytosol into the ER where peptides are
bound to major histocompatibility complex I (MHC-I) molecules. Peptide-MHC
complexes are transported to the cell surface and make the cell subsequently
available for immune surveillance by T cells. Thus, tumours with a reduced TAP
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functionality show a decreased MHC surface expression and therefore have an
alleviated T cell mediated immune pressure. Mutations have frequently been
reported in various tumour types, e.g. in more than 50% of cervical carcinoma
[36]. TAP mutations can have various effects on several levels ranging from altered
TAP-mRNA stability [37] to functional changes in peptide transport [38].
Furthermore several viruses with oncogenic potential are known to reduce ei-
ther TAP mRNA levels (Adenovirus 12, [39]) or inhibit its peptide transporting
function (US6, HCMV, [40]).
1.3. Differences as observable by the adaptive
immune system
The immune system is potentially able to recognize every intracellular change
leading to altered mRNA translation products and/or proteins, provided the al-
teration can be processed and presented on MHC molecules. Defective ribosomal
products (DRiPs) [41] and/or proteins are degraded within the cell by proteases
such as the proteasome [42]. Thus generated peptides are transported into the
ER via TAP [43] and subsequently loaded on MHC-I. MHC-peptide complexes
are transported from the ER onto the cell surface and are there accessible for T
lymphocytes.
1.3.1. Antigen recognition by T lymphocytes
T lymphocytes mediate adaptive cellular immunity via their αβ T cell receptor
(TCR), which is present on the majority of T cells, and which recognizes MHC-
peptide complexes [44]. T cells expressing the co-receptor CD8 (CD8+ T cells)
recognize MHC-I molecules with bound 8-12mer peptides, derived mainly from
intracellular source proteins. CD4 expressing T cells (CD4+ T cells) recognize
9-25mer peptides in the context of MHC-II molecules. Under normal conditions,
MHC-II molecules are exclusively expressed on immune cells and the MHC-II
bound peptides are mainly derived from extracellular sources [45].
In order to be able to respond properly to non- or altered-self peptides, pre-
sented on MHC-I molecules, CD8+ cytotoxic T lymphocytes (CTLs) have to
be activated by dendritic cells. DCs are professional antigen presenting cells,
which are most effective in priming CTL responses [46]. After differentiation
and activation, CTLs recognizing a specific epitope are able to migrate into the
periphery to exert their effector function, e.g. migration into tumour tissue and
eliciting an anti-tumour response. This response can for example be apoptosis
of the target cell either via the Fas pathway and/or by perforin and granzyme
[47]. Furthermore, activated CTLs can produce cytokines like interferon gamma
(IFN-γ) which can inhibit tumour angiogenesis and proliferation [48].
4
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1.3.2. Tumour antigens
For several different types of tumours it has been observed that even established
tumours can be overcome by the body’s own immune system [49]. The principle
that tumours can be controlled by the immune system is the basis for cancer
immunotherapy. For any cancer immunotherapeutic approach it is crucial to
identify target structures, so called tumour antigens, which have to be as specific
as possible for the tumour tissue. Tumour antigens in general are proteins that are
produced by the tumour itself and are exclusively expressed in the tumour tissue.
Hitherto known tumour antigens can be divided into five sub-classes: cancer-
testis antigens, tumour specific antigens, tumour-virus antigens, differentiation
antigens, and overexpressed antigens [50]. Yet, hitherto only about 100 tumour
epitopes are known [51].
Table 1.2.: Selection of tumour antigens and their T cell epitopes. CDK4, cyclin-
dependent kinase 4, CEA, carcinoembryonic antigen; HPV, human papil-
lomavirus; MAGE, melanoma antigen; MUC1, mucin 1; PSMA, prostate-
specific membrane antigen. This table has been adapted from [50]. A
comprehensive listing of tumour antigens can be found in [51] or under
http://www.cancerimmunity.org.
Antigen class Tumour antigen
CTL epitope
(sequence) HLA
CD4
Helper
epitope
known
References
Cancer-testis MAGE1 EADPTGHSY A*0101 + [52]
MAGE3 FLWGPRALV A*0201 + [53]
NY-ESO-1 SLLMWITQC A*0201 + [54]
Tumour specific CDK4 ACDPHSGHFV A*0201 - [55]
β-Catenin SYLDSGIHF A*2402 - [56]
Caspase-8 FPSDSWCYF B*3501 - [57]
Tumour virus HPV16 E7 TLGIVCPI A*0201 - [58]
Differentiation Tyrosinase SEIWRDIDF B*4402 + [59]
GP100 ALLAVGATK A*0301 + [60]
PSMA ALFDIESKV A*0201 - [61]
Overexpressed ERBB2 KIFGSLAFL A*0201 - [62]
MUC1 LLLLTVLTV A*0201 - [63]
CEA HLFGYSWYK A*0301 - [64]
In order to use CTLs for the elimination of tumour cells, T cell epitopes derived
from such tumour antigens have to be defined. As the expression of most tumour
antigens is frequently restricted to distinct tumour types and patients, they are
not ubiquitously utilizable in tumour immunotherapy. Moreover, the actual HLA
alleles expressed by a specific patient limit the known tumour-antigen-derived
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epitopes which can be taken into account for an individual CTL-based tumour
immunotherapy.
Due to this lack of tumour specific target structures, tumour immunothera-
peutic approaches frequently resort additionally to tumour associated antigens
(TAAs). TAAs are proteins which are highly overexpressed in tumour tissue but
can also found in at least some normal tissues [50]. Therefore, all TAA based
approaches bear the risk of inducing autoimmunity, in contrast to tumour anti-
gen based approaches. TAAs can be subdivided into differentiation antigens and
overexpressed antigens. Table 1.2 lists a selection of human tumor (associated)
antigens with their corresponding T cell epitopes and HLA restrictions.
1.3.2.1. Cancer-testis antigens
Cancer-testis antigens are named according to their expression pattern. Regard-
ing benign tissues, they are expressed exclusively in spermatocytes of the testis
and sometimes in placenta [65]. As these cells lack HLA expression [66], CTLs
in healthy individuals are normally not tolerized against these cancer-testis anti-
gens. In certain tumours the expression of cancer-testis antigens can be induced
and thus provide a target for CTL based tumour immunotherapy. However, as
no physiological function of these molecules is known, an immune escape of the
tumour by downregulation of the cancer-testis antigen is well possible [67].
1.3.2.2. Tumour specific antigens
Tumour specific antigens develop by amino acid changes in the protein sequence
or by posttranslational modifications which do not occur in normal tissue. Ex-
amples of posttranslational modifications are altered glycosylation [68] or altered
amino acid side chains [69]. Specific changes in the protein sequence can occur
at the fusion site of chromosomal translocations, which has been described for
hematopoietic malignancies like chronic myelogenous leukemia (CML) [70, 71].
Moreover, DNA point mutations [56] as well as alternatively spliced mRNA may
result in tumour specific antigens. Furthermore, mRNA transcription can be ini-
tiated at non classical start codons leading to cryptic translation products [72, 73].
Tumour specific CTL epitopes can be generated by posttranslational splicing by
the proteasome. However, not all epitopes derived from spliced peptides are tu-
mour specific [74]. Finally, B cell lymphomas represent a special case: As they
all share a common idiotypic B cell receptor, which is – due to its generation by
somatic recombination – unique and thus tumour specific.
1.3.2.3. Tumour-virus antigens
Tumour-virus antigens are proteins which are introduced into a benign cell by an
oncogenic virus and thus are present only in virus-infected cells. Therefore, an
immunotherapy which is targeted against these viral proteins is highly specific.
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It has been shown that herpes viruses (HHV) are the causative agent for 99.7%
[75] of cervix carcinoma (thereof, more than 70% are caused by the types HPV-16
and HPV-18 [76]). Gardasil and Cervarix, two vaccines targeted against HPV L1,
have shown to be of substantial impact regarding protective immunity against
cervical cancers [77].
1.3.2.4. Differentiation antigens
Differentiation antigens are shared between the tumour and the normal tissue
from which the tumour was originating. Most of these TAAs belong to the
melanoma/melanocyte group and are involved in the melanin biosynthesis [51].
In order to use such TAAs in immunotherapy, a potential tolerance against these
antigens has to be broken. Thus, autoimmunity against the original normal tissue
can be triggered, leading for example to vitiligo in the case of melanocytes [78].
Compared to the potential therapeutic benefit, these side-effects are negligible.
An other example for differentiation antigens are prostate specific TAAs. As
the prostate is frequently resected completely in prostate cancer patients, no
adverse effects are to be anticipated using CTLs against prostate specific TAAs
for tackling remaining prostate cancer cells.
1.3.2.5. Overexpressed antigens
This class of antigens is expressed in many normal tissues, however in lower levels
compared to the tumour tissue. Although a marked T cell tolerance has to be ex-
pected, this group of TAAs is biggest in number [51]. Many of the overexpressed
antigens are regulatory factors – needed e.g. for tumour survival or sustained
growth – and thus can be found in various tumour types [79]. Therefore, they are
applicable quite broadly as therapeutical targets. However, using overexpressed
antigens for tumour immunotherapy both T cell tolerance and induction of au-
toimmunity are major impediments. Nevertheless, several overexpressed antigens
have been used in clinical trials showing both low risk of autoimmunity and the
possibility to induce specific T cells [80, 81].
1.3.3. Identification of TAAs
Although a considerable amount of TAA-derived T cell epitopes are known, the
number is far from being sufficient for a comprehensive CTL-based tumour im-
munotherapy. This is can be partially explained by two biases in the identification
process of tumour antigens and TAAs. On the one hand, many studies are per-
formed using melanoma samples – a model cancer in tumour immunotherapy.
On the other hand, studies are frequently performed with HLA-A*02 positive
patients, as this is the most frequent MHC-I allele in the Caucasian population
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[82]. Thus, CTL epitopes suitable for tumour immunotherapy are lacking for
many tumour types and for less frequent HLA alleles.
1.3.3.1. Epitope mapping, isolation of CTLs and subsequent
identification of T cell specificity
CTLs derived from tumour patients are isolated and used to screen expression
libraries derived from tumour cells which are recognized by specific CTLs. Thus,
the gene recognized by the tumour specific T cells can be identified. For example,
by truncation of the TAA gene MAGE1 [83] and subsequent usage of overlapping
9-15 mer peptides, the A*01-restricted CTL epitope EADPTGHSY (MAGE1, aa
161-169) was identified [52].
Based on this approach, several further developments have been used for the
identification of tumour-derived T cell epitopes. On the one hand, viral expres-
sion libraries can be used, which allow the enrichment of expression constructs
recognized by specific CTLs [84]. On the other hand, MHC-bound peptides can
be isolated directly from a cell line, recognized by tumour specific CTL lines.
After separation of the isolated peptides by HPLC, fractions are tested for their
potential to stimulate the tumour specific CTL lines. Using this approach, the
peptide YLEPGPVTA (gp100 aa 280-288) was identified by mass spectrometry
in the HPLC fraction recognized by the CTLs [85].
1.3.3.2. Reverse immunology, epitope prediction from defined antigens
As HLA molecules have an allele-specific peptide motif [86], CTL epitopes can be
predicted for a combination of a tumour antigen of interest with an HLA allele
of interest. This can be done using epitope prediction programs like BIMAS or
SYFPEITHI. Additionally, proteasomal processing as well as binding affinity to
the TAP molecule can be taken into account ([87]; PREDTAP , [88]). Finally, all
three prediction steps can be integrated in combined approaches (NetCTL, [89];
MHC-Pathway, [90]). For experimental validation of predicted T cell epitopes,
the peptides of interest are synthesized and used to stimulate T cells derived from
e.g. healthy blood donors or tumour patients. Finally, peptide specific T cells
have to be tested against tumour cells expressing the antigen of interest, in order
to verify that the identified peptide is processed naturally [91].
1.3.3.3. The ‘Tübingen approach’, combining mass spectrometry, gene
expression analysis and T cell monitoring
The identification of patient specific tumor antigens or TAAs for tumor im-
munotherapy is still a bottleneck. Thus, the ‘Tübingen approach’ combines on a
patient individual basis large scale identification on MHC-bound peptides from
tumour tissue with gene expression analysis [92]. The peptide analysis identifies
peptides actually presented on MHC, which are thus potentially recognizable by
8
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CTLs. The gene expression analysis identifies which of the genes corresponding
to the identified peptides are uniquely expressed or overexpressed in the tumour
tissue. Thus, the combination of the identified peptide sequence and the gene
expression data results in a patient specific list of candidate epitopes derived from
TAAs. Finally, these candidate TAA epitopes are to be confirmed either by in
vitro T cell assays [63, 93] or by immuno monitoring of in vivo T cell responses
in patients vaccinated with candidate TAA epitopes.
1.4. Differences in tumour vs. normal tissue:
Immunotherapeutic obstacles and their
overcome
Although the identification of T cell epitopes derived from tumour antigens or
TAAs is a prerequisite for a molecularly defined, CTL-based tumour immunother-
apy, it is not sufficient for effective, long lasting anti-tumour responses in vivo.
On the one hand, the tumour microenvironment can suppress immune responses
actively by manipulating immune cells in a way that they e.g. produce im-
munosuppressive chemokines like TGF-β, IL-10, VEGF, and IL-6 [26] or express
co-inhibitory ligands such as B7-H1 [28] and IDO [27]. On the other hand, it
has been shown that CD4+ T cell help is crucial for maintenance of CTL re-
sponses and the induction of CD8+ memory T cells [94, 95]. Thus, an effective
T cell-based immunotherapy has to be based on three major pillars:
First, the identification of as many tumour antigens and TAAs as possible.
This would result in a large set of possible target structures, providing a broad
arsenal from which the best candidates for an individual therapy could be chosen.
Second, the identification of the herein contained CD4 and CD8 T cell epitopes
for maximal amount of HLA alleles. The combination of matching CD4 and CD8
T cell epitopes would allow a long lasting anti-tumour responses. The chance
that tumour escaped the therapy could be further reduced, if several different
epitope pairs would be used in parallel for a patient-specific therapy.
Third, appropriate therapeutical settings have to be found, which break the
immunosuppressive features of the tumour microenvironment and thus allow an
effective immune response.
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2. Introduction II: LC-MS based protein
and peptide quantification using
stable isotope labels
This chapter is part of a review article published in Biotechnology and Genetic
Engeneering Reviews, 23:21-39, 2006 by:
Andreas O. Weinzierl and Stefan Stevanović.
The author of this thesis was majorly responsible for writing the article and
designed Figures 2.1 and 2.2.
2.1. Introduction
Detailed quantitative comparisons of different cellular states are a key prerequisite
for the profound understanding of various complex cellular pathways on a molec-
ular basis. These molecular mechanisms of interest can range from regulatory
consequences of a triggered signal cascade to a deep understanding of malignant
cellular behaviors like in tumors. Different levels of quantitative comparisons of
cellular states became a feasible technique in the last years.
Regarding the transcriptome, quantification has been well established for many
years [1]. Single gene products can be quantified using qRT-PCR and even the
complete entity of different transcriptomes are quantitatively comparable in one
single gene chip experiment. But due to poor correlation between the tran-
scriptome and the proteome [2, 3] no general statements can be deduced from
quantitative mRNA results in respect to changes in protein expression.
In addition to the lack of correlation between the amount of a mRNA species
and its corresponding protein, mRNA expression analyses are blind for post-
transcriptional modifications of proteins [4]. Thus up to now a molecular analysis
of a cellular state has to be carried out on the proteome level. The higher chemi-
cal complexity of protein mixtures makes the proteome not as easily quantifiable
as the transcriptome, but within the last decade several approaches made quanti-
tative comparisons between proteomes possible in a high throughput manner [5].
In general all these approaches dealing with protein quantification have to
solve several general problems. At first, the complexity of the proteome has to
be reduced to an analyzable size, at best without losing valuable information and
sensitivity. Second the information gained in the experiment has to be inter-
pretable in a high-throughput way and at last the method has to be reproducible
to be able to detect also minor changes in protein levels.
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Figure 2.1.: Schematic representation of stable isotope labeling sites for protein labeling
in quantitative proteomics. Light isotope marks are shaded in grey, heavy
isotope marks in black and unmarked amino acids are white. A and D:
Metabolic labeling: Proteins are labeled metabolically by incorporation of
15N, 13C or isotope labeled amino acids present in the cell culture medium.
B and E: Side chain modification: Proteins are labeled at specific side chains
with isotope containing reagents. The reagents can also contain affinity tags
for selective enrichment of tagged proteins. C and F: Terminal modifica-
tion: Proteins are labeled C- or N-terminally using e.g. enzymatic cleavage
in H218O or chemical modification at the N-terminus with isotope contain-
ing reagents. Samples are digested after isotope labeling respectively for
terminal labeling are labeled after digestion. Afterwards samples are quan-
titatively analyzed by mass spectrometry (D-F, ratio determination). For
metabolic labeling and side chain modification various differences in the
distance between light and heavy modified peptides (D and E) as well as
unmodified peptides (D, peptide 4 and E, peptide 3) can be observed. Ter-
minal modification shows a more uniform peptide pattern as no unmodified
peptides emerge and distances between light and heavy modified peptides
are equal (F). In a final step peptides are sequenced by tandem MS/MS
experiments (D-F, sequence analysis).
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2.2. 2D-Gel electrophoresis based quantification
techniques
The fist attempt in protein quantification which met many of the prerequisites
given above was two-dimensional gel electrophoresis (2D-GE) [6, 7]. Here the
complexity of a protein mixture is reduced by isoelectric focusing and subse-
quent size separation of the proteins. After separation of the proteins they are
stained in gel, isolated, enzymatically digested and identified by MALDI-TOF
based peptide mapping [8, 9]. Although 2D-GE coupled to MS-analysis is in
general a valuable approach in quantitative proteome analysis, the classic quanti-
tative 2D-GE has some major impediments. The lack of reproducibility between
different gels hampers the distinction between variations of the sample and the
system. Sensitivity of the system is limited e.g. due to the used protein dye for
protein visualization and to the protein recovery rate from the gel [10]. A major
improvement of quantitative 2D-GE was achieved by Unlu and co-workers [11].
They introduced the difference gel electrophoresis (DIGE) allowing analysis of
several samples to be compared in one single 2D gel with increased sensitivity
and reproducibility. In this approach up to three samples are prelabeled with
spectrally different fluorescence dyes, afterwards the samples are mixed and sep-
arated in the same gel. The consecutive spot detection is carried out with a
scanner after laser excitation of the fluorescence dye. Protein identification is
still carried out after spot isolation and enzymatic digest by MALDI-TOF. Yet
one last major issue in 2D-GE proteomics is high throughput analysis mainly
exacerbated by protein spot picking from the gel. At least for coomassie stained
gels this can be automated using robots [12] yet accuracy and sensitivity of this
automation is still technically elaborated.
2.3. LC-MS based quantification techniques
In order to circumvent difficulties resulting from 2D gel electrophoretic separation
of proteins alternative quantitative proteomics techniques have been developed.
Common to all of these techniques is the replacement of gel electrophoresis by
liquid chromatography (LC) for protein separation and complexity reduction. In
general in all techniques the proteins are enzymatically digested prior to separa-
tion, peptides are separated chromatographically and directly analyzed with an
online coupled mass spectrometer (LC-MS). At some point in time of that work-
flow, depending on the respective approach, the peptide mixture is differentially
labeled with isotope-coded tags. This approach is advantageous in several re-
spects. On the one hand peptide separation and data acquisition are automated
per se and therefore high throughput analysis is easily possible. On the other
hand the method is highly reproducible and therefore sensitive even for minor
changes in protein levels.
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The fundamental obstacle in quantification by mass spectrometry is the fact
that the signal a peptide yields in an MS-experiment does not correlate to its to-
tal amount and is not accurately reproducible in consecutive experiments. This
is true for MS experiments irrespective of the ionization technique or the used
MS device [13]. The ionization efficiency of a specific peptide depends on the
peptide sequence and on the nature and amount of co-eluting peptides which
are not necessarily constant especially when analyzing quantitative differences
between proteomes. This obstacle is circumvented by using isotope-coded labels
which differ in mass but not in their physio-chemical behavior on the LC-column
[14]. Therefore both species of a differentially labeled peptide elute at the same
retention time from the chromatography column but are distinguishable in the
recorded mass spectrum due to their different isotope-coded label. In this case,
the ionization efficiency for both peptide species is equal and relative quantifica-
tion is possible. This approach can principally also be used for absolute quantifi-
cation (AQUA, [15]) provided that one isotopically labeled peptide species is a
spiked peptide of known amount.
This basic principle depicted above comes in several different flavors differing
mainly in kind of the label itself and in place of label introduction (Fig. 2.1-A to
C). In the following section various isotope-coded modification reagents developed
in recent years are discussed. Detailed examples of quantitative results using
the differential N-terminal isotope coding (dNIC) strategy are given in the last
section.
2.3.1. Metabolic labeling
Metabolic labeling of proteins occurs during protein biosynthesis within the cell
(Fig. 2.1-A). Therefore cells have to be grown in media enriched in the stable iso-
topes 15N [16, 17] or 13C [18] or which are supplemented with isotope-incorporated
amino acids like D3-leucine [19] and arginine containing various numbers of 13C
and 15N e.g. 13C6-Arg, 13C6-15N4-Arg (both [20] or 15N2-Arg [21] (Fig. 2.2).
The usage of 15N enriched medium has proven to be an accurate quantifica-
tion method and is more frequently used than 13C-modified media. In order to
reduce difficulties and expenses in preparing 15N enriched media for mammalian
cells the usage of stable isotope labeling by amino acids in cell culture (SILAC)
was introduced in 2002 for differential proteomics by Ong et al 2002. Several
quantitative analyses have been carried out ranging from analysis of proteome
dynamics of the nucleolus [20], proteome changes in muscle cell differentiation
[19] to repertoire changes of major histocompatibility complex class I (MHC-I)
peptides after Salmonella enterica infection [21].
A principle obstacle concerning metabolic labeling is that the number of heavy
atoms respectively amino acids incorporated into one peptide is not deducible
without sequence information. As mass differences between isotopic labeled pep-
tides depend on the sequence they differ from peptide to peptide (Fig. 2.1-A
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Figure 2.2.: Structure formulas of isotope bearing modification reagents described in this
review. Sites bearing heavy isotopes in the respective heavy isotope-reagents
are marked with X, Y and Z. For further details regarding the reagents see
the respective sections of the text. * The heavy cICAT reagent contains nine
13C-atoms out of the ten C-atoms in total. The exact position of these nine
13C-atoms is a corporate secret of Applied Biosystems, Framingham, MA.
and D, compare peptides 1-4). An additional restraint is the fact that highly
abundant peptides leading to just one MS-signal are not distinguishable from
also existing unlabeled peptides (Fig. 2.1-D, peptide 4). This in turn reduces the
impact of quantifiable MS-data without sequence information dramatically.
2.3.2. Chemical labeling
For proteomic samples which cannot be derived from in vitro cultured cells the
metabolic labeling approach is not applicable. These samples can be chemically
modified with isotope labels at their terminus or at side chains. This chemical
modification can be divided into side chain modifications (Fig. 2.1-B and E) and
terminal modifications (Fig. 2.1-C and F). The major difference between side
chain modification and terminal modification is not only the modification reagent
(see Fig. 2.2 dNIC and ICPL) but mainly the number of peptides available for
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modification and thus for quantification. After side chain labeling, only peptides
containing the targeted amino acid are modified and the number of labels per
peptide is also sequence dependent (Fig. 2.1-B and E, compare peptides 1-4),
whereas terminal labeling introduces exactly one label in every peptide (Fig.
2.1-C and F, compare peptides 1-4).
2.3.3. Side chain labeling
Favorite targets for specific modifications of side chains are mainly the amino
group of lysine residues or the thiol group of cysteines. In principle proteins
are at first isolated then modified and digested enzymatically and subsequently
subjected to MS-analysis (Fig. 2.1-B).
2.3.3.1. ICAT and cICAT
Gygi et al introduced in 1999 the first isotope-coded affinity tag (ICAT). The
ICAT reagent consists of a biotin tag, an isotope carrying linker and a reactive
sulfhydryl group for the attachment of the ICAT reagent to reduced cysteine
residues. The biotin tag allows the purification of labeled peptides, reducing the
sample complexity on the one hand and omitting singular signals from unmod-
ified peptides on the other. Although this ICAT reagent was successfully used
in the analysis of differences in the Saccaromyces cerevisiae proteome, induced
by galactose or ethanol as carbon source [2] the ICAT reagent itself has some
restraints. The biotin isotope tag is relatively large (442 Da) and can result
in incomplete peptide sequence information [13], the purification via the biotin-
avidin interaction is susceptible to unspecific binding and incomplete elution [22]
and finally the eight deuterium atoms of the heavy ICAT reagent caused a rela-
tively strong isotope effect on the chromatography column, which could partially
resolve isotopic peptide pairs [23]. These problems were largely solved with sev-
eral improvements of the ICAT reagent. The cleavable ICAT (cICAT, Fig. 2.2)
has two major improved features. It contains an acid-cleavable linker, which
allows removal of the biotin tag from the labeled peptide. This removal of the
biotin decreases the mass of the ICAT-tag for MS-analysis and results in better
interpretable peptide fragmentation spectra. Additionally the isotope effect in
chromatography was omitted by replacement of the deuterium with 13C-isotope
labels [24].
2.3.3.2. ICROC and ALICE
Several other strategies vary the basic idea of ICAT modification. For the isotope-
coded reduction off of a chromatographic support (ICROC, Fig. 2.2) method
[25] proteins are also reduced and cleaved with trypsin. The thus generated
cysteine containing peptides are covalently coupled to pyridyl disulfide beads.
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After washing the cysteine peptides are eluted using a reducing agent. Afterwards
the free cysteine thiol groups are alkylated either with N-ethyl or with N-D5-ethyl-
iodacetamide and subjected to LC-MS for quantitative analysis.
The usage of acid-labile isotope-coded extractants (ALICE, Fig. 2.2) [26] also
circumvents biotin/avidin based purification of cysteine-peptides. Cysteine con-
taining peptides derived from tryptic digests are linked with their thiol group to
the ALICE reagent, which contains apart from a thiol group an isotope-coded
linker and an acid labile unit, which is covalently coupled to an inorganic resin.
After linking the cysteine peptides to the resin, they are washed and afterwards
eluted by acid treatment and analyzed consecutively.
2.3.3.3. PhIAT
The principle of ICAT was also conveyed to the quantitative analysis of phosh-
porylated proteins using phosphoprotein isotope-coded affinity tags (PhIAT). In
2001 Oda et al. [27] developed a labeling strategy for phosphorylated proteins
with a reagent resembling ICAT. Proteins were subjected to tryptic digestion,
thiol groups of cysteine residues were oxidized to cysteic acid and thus blocked
from further reactions. Phosphate residues were removed by β-elimination using
high pH-conditions. This elimination results in a replacement of the phospho-
group with an unsaturated residue to which ethanedithiol (EDT) is added. Fi-
nally a biotin bearing linker structurally related to the ICAT linker is introduced
to the free thiol group of the EDT. The further steps of processing are equal as
for ICAT labeled peptides, namely biotin based purification, subsequent elution
and LC-MS analysis. This approach is easily applicable for quantification using
EDT-H4 and EDT-D4 for induction of isotope bearing tags (Fig. 2.2) for peptide
modification [28].
2.3.3.4. ICPL
The purification of cysteine peptides to reduce the complexity of the peptide
mixture about 10 fold is a major advantage of the ICAT method, but can also
become one of its pitfalls. The reduction of complexity leads also to a reduction
of protein coverage as cysteine is one of the rarest amino acids. For example
approximately 66% of all E. coli open reading frames contain less than 5 cysteine
residues [29].
Apart from cysteine thiol groups, the much more frequent amino group in lysine
side chains is as well modifiable in a selective way. More than 80% of all proteins
have a high lysine content and are therefore available for isotope-coded protein
labels (ICPL, Fig. 2.2) using either D4-nicotinic acid [29] or 13C6-nicotinic acid
[30] as heavy modifying reagent. Like for cysteine based quantification approaches
proteins are first modified, then mixed and digested. As lysine modification
impairs protein digestion with trypsin, proteins have to be digested with other
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proteases such as endoproteinase Glu-C.
Although the higher protein coverage of the ICPL-technique can be very valu-
able, some limitations are intrinsic to this approach. Unlabeled peptide portions
are not separated from the modified peptide pool and thus singulet peptide peaks
in LC-MS analysis derive from highly abundant peptides as well as from unmod-
ified ones. Additionally a multiple labeling of one peptide is likely due to the fact
that lysine is a frequent amino acid. This multiple labeling in turn complicates
identification of peptide pairs (Fig. 2.1-E).
2.3.4. Terminal labeling
In principle terminal labeling has one major advantage as every peptide is labeled
and thus all peptides are available for quantification. Proteins labeling after
digestion bears vice versa the restraint that mixing of samples is later than in all
other approaches (Fig. 2.1-C). This makes this approach per se more prone to
artefacts due to separated sample preparation.
2.3.4.1. Enzymatic digest in presence of H218O
One of the first strategies used for quantitative comparisons of protein samples
was the enzymatic digestion of protein samples in 18O-labeled water, marking the
C-terminus of the generated peptide by a mass shift of 2 Da compared to peptides
digested in H216O [31, 32]. Although this approach is elegant and fast there are
some restraints. The small mass change of the peptide mass due to incorporation
of 18O results in an overlay of the isotope pattern of light and heavy tagged
peptides. Furthermore the 2 Da mass difference between differentially tagged
peptides can be altered due to rebinding of trypsin to peptidic arginine and
lysine residues after cleavage. The rebinding leads to incorporation of a second
18O into the peptide [33] complicating the quantitative analysis of the sample.
2.3.4.2. Acetylation and TMAB
Acetylation of free aminogroups in a peptide is chemically simple and quantitative
and thus allows easily the introduction of an isotope-coding tag into a peptide.
Several protocols have been described either for specific acetylation of the N-
terminus after blocking free amino groups in lysine side chains ([34], see also
dNIC section) or the unspecific acetylation of all free amino groups in a peptide
[35], which is less favorable for analysis.
Irrespective the specificity of the reaction, acetylation reduces the nucleophilic
character of the modified aminogroup dramatically, resulting in very ineffective
ionization efficiencies of the acetylated peptides (Fig. 2.3). Therefore other N-
terminal modification reagents, which preserve a positive N-terminal charge, are
more favorable.
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One example of such a reagent is 4-trimethyl-ammoniumbutyryl (TMAB, Fig.
2.2, [14]) which also reacts with every free amino group. In 2005 Che and co-
workers used this reagent without blocking lysine side-chains successfully for
quantification of neuropeptides in mice [36].
2.3.4.3. dNIC
Figure 2.3.: Recoveries of different peptide derivatives. The four synthetic peptides
(AETSYVKVL, KLSLGLPGL, SLGLQLAKV and VLDPRGIYL) present
in equimolar concentrations were either acetylated, guanidinated and acety-
lated or guanidinated and nicotinylated. After complete derivatization, each
peptide mixture was combined with the initial nonmodified peptide mix-
ture (thus expecting equimolar yields of both species) and quantified by
nanospray-ESI-MS analysis. This figure is adapted from Lemmel et al. 2004
[34].
Lemmel et al. 2004 introduced an approach to provide a differential N-terminal
isotope coding (dNIC) selectively at the N-terminus [34]. To prevent isotope la-
beling of lysine side chains, these amino groups are selectively guanidinated at
a pH above 10.5 using O-methylisourea [37] (for workflow see Fig. 4.1). The
peptides are desalted on C18-colums and afterwards the dNIC label is solely in-
troduced at the N-terminus. This approach is advantageous in various respects.
Every peptide is modified with exactly one dNIC-label, meaning, that singlet
LC-MS events can not emerge from unlabeled peptides but are due to singularly
existing peptides in one of the samples. The dNIC-label is very light (110 Da) and
thus has not the impairments of ICAT-labels in respect of peptide sequencing.
Furthermore the dNIC-label as well as the guanidination enhance MS sensitivity
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[38, 39], which compensates losses during peptide labeling quantitatively (Fig.
2.3).
2.4. Conclusions
Although there is still much space for further improvements regarding e.g. quan-
tification of very low abundant proteins or peptides and automation, quantitative
comparisons of proteins using LC-MS became a well established technique dur-
ing the last decade.Several different modification reagents cover a broad range
of biological applications from total proteome comparisons using ICAT or ICAT-
abutted techniques to reagents suited for phosphoprotein or MHC ligand quantifi-
cation. Common to all these techniques is a good reproducibility and sensitivity
as well as a broad dynamic range, altogether needed for accurate quantification
experiments. Taken all together it can be expected that protein quantification
will be used more frequently in the future, tackling multifaceted problems in var-
ious biological systems. There it will complement largely available quantitative
mRNA data to a refined view of the addressed question [4].
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3. Aims of the thesis
At the beginning of this thesis, the differential N-terminal isotope (dNIC) strategy
had already been established profoundly by Claudia Lemmel (Lemmel et al., Nat
Biotechnol. 2004 Apr;22(4):450-4.). However, the reliability of this strategy had
not yet been tested in complex samples.
Thus, the first aim of this thesis was to test the reliability of the dNIC strategy
in complex samples like MHC-peptide extracts from cell lines or primary tissue.
Additionally, the mixing procedure of two samples, to be compared with each
other, was to be optimized.
The second aim was the identification of patterns according to which TAP
defective tumours could be made available for tumour immunologic approaches.
Therefore, this optimized dNIC strategy was used for a comparison of a TAP
expressing cell line with a hereof derived TAP deleted mutant cell line.
The third aim was to analyse the correlation between HLA ligand ratios and
mRNA rations in order to assess the potential of gene expression based identifi-
cation of tumour (associated) antigens. Thus, the differential analysis was used
for a comparison of tumour and autologous normal tissue regarding HLA peptide
presentation and gene expression.
Fourth, a T cell epitope, identified by the dNIC approach was to be defined
in order to demonstrate the power of the dNIC approach in the identification of
tumour (associated) antigens.
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4. Results I: Peptide quantification
using dNIC
This chapter is partly derived from a review article published in Biotechnology
and Genetic Engeneering Reviews, 23:21-39, 2006 by:
Andreas O. Weinzierl and Stefan Stevanović.
The author of this thesis designed and performed all experiments described
herein. Figure 4.4-A and -B were created by Jens Joachim.
4.1. Quantitative analysis of MHC-I ligands
MHC-I molecules are cell surface proteins presenting a non-covalently bound
peptide [1]. These MHC ligands mainly derived from endogenous proteins are
displayed primarily to cytotoxic T-cells for [2]. Several features of MHC lig-
ands withdraw them from ICAT based quantification but make them perfectly
suited for N-terminal modification using the dNIC-approach. The MHC-bound
peptides range in size from 8-10 amino acids [3] and seldom contain cysteine
residues (as can be seen from the MHC ligand database at www.syfpeithi.de).
Thus all ICAT based approaches are not suited for quantitative MHC analysis.
Fortunately the complexity of a MHC ligand preparation is in a magnitude which
does not need reduction prior to LC-MS analysis. Ringrose et al therefore used
metabolic labeling with 15N-arginine to analyze differential HLA-B*2704 peptide
presentation after Salmonella enterica infection [4]. The studied HLA-B*2704
molecule binds mostly peptides which bear in their second position an arginine
as so called anchor residue. Therefore merely all isolated HLA-B*2704 ligands
were differentially marked in position two.
This approach is not generally conferrable to other MHC ligand pools as most
MHC motifs are not that restrictive in their anchor amino acids as HLA-B*2704.
A metabolic labeling with a more abundant amino acid would impair the same
general problems as described above for metabolic labeled proteins. Due to the
fact that protein coverage of MHC-bound peptides per se is very low, it is in
this context especially important, that virtually every peptide is quantitative
analyzable. Therefore also a quantification based on lysine side chain labeling
like ICPL which has no separation of labeled from unlabeled peptides would be
inadequate.
All these restraints hampering metabolic and side chain labeling do not apply
for the dNIC approach (Fig. 4.1) as it is independent from amino acid composi-
tion and all peptides are available for quantification (Fig. 2.1-C).
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Figure 4.1.: Workflow for dNIC based quantitative comparison of MHC-I ligand levels
isolated from two samples.
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4.2. Kinetics of MHC-I ligand nicotinylation
Figure 4.2.: Kinetic analysis of peptide nicotinylation. A mix of eight synthetic peptides
was guanidinated and afterwards subjected to nicotinylation for 15 min in
total. First peptides were pulsed with 10 mM H4-NIC for different times
indicated in the diagram. Afterwards H4-NIC was removed and for the
remaining time 10 mM D4-NIC was added for chase. For each peptide and
point in time ratios of peptides modified with light and heavy nicotinic acid
were calculated. The used fitting function is indicated in the diagram.
Peptide modification at NH2 of lysine side chains or at the N-terminus with
N-nicotinoyloxy-succinimide (NIC-NHS) esters is carried out from 1 h [5] to 2.5 h
[6, 7]. To optimize reaction time and NIC-NHS usage, we investigated nicotinyla-
tion kinetics in a pulse-chase experiment (Fig. 4.2). A mix of eight synthetic pep-
tides (4 nmol each peptide) was on-column modified within 15 min in total with
10 mM light or heavy nicotinylation reagent. For pulsing the pre-guanidinated
peptide mix was incubated for 10 sec to 15 min with H4-NIC. The chase was
carried out by replacing light nicotinylation solution with D4-NIC to give a total
nicotinylation time of 15 min. For kinetic analysis, the H4-NIC to D4-NIC ratio
of modified peptides was determined by mass spectrometry. Summarizing the re-
sults, a nicotinylation efficiency of 99% was achieved for every synthetic peptide
after 15 min and thus the protocol for the dNIC approach could be optimized.
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4.3. Appropriate mixing of dNIC-labeled MHC-I
ligands
Table 4.1.: Proof of principle for densitometry based mixing of peptides modified with
the dNIC strategy. 42 nmol of a peptide mix were guanidinated and split
into portions of 6, 12 and 24 nmol. These portions were separately modified
with H4-NIC (6 and 24 nmol) and D4-NIC (12 nmol). The optical density at
262 nm was determined for each sample after modification. The 6 nmol and
12 nmol portion were mixed according to their optical density in a 1:1 ratio.
The 12 and 24 nmol portions were mixed in a 0.8:1 ratio respectively. Actual
peptide ratios were determined by MS.
amount of modified
peptide 6nmol 12nmol 24nmol 12nmol
Intensity Intensity
Peptide sequence NIC dNIC ratio NIC dNIC ratio
PGSYTYEWNFRKDVN 386 393 0.98 612 755 0.81
DVETQFNQYK 547 506 1.08 966 1217 0.79
KLKEFIPKV 495 460 1.08 514 629 0.82
GLDEVKSSL 696 607 1.15 1021 1251 0.82
VVQLTLAFR 1683 1633 1.03 1777 2462 0.72
ILNSWNISK 799 703 1.14 1286 1444 0.89
average 1.08±0.06 0.81±0.05
expected 1.00 0.80
Adequate mixing of the samples prior to quantification analysis is one of the
most crucial steps for every quantitative application. Regarding adequate mix-
ing, metabolic labeling is generally advantageous as with no other isotope labeling
method different samples can be mixed that early in the workflow (Fig. 2.1-A).
For quantitative analysis total cell preparations can be normalized to equal cell
number or total protein content, directly mixed and processed together. This
early mixing procedure reduces any artificial protein quantification differences
resulting from different handling of the samples. Principally terminal modifica-
tion implies a later mixing than all other modification techniques, but this does
not apply to MHC-I ligand samples to full extent. MHC-I ligands are short pep-
tides, therefore an enzymatic digestion step is surplus. Nevertheless accurate
determination of total MHC ligands content is difficult. Before acid treatment
of immunoprecipitated MHC the total amount of MHC can be determined and
hence the quantity of the thereof isolated MHC ligands can only be roughly de-
duced.
Due to the sensitivity of LC-MS based dNIC quantification experiments a more
accurate determination of total peptide content of a sample prior to mixing is
required. As peptide nicotinylation introduces a strongly UV-absorbing nicotinic
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acid into every peptide the total amount of peptide in a sample can be determined
by UV-absorption at 262 nm. To prove that this densitometric based mixing is
in principal appropriate for LC-MS quantification experiments pools of synthetic
peptides were differentially labeled and mixed in fixed ratios according to their
OD262nm. Afterwards the actual peptide ratios were determined by MS. In detail
6, 12 and 24 nmol of six synthetic peptides were modified either with light or
heavy nicotinic acid. After elution from the C18 columns OD262nm was determined
for each sample, whereas an equally treated sample without peptide served as
blank. According to their optical densities, the samples were mixed in a ratio
of 1:1 respectively 0.8:1. The actual peptide ratios were determined by mass
spectrometric analysis (Tab. 4.1). The results from this experiment demonstrate
that UV-absorption based peptide mixing is accurate for nicotinylated peptides
as the relative error was as low as 8% which is in a range similar to that obtained
with other isotope based quantification strategies [8].
Figure 4.3.: Densitometry based mixing of two complex peptide samples after dNIC mod-
ification. MHC-I ligands were isolated from two preparations of LCL721.45,
modified with D4-NIC respectively H4-NIC and mixed according to their
OD262nm in a 1:1 ratio. A frequency count (bin size 0.157) of the logarith-
mized ratios of dNIC to NIC modifiedligands was performed and fitted using
a Gaussian curve, modus and R2 are indicated within the figure.
This mixing method was also successfully applied to more complex samples.
Total MHC ligands were isolated independently from two batches of the cell line
LCL721.45 and modified with D4-NIC respectively H4-NIC (Fig. 4.3). Here most
MHC ligands seem to be equally presented on both batches of the LCL721.45
cell line. Assuming a Gaussian distribution of the logarithmized ratio of dNIC to
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NIC modified peptides (R2=0.94), the ratios can be further normalized setting
the modus of the curve at zero.
4.4. Automatization of peptide quantification
using dNIC-labels
The dNIC strategy labels every peptide and introduces a mass shift from light
to heavy modification reagent of 4 Da, independent from the peptide sequence.
This constant mass difference and the isotopic effect of the peptides modified
with the deuterium bearing nicotinic acid can be used for reliable automated
analysis of peptide pair ratios. This makes the dNIC quantification approach
well suited for high-throughput experiments. Figure 4.4 shows an example how
an automated quantification can be approached. Individual measured values of
one peptide including its isotope pattern eluting from the HPLC (Fig. 4.4-A) is
integrated using a two-dimensional model consisting of an elution profile and a
theroretical isotope pattern (Fig. 4.4-B). Finally the room integral of such fea-
tures is calculated. Pairs of feature ((Fig. 4.4-C) are easily allocatable due to the
mass difference and the isotopic shift in retetnion time. Such automated analysis
have been integrated in the OpenMS software (http://open-ms.sourceforge.net).
Figure 4.4.: Exemplaric approach of an automated peptide quantification analysis in an
LC-MS experiment. A, The individual measured m/z values and intensi-
ties of one peptide which eluting from the HPLC are depicted. B, Two-
dimensional model of an elution profile combined with a theroretical isotope
pattern. The measured values of the peptide depicted in A is depicted. C,
Three-dimensional image using data of a modified peptide pair with a m/z
= 2 mass shift. The dNIC peptide is eluting earlier due to the isotopic effect
of deuterium.
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4.5. Facilitated de novo sequencing by
dNIC-labeling
Figure 4.5.: Faciliated de novo sequencing of the modified peptide IITKEVLAP us-
ing the dNIC approach. A, MS/MS fragmentation spectrum of synthetic
IITKEVLAP modified with D4-NIC after guanidination. B, MS/MS frag-
mentation spectrum of IITKEVLAP isolated from LCL721.174 also modi-
fied with D4-NIC after guanidination. C, MS/MS fragmentation spectrum of
guanidinated and H4-NIC modified IITKEVLAP, isolated from LCL721.174.
D, Nomenclature of MS/MS fragments derived from modified IITKEVLAP.
Apart from the fact that N-terminal modification with heavy and light nico-
tinic acid enables quantitative comparison of two samples, it also facilitates de
novo peptide sequencing. Identical peptides modified with light and heavy dNIC-
reagent result in identical MS/MS-spectra except that every fragment containing
the N-terminus differs in mass by 4 Da. Taking advantage of that fact, we could
de novo sequence the MHC ligand IITKEVLAP, which origins only in an ex-
pressed sequence tag (EST) corresponding to a yet unknown protein (Fig. 4.5).
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The modified synthetic peptide (Fig. 4.5-a) displays an identical fragmentation
pattern compared to the MHC ligands isolated from the LCL721.174 cell line
modified with light or heavy modification reagent (Fig. 4.5-b/c). Another fea-
ture of nicotinylation facilitating sequencing is the fact that the N-terminal b-ion
(Fig. 4.5-d) becomes observable in MS/MS fragmentation spectra. Normally
N-terminal b1-ions (Fig. 4.5-d) are not generated during peptide fragmentation
as b-ion generation requires cyclic transition states [11]. Instead b2-ions are gen-
erally well observable. As nicotinylation introduces a new peptide bond at the
N-terminus the b2-ions generated from nicotinylated peptides contain only nico-
tinic acid and the N-terminal amino acid and thus make the N-terminal amino
acid easily identifiable.
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5. Results II: Features of
TAP-independent MHC class I
ligands revealed by quantitative mass
spectrometry
This chapter has been submitted for publication by:
Andreas O. Weinzierl, Despina Rudolf, Nina Hillen, Stefan Tenzer, Peter van
Endert, Hansjörg Schild, Hans-Georg Rammensee and Stefan Stevanović.
The author of this thesis designed and performed all HLA quantification and
FACS experiments as well as gene expression and bioinformatical analyses.
5.1. Summary
The TAP transporter is responsible for transferring cytosolic peptides into the
ER where they can be loaded onto MHC molecules. Deletion of TAP results in
a drastic reduction of MHC surface expression and alters the presented peptide
pattern. This key molecule in antigen processing is tackled by several viruses
and in some tumours rendering the altered cells less vulnerable to T cell based
immune surveillance. Using the TAP deficient cell line LCL721.174 and its TAP
expressing progenitor cell line LCL721.45, we have identified and quantified more
than 160 HLA ligands, 50 of which were presented TAP-independently. Peptides
which were predominantly presented on the TAP deficient LCL721.174 cell line
had a decreased MHC binding affinity according to their SYFPEITHI and BIMAS
score. About half of the identified TAP-independently presented peptides were
not derived from signal sequences and may partly be generated by the proteasome.
Furthermore, we have excluded the possibility that different HLA presentation
ratios were due to varying expression of the respective protein or due to changes
in the antigen loading complex. Features of peptides presented independently of
TAP as well as proteasomal contribution to their generation provides an insight
into basic immunological mechanisms.
5.2. Introduction
Peptides derived from endogenously expressed proteins are displayed on the cell
surface by MHC-I molecules to cytotoxic T Lymphocytes (CTLs), enabling the
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CTLs to distinguish normal cells from infected cells.
Proteins are degraded within cells by the proteasome – generating 3-22 aa
peptides [1], which can be further trimmed in the cytosol by proteases like the
tripeptidyl peptidase II (TPP2) [2]. Such generated peptides – with an optimal
length of 9-16 aa [3] – are transported into the ER by the TAP complex. Before
the peptides are loaded onto MHC-I molecules they can be further trimmed by
the ER aminopeptidase associated with antigen processing (ERAAP) [4]. The re-
sulting peptides with a length of 8-11 aa [5] are loaded onto MHC-I molecules by a
complex consisting of tapasin, calreticulin and ERp57. Finally, the MHC:peptide
complexes are exported via the Golgi network onto the cell surface.
Apart from this major pathway, it has been described [6, 7] that TAP1/2 de-
ficient cells display signal sequence derived peptides which have been liberated
in the ER by the signal peptidase (SP) complex. Both reports found 4, respec-
tively 3, HLA-A*02-bound peptides derived mainly from the signal peptide of the
lysosomal thiol reductase IFI30. Up to now, about 10 human TAP-independent
MHC-I ligands are known [8], mostly restricted to HLA-A*02. This is due to the
fact that the HLA-A*02 can bind signal sequence derived peptides with a higher
affinity than most other HLA types because its HLA motif has a high similarity
to the protein signal sequence pattern.
The use of TAP blockade or deletion as a means of evading CTL immune
surveillance has been described for various viruses such as HSV or HCMV [9] or
in the case of several tumours [10]. In tumours, TAP deletion correlates with
poor prognosis and tumorigenesis [11].
5.3. Materials and Methods
5.3.1. Elution of HLA presented peptides
HLA presented peptides were obtained by immune precipitation of HLAmolecules
from LCL721.45 and LCL721.174 cell lines [13] as described elsewhere in detail
[12] using the pan-HLA antibody W6/32. 1.1010 LCL721.45 cells respectively
5.1010 LCL721.174 [14] cells were used for the isolation of HLA peptides. Elution
experiments were performed twice.
5.3.2. Peptide modification and analysis
Modification of peptides was carried out as previously described [15]. LCL721.174
and LCL721.45-derived peptides were modified with heavy (4 hydrogens replaced
by deuterium), respectively light (all hydrogen), dNIC-NHS solution. Using in-
verted labels, the reproducibility of the quantification was assessed to be on
average about 90% (data not shown). For quantification, HLA peptides isolated
from LCL721.45 and LCL721.174 were mixed in a total peptide ratio of 1:1 and
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recorded in a single LCMS experiment without fragmentation using a Q-TOF-II
(Micromass, Manchester, UK). For sequence analysis each HLA peptide sample
was analyzed separately in individual LC-MS/MS experiments. Interpretation of
MS/MS fragmentation spectra was carried as described [15].
5.3.3. Gene expression analysis
RNA isolation and gene expression analysis were carried out using Affymetrix
Human Genome U133 Plus 2.0 oligonucleotide microarrays (Affymetrix, Santa
Clara, CA, USA). Data were analyzed with the GeneChip Operating Software
(GCOS, Affymetrix, Santa Clara, CA, USA). Pairwise comparisons between tu-
mor and autologous normal kidney were calculated using the respective normal
array as baseline. Microarray data are available from the Gene Expression Om-
nibus repository (www.ncbi.nih.gov/geo, GSE9437).
5.3.4. Subfractionation of cellular extracts and tryptic
digest
Differential detergent fractionation [16] and centrifugal fractionation [17] were
performed as previously described. All fractions were precipitated using the Pro-
teoExtract Protein Precipitation Kit (Merck, Darmstadt, Germany) and solu-
bilized in 25 mM ammonium bicarbonate containing 0.1 % RapiGest (Waters,
Eschborn, Germany). Proteins were reduced by adding 5 mM DTT and free
cysteines alkylated with iodoacetamide (Sigma, Taufkirchen, Germany). 0.2 µg
porcine sequencing grade trypsin (Promega, Mannheim, Germany) was added
and the samples were incubated overnight at 37°C. After digestion, RapiGest
was hydrolyzed by adding 10 mM HCl and the resulting precipitate was removed
by centrifugation. The supernatant was analyzed by LCMS/MS.
5.3.5. LCMS/MS analysis of tryptic digests
Capillary liquid chromatography of tryptic peptides was performed with a Wa-
ters NanoAcquity UPLC system online coupled to a Waters Q-TOF Premier
API system as described [18]. The continuum LCMSE data were processed and
searched using the IDENTITYE-Algorithm of ProteinLynx Global Server (PLGS,
v2.3). Protein identifications were assigned by searching the UniProtKB/Swiss-
Prot Protein Knowledgebase Release 52.3 for human proteins (16150 entries).
Peptide identifications were restricted to tryptic peptides with no more than one
missed cleavage. For valid protein identification, the following criteria had to be
met: at least 2 peptides detected together with at least 7 fragments. All reported
peptide identifications provided by the IDENTITYE-algorithm were correct with
>95% probability. The false positive rate for protein identification was set to 1%
based on search of a reversed database.
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5.3.6. Proteasomal processing
Purification of 20S proteasomes, in vitro degradation of precursor peptides, sep-
aration, and analysis of cleavage products were performed as described [19]. 10
nmol of the peptides (HPLC purity >95%) were incubated for 6 h with 2 µg
immunoproteasome or for 6 h with 2 µg of constitutive proteasome, respectively,
in digestion buffer (20 mM Tris-HCl; pH 7.6; 10 mM NaCl; 10 mM KCl; 2 mM
MgCl2; 0.5 mM DTT) and the reaction stopped by adding formic acid to a final
concentration of 0.5% and freezing the reaction mixture at -80ºC. Fragments were
analyzed as described [18].
5.3.7. Cell culture and protease inhibition assay
LCL721.45 and LCL721.174 cells were cultivated in RPMI 1640 (C.C.Pro, Neustadt,
Germany) medium containing 10% FCS (Pan, Aidenbach, Germany). For the
protease inhibition assay, 2.105 LCL721.174 cells were incubated at 37°C in 200
µl cell culture medium containing 20 µM Ala-Ala-Phe-chloromethylketone (AAF-
CMK, Bachem, Weil am Rhein, Germany), 200 µM Butabindide (Tocris Bio-
science, Bristol, UK), 50 µM Lactacystin (biomol, Hamburg, Germany), 2 µM
Epoxomycin (biomol, Hamburg, Germany), 5 µg/ml Chloroquine (Sigma-Aldrich,
Taufkirchen, Germany) or 7.5 mM NH4Cl. After 6 h HLA surface expression was
analyzed by flow cytometry as described below.
5.3.8. FACS analysis
After washing, cells were incubated for 30 min on ice with the primary antibody
W6/32 (HLA-A, -B, C), B1.23.2 (HLA-B, C) or BB7.2 (HLA-A). Subsequently,
cells were washed three times and incubated with an FITC-conjugated goat anti-
mouse antibody (Jackson ImmunoResearch Laboratories, Newmarket, Suffolk,
UK) for 30 min on ice. Cells were analyzed by flow cytometry on a FACSCalibur
cytometer (BD Biosciences, Heidelberg, Germany). Dead cells were stained with
7-AAD (BD Biosciences, Heidelberg, Germany) and excluded from the analysis.
5.4. Results and Discussion
5.4.1. Validation of the experimental setting
In this report we quantitatively analyze the MHC:peptide repertoire of the TAP1/2-
deficient cell line LCL721.174 in comparison to its TAP expressing progenitor cell
line LCL721.45 (5.1-A). To exclude influences on MHC:peptide levels caused by
alterations in the respective mRNA and protein levels, both cell lines were addi-
tionally compared on the protein and mRNA level.
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Figure 5.1.: LCL721.45 and LCL721.174 differ only slightly in protein and mRNA expres-
sion. A, Schematic overview of the quantitative comparison of LCL721.174
and LCL721.45 on the mRNA, protein and HLA ligand level. B and C,
Relative gene and protein expression levels were evaluated in a histogram
analysis. The full width at half maximum (w) was calculated assuming a
Gaussian distribution. DDF: differential detergent fractionation, CF: cen-
trifugal fractionation.
mRNA levels of LCL721.174 and LCL721.45 were compared in a gene chip
experiment. Figure 5.1-B shows that 90% of all genes differed at the most by a
factor of two in their expression. A similar analysis was performed on the pro-
tein level, whereby cells were fractionated into cytosolic, nuclear and membrane
bound proteins. In order to minimize methodical influences, two independent
fractionation methods were used: differential detergent fractionation (DDF) and
centrifugal fractionation (CF). Tryptic digests of the different fractions were an-
alyzed in five repetitive HPLC-MS/MS experiments. The identification of a spe-
cific protein was judged to be valid if it was identified in at least three out of five
HPLC-MS/MS experiments.
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Table 5.1.: A quantitative analysis of protein and mRNA levels demonstrates partial dele-
tion of chromosome 6p21.3. The analysis comprised constitutive proteasomal
subunits (PSMB1, 2 and 5), immunoproteasomal subunits (LMP7, 2 and
MECL1), subunits of the immunoproteasomal regulator PA28 (PSME1-3),
proteins of the HLA peptide loading complex (TAP1 and 2, tapasin, calreti-
culin, calnexin and PDIA3), HLA class I and II (HLA-A, -B, -C, -DR, -DP
and -DQ), the endoplasmic reticulum aminopeptidase associated with anti-
gen processing (ERAAP) and proteins of the SEC61 translocon which can be
involved in peptide export from the ER. Genes encoded in the deleted region
of chromosome 6p21.3 in LCL721.174 cells are highlighted in bold.
Gene Gene 2log (LCL721.174 vs. LCL721.45)
Symbol Title protein mRNA
PSMB1 proteasome subunit beta 1 -0.29 n.d.
PSMB2 proteasome subunit beta 2 -0.54 n.d.
PSMB5 proteasome subunit beta 5 LCL721.174 only 0.2
LMP7 proteasome subunit beta 8 721.45 only 721.45 only
LMP2 proteasome subunit beta 9 721.45 only 721.45 only
MECL1 proteasome subunit beta 10 721.45 only -1.4
PSME1 proteasome activator subunit 1 -0.82 -0.7
PSME2 proteasome activator subunit 2 -0.56 0.3
PSME3 proteasome activator subunit 3 721.45 only 0.9
CALR calreticulin n.a. 0.1
CANX calnexin n.a. -1.0
TAP1 transporter 1, ATP-binding cass. 721.45 only 721.45 only
TAP2 transporter 2, ATP-binding cass. 721.45 only 721.45 only
TAPBP Tapasin 721.45 only -1.7
HLA-A major histocomp. complex I A -2.78 -0.8
HLA-B major histocomp. complex I B n.s.d. -1.1
HLA-C major histocomp. complex I C -2.04 -1.0
HLA-DP major histocomp. complex II DP 721.45 only 721.45 only
HLA-DQ major histocomp. complex II DQ 721.45 only 721.45 only
HLA-DR major histocomp. complex II DR 721.45 only 721.45 only
PDIA3 protein disulfide isomerase A3 n.a. -0.8
SEC61A1 Sec61 alpha 1 subunit 721.45 only -0.2
SEC61A2 Sec61 alpha 1 subunit n.d. -0.1
SEC61B Sec61 alpha 1 subunit 721.45 only -0.3
SEC61G Sec61 alpha 1 subunit n.d. -0.9
ERAP1 ER aminopep. assoc. w. antigen process. n.d. 0.7
n.d. not detected, n.s.d. no significant detection (n < 3) , n.a. no definite ratio available
This proteome analysis revealed an even higher similarity between LCL721.174
and LCL721.45 compared to the gene chip experiment. Figure 5.1-C shows that
over 95% of all proteins for which an expression ratio was available differed be-
tween LCL721.174 and LCL721.45 at the most by a factor of two.
Table 5.1 shows an overview of mRNA and protein ratios of the key molecules
involved in antigen processing, MHC-peptide loading and antigen presentation.
During its generation, the LCL721.174 cell line has lost part of chromosome
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6q21.3, including the genes of TAP1 and 2, LMP2 and 7 as well as MHC class II.
This was detectable both on mRNA and on the protein level. Apart from these
differences we could not observe any major changes in the antigen presentation
machinery.
5.4.2. Analysis of HLA ligands by mass spectrometry
Due to TAP deletion, the total HLA surface expression was reduced by a factor
of five in LCL721.174 (Fig. 5.2-A, left panel). HLA-A*0201 surface expression
was sustained in LCL721.174 to some extent (Fig. 5.2-A, middle) due to the
presence of signal peptide fragments in the ER. The expression of HLA-B*5101
expression was reduced by about forty fold (Fig. 5.2-A, right panel).
For quantification experiments, 15 nmol of HLA:peptides were isolated from
LCL721.174 and LCL721.45 and each modified with a stable isotope label (Fig.
5.1-A). In total, 48 peptide sequences which were presented on the TAP1/2 defi-
cient LCL721.174 cell line could be identified (Tab. 5.2). 25 of these peptides were
also presented on LCL721.45; for 2 peptides no quantification was possible. 116
peptides specifically presented on LCL721.45 were identified; quantification was
possible for 105 peptides (Supplementary Tab. A.6). The number of identified
peptides, their presentation ratio and their HLA assignment is summarized in Fig-
ure 5.2-B. 91% of the peptides which were over-presented on LCL721.174 by a fac-
tor greater than ten were presented on HLA-A*0201 and were predicted to be de-
rived from signal sequences (SignalP, http://www.cbs.dtu.dk/services/SignalP).
Interestingly, five HLA-A*0201 presented peptides were not derived from signal
sequences. Furthermore, both HLA-B*5101-bound peptides in this group were
actually derived from signal sequences; however, the C-terminus was most prob-
ably not generated by the SP complex.
This observation that TAP deletion does not restrict the HLA-peptide reper-
toire solely to signal peptide derived, SP cleaved peptides is even more obvious
for peptides presented both on LCL721.174 and LCL721.45 cells. About 50%
of such peptides were presented on HLA-B*5101 and only one-third was derived
from within in the signal sequence.
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Table 5.2.: 52 peptides isolated from the TAP-deficient cell line LCL721.174 were se-
quenced by mass spectrometry. Signal sequence cleavage sites were predicted
using SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/); peptides lo-
cated within the putative signal sequence are highlighted in bold. Signal
sequence-derived peptides which required additional trimming were marked
with an asterisk. Predominantly TAP-independently presented peptides are
found above the dashed line.
Sequence GeneSymbol Gene Title position
signal
seq. HLA
HLA
present.
721.174 vs.
721.45
LLSAEPVPA CD79B CD79B antigen 20-28 28 | 29 A*0201 556.8
LLGPRLVLA TMP21 transmembrane trafficking protein 22-31 31 | 32 A*0201 253.2
SLWGQPAEA COL4A5 collagen, type IV, alpha 5 18-26 26 | 27 A*0201 124.4
VLAPRVLRA RCN1 reticulocalbin 1 21-29 29 | 30 A*0201 120.3
ALVVQVAEA HEXB hexosaminidase B 34-42 42 | 43 A*0201 116.1
HGVFLPLV KIAA0247 KIAA0247 21-28* 39 | 40 B*5101 92.3
LLAAWTARA APP amyloid beta A4 precursor protein 9-17 17 | 18 A*0201 91.9
VLLKARLVPA KIAA1946 KIAA1946 19-28 28 | 29 A*0201 47.7
KMDASLGNLFA FAM3C family with seq simil. 3, member C 30-40 24 | 25 A*0201 36.4
LLFSHVDHVIA SLC8A1 solute carrier family 8, member 1 25-35 35 | 36 A*0201 28.1
FLGPWPAAS LRPAP1 LDL rec.-rel. prot. assoc. prot. 1 22-30* 32 | 33 A*0201 23.7
SLYALHVKA VKORC1 vit. K epoxide reduc. complex 23-31 31 | 32 A*0201 23.1
LLLSAEPVPA CD79B CD79B antigen 19-28 28 | 29 A*0201 22.2
AMAPPSHLLL PELP1 Pro-Glu-Leu-rich protein 1 473-482 21 | 22 A*0201 18.3
MAPLALHLL IL4I1 interleukin 4 induced 1 1-9* 21 | 22 B*5101 18.0
FLLGPRLVLA TMP21 transmembrane trafficking prot. 22-31 31 | 32 A*0201 17.9
LLLDVPTAAV IFI30 interferon, gamma-induc. prot. 30 15-24* 26 | 27 A*0201 17.8
LLLDVPTAAVQA IFI30 interferon, gamma-induc. prot. 30 15-26 26 | 27 A*0201 14.8
LLLDVPTAA IFI30 interferon, gamma-induc. prot. 30 15-23* 26 | 27 A*0201 14.7
LLDVPTAAV IFI30 interferon, gamma-induc. prot. 30 16-24* 26 | 27 A*0201 14.4
VLFRGGPRGLLAVA SSR1 signal sequence receptor, alpha 19-32 20 | 21 A*0201 12.8
ALLSSLNDF NIF3L1 NIF3 NGG1 interacting factor 3-like 1 5-13 no A*0201 12.8
IITKEVLAP EST sequence EST sequence frame 3 n.d. A*0201 12.8
QLQEGKNVIGL TAGLN2 transgelin 2 166-176 no A*0201 7.9
ILAPAGSLPKI TERE1 transitional epithelia response protein 328-338 no A*0201 6.2
MASRWGPLIG Cab45 calc. bind. prot. Cab45 prec. 8-17* 36 | 37 B*5101 4.5
AVLALVLAPAGA NRP1 neuropilin 1 10-21 21 | 22 A*0201 4.3
LAPRVLRA RCN1 reticulocalbin 1 22-29 29 | 30 A*0201 4.2
AALLDVRSVP GDF5 growth differentiation factor 5 275-284 27 | 28 A*0201 3.8
SLPKKLALL HSPC023 HSPC023 protein 72-80 no A*0201 3.2
KAPVTKVAA PDLIM1 PDZ and LIM domain 1 241-249 no B*5101 1.7
NPLPSKETI TMSB4X thymosin, beta 4, X-linked 27-35 no B*5101 1.2
MFPLVKSAL COX7B cytochrome c oxidase subunit VIIb 1-9 no B*5101 0.9
MAPRTLVL HLA-A m. histocomp. complex, I-A 4-11* 24 | 25 B*5101 0.5
TLLGHEFVL CDC27 cell division cycle 27 605-613 no A*0201 0.4
LPHVPLGVI AUP1 ancient ubiquitous protein 1 374-382 37 | 38 B*5101 0.3
YLTAEILEL HIST1H2AJ histone 1, H2aj 58-66 no A*0201 0.3
LPREILNLI LOC116064 hypothetical protein LOC116064 259-267 no B*5101 0.3
LLDRFLATV CCNI cyclin I 72-80 no A*0201 0.2
GSHSMRYF HLA-A/B/C/G m. histocomp. complex I-A,-B,-C,-G 25-32 24 | 25 B*5101 0.2
HLINYIIFL TMEM41B transmembrane protein 41B 240-248 no A*0201 0.2
YVPRAILV TUBB3 tubulin, beta 3 59-66 no B*5101 0.1
TLAEIAKVEL NONO non-POU domain cont., octamer-bind. 120-129 no A*0201 0.1
DALDVANKIGII RPL23A ribosomal protein L23a 145-156 no B*5101 0.1
RIIEETLAL ARPC2 act. rel. prot. 2/3 complex. 9-17 no A*0201 0.1
DGLVVLKI EIF3S3 eukar. transl. initiat. fact. 3. 42-49 no B*5101 0.1
MAPRTLLL HLA-A/B/C m. histocomp. complex, I-A,-B,-C 4-11* 24 | 25 B*5101 0.1
VMAPRTLVL HLA-A m. histocomp. complex, I-A 3-11* 24 | 25 A*0201 0.1
n.d. not determinable, n.a. ratio not available
5.4.3. Features of TAP-independent presented HLA ligands
The bulk of TAP independently presented peptides allowed an analysis of their
HLA-binding features in comparison to a TAP-dependent peptide repertoire
identified from the parental LCL721.45 cell line. For both groups of peptides
the SYFPEITHI score (http://www.syfpeithi.de), as well as the BIMAS score
(http://www-bimas.cit.nih.gov/molbio/hla_bind/), were calculated. The SYF-
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Figure 5.2.: Surface HLA and its ligands on LCL721.45 and LCL721.174. A, HLA ex-
pression of LCL721.174 and LCL721.45 was assessed by FACS analysis using
the antibodies W6/32 (HLA-A, -B, -C), BB7.2 (HLA-A*0201) and B1.23.2
(HLA-B, -C). B, Overview of HLA ligands identified in LCL721.174 and
LCL721.45 including their presentation ratio and HLA allele assignment.
PEITHI analysis assessed the quality with which the peptide matched its HLA
motif; a SYFPEITHI score above 25 indicates high HLA affinity. With an excess
of peptide in the ER (LCL721.45, TAP+), only peptides with a strong affinity
managed to be exported as MHC:peptide complexes to the cell surface (Fig. 3-A,
left). However, in the case of an excess of HLA molecules with limiting peptide
amount (LCL721.174, TAP-), HLA molecules were less specific in their peptide
selection. This resulted in a drop in the SYFPEITHI score from 27 to approxi-
mately 22. This decrease in stringency of HLA-molecules regarding their peptide
choice was also reflected by the BIMAS score, which is a measure for the half-time
of HLA:peptide dissociation. On average, TAP-independently presented peptides
had a 15-fold decrease in their BIMAS score, also indicating a reduced binding
affinity to their respective HLA molecules (Fig. 5.3-A, right).
5.4.4. Generation of non signal sequence-derived peptides
According to the SignalP prediction, 24 out of the 50 HLA ligands which were
identified on LCL721.174 cells were not derived from signal sequences. To identify
proteases required for generating these peptides, we analyzed the HLA-surface
expression of LCL721.174 after inhibition of TPP2, the proteasome, or lysosomal
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Figure 5.3.: HLA ligands of LCL721.174 bind HLA with low affinity and are dependent
of proteasome activity. A, SYFPEITHI and BIMAS scores were calculated
for peptides which were presented in a TAP-dependent (black) or TAP-
independent (white) manner. SYFPEITHI scores above 25 indicate high
HLA affinity; the BIMAS score is a measure for the HLA:peptide dissociation
half-time. B, Reduction of surface HLA expression in LCL721.174 cells upon
6 h incubation with inhibitors of various proteases as revealed by FACS
analysis. The color of the bars indicate the inhibited protease respectively
compartment. All error bars represent the SEM.
proteases (Fig. 5.3-B). Only proteasomal inhibition resulted in a decrease of HLA
surface expression, indicating that proteasome activity was necessary to process
TAP-independently presented peptides which are not located in signal sequences.
In order to strengthen this hypothesis, prolonged precursors of 13 non signal se-
quence peptides were synthesized and digested in vitro with purified constitutive
proteasomes (expressed in LCL721.174) and immunoproteasomes (predominantly
expressed in LCL721.45). The C-terminus of eight of these peptides was generat-
able by the proteasome; for three peptides the cleavage efficiency differed slightly
between the two proteasomes (Supplementary Tab. A.7). Therefore, the pro-
teasome could be responsible for generating the C-terminus for a part of the
TAP-independently presented peptides not derived from signal sequences. Thus,
precursors of HLA-ligands might be transported into the ER via the Sec translo-
con or a pathway that is not yet known. HLA surface expression was reduced
by over 30%. Considering the fact that a residual activity remains despite pro-
teasomal inhibition, this could correlate with the observation that approximately
50% of all identified TAP-independent peptides were not derived from signal
sequences.
5.4.5. Concluding Remarks
Previous reports have identified only low monadic numbers of TAP-independently
presented peptides. This low number prevented the deduction of common features
possessed by such peptides except for the fact that most peptides were derived
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from signal sequences and were bound to HLA-A*0201.
We could verify the finding that HLA ligands that are predominantly pre-
sented in a TAP-independent manner are mainly derived from the C-terminus
of the respective signal peptide. However, this is only true for abundant pep-
tides presented on HLA-A*02. In our analysis, more than 30% of all identified
TAP-independent peptides were presented by HLA-B*5101 and about 50% were
derived from mature protein chains. These peptides could not be created by the
catalytic activity of the SP complex but may be generated partially by the pro-
teasome. However, the exact mechanism by which peptides derived from within
mature proteins were translocated into the ER remains unclear. Furthermore,
TAP-independently presented peptides had on average a reduced HLA affinity.
A detailed understanding of such features of TAP-independently presented pep-
tides will facilitate the identification of tumour and virus-derived CTL epitopes
which are specific for cells with deleted or blocked TAP transporter.
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6.1. Summary
The major histocompatibility complex (MHC) presents peptides derived from
degraded cellular proteins to T-cells and is thus crucial for triggering specific
immune responses against viral infections or cancer. Up to now, there has been
no evidence for a correlation between levels of mRNA (the ‘transcriptome’) and
the density of MHC:peptide complexes (the ‘MHC ligandome’) on cells. Since
such dependencies are of intrinsic importance for the detailed understanding of
translation efficiency and protein turnover, and thus for systems biology in gen-
eral and for tumour immunotherapy in practical application, we quantitatively
analysed the levels of mRNA and corresponding MHC ligand densities in sam-
ples of renal cell carcinomas and their autologous normal kidney tissues. Relative
quantification was carried out by gene chip analysis and by stable isotope peptide
labeling, respectively. In comparing more than 270 pairs of gene expression and
corresponding peptide presentation ratios, we demonstrate that there is no clear
correlation (R = 0.32) between mRNA levels and corresponding MHC peptide
levels in RCC. A significant number of peptides presented predominantly on tu-
mour or normal tissue showed no or only minor changes in mRNA expression
levels. In several cases, peptides could even be identified in spite of the virtual
absence of the respective mRNA. Thus we conclude that a majority of epitopes
from tumour associated antigens will not be found in approaches based mainly
on mRNA expression studies, as mRNA expression reflects a distorted picture of
the situation on the cell surface as visible for T cells.
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6.2. Introduction
Major histocompatibility complex (MHC) bound peptides reflect a snapshot of
the dynamic protein pool [1] and can therefore provide insights into protein
turnover and the transient cellular proteome [2–4]. Class I MHC molecules
present peptides (8-11 AA in length) [5] from degraded proteins on the cell sur-
face to cytotoxic T-cells in order to allow the T-cells to discriminate between
self and non-self [6]. Additionally to its original purpose, this detection sys-
tem can be used for the selective removal of mutated cells displaying aberrant
MHC:peptide complexes on their cell surface [7]. Therefore the identification of
disease-related MHC:peptide complexes is of utmost interest for immunodiagnos-
tics and -therapy. Huge efforts are being undertaken in order to identify cancer
specific MHC:peptide complexes applicable for tumour immunotherapy [8–10]. In
this context, the identification of tumour associated antigens (TAAs), which are
predominantly expressed in tumour tissue, is one strategy being followed. Apart
from differential comparisons of tumour and normal tissue proteomes [11], mRNA
based techniques are also being widely applied. DNA expression cloning, for ex-
ample, has proved to be one successful method for the identification of TAAs [12]
but it is being increasingly complemented by large scale gene expression analysis
using DNA microarrays [13, 14].
The generation of MHC:peptide complexes starts in the cytosol, where pro-
teins are degraded by the proteasome [15]. The source proteins for proteasomal
digestion range from long-lived proteins over short-lived proteins to defective ri-
bosomal products (DRiPs) [16] which do not reach proper folding and functional
state. DRiPs are thought to be responsible for more than 30% of all MHC bound
peptides [17]. Irrespective of their origin, a small part of peptides generated in
the cytosol escapes further degradation and is transported via the transporter
associated with antigen processing (TAP) into the endoplasmatic reticulum [18]
where they can be further trimmed N-terminally by proteases such as the endo-
plasmic reticulum aminopeptidase associated with antigen processing (ERAAP)
[19]. Finally, the peptides are loaded onto MHC molecules with the help of sev-
eral proteins that includes tapasin, calnexin and calreticulin, and are exported as
MHC:peptide complexes onto the cell surface. An alteration which is thought to
be crucial for the repertoire of MHC ligands is the induction of immunoproteaso-
mal subunits by interferon gamma (IFNγ), for example. Upon IFNγ stimulation
cells exchange the three proteolytic subunits of the proteasome (PSMB1, 2, and
5) with subunits of different proteolytic activity (LMP2, LMP7, and MECL1), a
hallmark for converting normal proteasomes into immunoproteasomes [20, 21].
The entire MHC pathway has been investigated in depth often with a focus on
the therapeutic potential. MHC bound peptides can be used for stimulation and
activation of cytotoxic T-cells which have, for example, been used successfully for
the treatment of melanoma [22, 23]. The identification of suitable T-cell epitopes
is one of the bottlenecks in the large scale use of this tumour immunological
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strategy. Utilisable T-cell epitopes have to be both tumour-associated and match
the patient’s MHC repertoire. Several T-cell epitopes for T-cell based tumour
immunotherapy have already been described but the identification is laborious
and not all in vitro defined T-cell epitopes are potent for triggering an immune
response also in vivo.
Gene chip analysis is frequently used for the identification of TAAs [24, 25],
but it has not yet been investigated whether an over-expression of mRNA also
results in an MHC over-presentation of peptides derived from the respective pro-
tein. Thus, in this study MHC peptide presentation levels are compared with
their corresponding transcription levels. We analysed human clear cell renal cell
carcinoma and autologous normal tissue in a combined transcriptome and hu-
man leukocyte antigen (HLA) ligandome approach. HLA:peptide levels were
quantified by mass spectrometry using stable isotope labels, mRNA levels were
determined by gene chip analysis using DNA microarrays.
6.3. Materials and Methods
6.3.1. Materials
The HPLC reagents, trifluoroacetic acid, acetonitrile, formic acid and HPLC
water, were purchased from Merck. Peptide modification reagent O-Methyl
isourea hemisulfate was purchased from Acros Organics, 1-([1H4/2D4] nicotinoy-
loxy)succinimide (light or heavy dNIC-NHS) was synthesized as described else-
where [26].
6.3.2. Elution of HLA presented peptides
HLA presented peptides were obtained by immune precipitation of HLAmolecules
from solid tissues using a slightly modified protocol [27] that involves the HLA-A,
-B and -C specific antibody W6/32 coupled to protein A-sepharose or CNBr-
activated sepharose (Roche) followed by acid elution and subsequent ultrafiltra-
tion.
6.3.3. Modification of peptides
Modification of peptides was carried out as described elsewhere [26] with slight
modifications. In brief, peptide solutions were adjusted to pH 11 using 10 M
NaOH and guanidinated at 65°C for 10 min using 2.5 M O-methyl isourea hemisul-
fate solution. The reaction was halted adjusting the pH to 3 and peptides were
desalted by using Peptide Cleanup C18 Spin Tubes (Agilent) as described in the
manual. Peptides were loaded three times in 200 µl aliquots onto the Spin Tube
columns. These were then washed three times with H2O and the peptides were
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nicotinylated on column for 15 min at room temperature. 500 µl of a 20 mM
light or heavy dNIC-NHS solution in 50 mM phosphate buffer pH = 8.5 were thus
passed over the C18-material with a flow rate of 33 µl/min. After washing the
columns as described above, aminolysis of unwanted Tyr-dNIC esters was carried
out by treatment with 500 µl 50% hydroxylamine for 10 min at room temperature
with a flow rate of 50 µl/min. Subsequently, the columns were washed again and
the peptides were eluted using four times 50 µl of 50% acetonitrile, 1% formic
acid.
6.3.4. Mixing of peptides
In order to mix tumour and normal MHC peptides in a total peptide ratio of
1:1, absorption of isotope labeled peptide pools was determined at 260 nm [28].
Peptide content of the tumour and normal sample were calculated using the molar
extinction coefficient for nicotinic acid in 50% acetonitrile ( = 1430 M−1) and
equal amounts of peptides were mixed.
6.3.5. Microcapillary LCMS
Peptide analysis was carried out as described elsewere [26] using an Ultimate
HPLC system (Dionex) with a gradient ranging from 15-55% solvent B within
170 minutes. Mixed tumour and normal samples were recorded in an LCMS
experiment without fragmentation using a hybrid quadrupol orthogonal acceler-
ation time of flight MS/MS (Q-TOF, Micromass), equipped with a micro-ESI
source. For sequence analysis tumour and normal samples were analysed sepa-
rately in individual LCMS/MS experiments.
6.3.6. Peptide sequence analysis and peptide quantification
Peptide sequence analysis was carried out manually. Therefore MS/MS spectra
were smoothed using the MassLynx 4.0 software (Savitzky-Golay, 3 smooth win-
dows, 2 smoothes). For manual peptide identification, sequence tag searches were
done using Mascot 2.0 software (peptide and MS/MS tolerance 0.2 Da, NCBInr
database monthly updated and restricted for search to human entries, 138263
entries for human proteins at the time when the searches were done) and relevant
hits were assessed manually and not by evaluation of the Mascot score. Criteria
for manual identification were: a reasonable interpretation of at least 95% of all
of all fragment peaks, complete sequence coverage with MS/MS fragments and
signal intensities of fragment ion peaks which match breakage probabilities of
the respective sequence. For more than 50% of all sequenced peptides MS/MS
spectra with both light and heavy dNIC isotope label were available, which facili-
tated manual sequencing of the peptides. Ions containing the N-terminus showed
a mass shift of 4 Da due to the dNIC isotope label (see Fig. 6.2-C and D). In total
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363 peptides were sequenced in the three analyzed RCC samples. All identified
peptides were blasted against the NCBInr database (see above) and all peptides
which could not be unambiguously allocated to only one protein sequence were
excluded from further analysis unless the mRNA expression ratios for these po-
tential source proteins were equal. For all peptides which could be linked to an
mRNA expression ratio Supplementary Tab. A.2 lists protein information, HLA
presentation ratio, mRNA expression ratio, HLA restriction, source, precursor
mass and charge state. All relevant MS/MS spectra used for peptide identifica-
tion can be found at
http://www.uni-tuebingen.de/uni/kxi/PaperSupplements/Weinzierl_MCP2006/.
For peptide quantification mixed tumour and normal tissue samples were ana-
lyzed in an MS experiment. Peptide pairs were identified manually. Afterwards
mass chromatograms for the light and heavy version of the peptide were calcu-
lated and scans containing the peptide of interest were summed up. For back-
ground subtraction an equal number of scans with a similar retention time was
subtracted. The relative amount of light and heavy dNIC peptide was calculated
using the peak heights of the first isotope peaks (see Fig. 6.2-B).
6.3.7. Assessment of false positive rate of peptide
identification
In order to estimate the false positive rate of the identified peptides, a database
was designed which contained both the EBI IPI-Human database (IPI, version
3.21, containing 60822 entries) and the reversed EBI IPI-Human database (rIPI).
50 randomly chosen peptides from RCC099 were searched using the manually
identified sequence tags in this database with the MASCOT software. In sum-
mary 20% of all searches returned only one peptide with a significant MAS-
COT score, 66 % of all searches returned only one hit (all in IPI). Only 6
% of all searches resulted in more than three peptide hits (both in IPI and
rIPI, Supplementary Tab. A.3). 8 of theses peptides and 8 additional pep-
tides – also identified in RCC099 – were chemically synthesized and modified
(Supplementary Tab. A.1). Fragmentation spectra of these synthetic peptides
were compared to the fragmentation spectra recorded from RCC099. All syn-
thetic peptides showed exactly the same fragmentation pattern as the peptides
identified in RCC099. Thus we conclude that the false positive rate in our se-
quence analysis is below 1%. Comparisons of MS/MS spectra obtained from
synthetic peptides and from RCC099 can also be found at http://www.uni-
tuebingen.de/uni/kxi/PaperSupplements/Weinzierl_MCP2006/.
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6.3.8. Gene expression analysis by high-density
oligonucleotide microarrays
RNA isolation from tumour and autologous normal kidney specimens as well as
gene expression analysis by Affymetrix Human Genome U133 Plus 2.0 oligonu-
cleotide microarrays (Affymetrix, Santa Clara, CA, USA) were performed as de-
scribed previously [29]. Data were analysed with the GCOS software (Affymetrix).
Pairwise comparisons between tumour and autologous normal kidney were cal-
culated using the respective normal array as baseline.
6.4. Results
6.4.1. Principles of quantitative peptide and mRNA
analysis
The general strategy used to assess the correlation between mRNA ratios and
their corresponding ratios of HLA presented peptides is depicted in Fig. 6.1-
A. mRNA was isolated from three different RCC tumour tissues and respective
autologous normal tissues for subsequent gene chip analysis. HLA presented
peptides were isolated from the same tumour and normal tissue samples [30]
and quantified relatively as shown in Fig. 6.1-B using the differential N-terminal
isotope coding (dNIC) strategy [26, 28]: The HLA ligandome isolated from tu-
mour tissue was derivatized with ‘heavy’ nicotinic acid (deuterium-bearing, Fig.
6.1-C) whereas for the HLA ligandome of normal tissue the ‘light’ nicotinic acid
(hydrogen-bearing, Fig. 6.1-C) was used. As a consequence, all peptides from
tumour tissue possessed the very same physico-chemical features as their coun-
terparts with identical sequence from normal tissue, but differed in mass by 4
Da. In order to achieve the highest possible accuracy and sensitivity both for
quantification and sequence identification, quantification and sequence identifi-
cation experiments were carried out seperately. Therefore, after derivatization
one aliquot of each peptide pool was used for relative quantification. Heavy
dNIC-peptides from tumour samples and light dNIC-peptides from normal tissue
were mixed in a total peptide ratio of 1:1 and subjected to liquid chromatogra-
phy online coupled to an electrospray ionization mass spectrometer (ESI-LCMS).
Pairs of identical peptides derived from tumour and normal tissue were identified
on the basis of a 4 Da mass difference introduced by the isotope label and due
to their identical retention times in chromatography. For differential quantifica-
tion, the ratio of signal intensities between monoisotopic peaks of the tumour
and normal tissue derived peptide was calculated (Fig. 6.1-B, right panel). For
peptide sequence analysis, the remaining aliquot of derivatized HLA ligand pools
was used for peptide sequence analysis by online coupled electrospray ionization
tandem mass spectrometry (ESI-LCMS/MS).
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Figure 6.1.: Strategy for differential mRNA and MHC ligand analysis. A, mRNA and
MHC ligands were isolated from tumour and autologous normal tissue. Rel-
ative quantification was carried out for both specimens and the correlation
between the quantitative data was determined. B, Modification strategy
for MHC ligands: Tumour derived ligands were modified with heavy dNIC
reagent, normal tissue with the light form. Sequence analysis was carried
out individually for tumour and normal samples, K* indicates a guanidi-
nated lysine side chain; for ratio analysis both samples were mixed in a total
peptide ratio of 1:1. C, dNIC modification reagent with X representing the
site of stable isotope labeling.
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Figure 6.2.: Peptide ratio analysis and sequence identification. A, For estimation of me-
thodical deviations a mix of six synthetic peptides was modified with the
dNIC strategy using either heavy or light dNIC in two independent experi-
ments. Heavy and light samples were mixed in a total peptide ratio of 0.8:1
and 1:1. Actual peptide ratios were determined by mass spectrometry, mean
and standard deviation are stated. B-D, MHC ligands were isolated from
RCC100 tumour and normal tissue and subsequently labeled differentially
with heavy respectively light dNIC. Ratio determination of differentially la-
beled ALASHLIEA was done in MS mode (B). MS/MS fragment spectra (C
and D) were used for sequence identification.
Fragmentation experiments were carried out separately for each tumor and
normal tissue (Fig. 6.1-B, bottom panel). Thus an unambiguous allocation to
tumor or normal tissue was possible for each peptide signal, even in the case
of peptides for which the corresponding sequence could not be determined. The
separate analysis of tumour and normal tissue also allowed the exclusion of singlet
signals, which occurred due to incomplete modification with dNIC, from further
analysis. Quantitative information was linked to sequence information by peptide
individual features combining mass, charge state and retention time. In order to
estimate the intrinsic methodological error, this quantification strategy was also
applied to synthetic peptide pools, resulting in a calculated error for peptide pairs
with high MS-signal intensity of less than 10% (Fig. 6.2-A).
6.4.2. mRNA vs HLA peptide: quantitative comparisons
In our study, this relative mRNA and HLA peptide quantification strategy was
extended to three RCC samples sharing two HLA-alleles: RCC099 (HLA-A*02,
-A*03, -B*27, -B*57), RCC100 (HLA-A*02, -A*03, -B*07, -B*18) and RCC110
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(HLA-A*02, -A*68, -B*18, -B*27). Tab. 6.1 gives an overview of the identi-
fied mRNA and HLA peptide ratios, the number of identified sequences and the
peptides for which sequence information could be linked to its corresponding pre-
sentation ratios. In total, intensity ratios between tumour and normal tissue were
determined for 728 peptide pairs (Fig. 6.2-B), 363 peptides of which could be
sequenced (Fig. 6.2-C and D). 273 peptide sequences could be linked to a specific
mRNA allowing the evaluation of a possible correlation between differences in
gene expression and HLA peptide presentation (Supplementary Tab. A.2).
Table 6.1.: Absolute numbers of evaluated mRNA ratios, HLA ligand ratios and peptide
sequences identified in this study. In the last column for all RCCs the number
of successful allocations of peptide sequences to the corresponding HLA ligand
ratios and mRNA ratios is given.
source mRNA
ratios
HLA
ligand
ratios
identified
peptide
sequences
allocated sequence,
peptide and mRNA
ratios
RCC099 18976 452 213 166
RCC100 24485 142 59 43
RCC110 26571 134 91 64
total 70032 728 363 273
In order to be able to combine the HLA-mRNA comparisons of all three RCCs
datasets, relative mRNA expression ratios and HLA peptide presentation levels
had to be normalised individually for each analyzed tissue pair (Fig. 6.3-A). To
do so, histograms of logarithmized HLA peptide presentation levels were plot-
ted and subsequently fitted assuming a Gaussian distribution. Each fitted HLA
histogram plot had its maximum near 0, representing a 1:1 ratio of presentation
on tumour and normal tissue. To take experimental inaccuracies into account
regarding the mixing of HLA peptides from each tumour and normal tissue pair,
the HLA presentation ratios were normalised such that the maxima of their fit-
ted histogram plots were located at 0. Normalised HLA peptide presentation
data of all three RCCs were cumulated and Gaussian fitted in order to determine
the presentation level representing the 5% highest over- or under-presentation
(xTOP5%, Fig. 6.3-B). An analogue normalisation and assessment of the xTOP5%
was carried out for the mRNA expression data.
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Figure 6.3.: Normalization of quantitative mRNA and MHC ligand data. mRNA ratios
(left panels) and MHC ligand ratios (right panels) between tumour and nor-
mal tissue were logarithmized, frequency counts were made with bin sizes
from 0.3 to 0.7. The bin sizes were chosen so that the Gaussian fit re-
sulted in the best R2-values. Using these Gaussian fit functions, the mean
value (xc) of each data set was calculated. Panel A, shows data sorted for
RCC099, RCC100, and RCC110. All data were normalised to xc=0. B, The
margins of relative gene transcript expression representing the 5% strongest
over/ under-expression (xTOP5%) were calculated as follows: Normalised
mRNA data for all RCCs were cumulated and Gaussian fitted, the area
under this curve was calculated and the x-values corresponding to 5% (for
under-presentation) and 95% (for over-presentation) of the area were deter-
mined. xTOP5% of the HLA ligandome ratios were calculated similarily.
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Finally, normalised mRNA ratios were plotted against their corresponding nor-
malised HLA presentation ratio Fig. 6.4) and the Spearman Rank correlation
coefficient was calculated at R = 0.32, showing an even weaker correlation of
transcriptome to HLA ligandome than the correlation of transcriptome to pro-
teome (R = 0.45) [4]. For qualitative data analysis and simplified data discussion
Fig. 6.4 was divided into nine areas by the TOP5%margins of mRNA and peptide
ratios as indicated by the dashed lines Fig. 6.3-B).
Figure 6.4.: Scatter plot representation of the correlation between relative mRNA ex-
pression and relative MHC ligand presentation. The 2log of the mRNA and
MHC ligand ratios of tumour vs. normal tissue were calculated and plotted
for 273 pairs of mRNA and MHC ligand ratios. Linear regression is shown
as a solid line and the Spearman Rank correlation coefficient was calculated.
Dashed lines designate the margins for the 5% of mRNA (x = ± 1.3) and
peptide (y = ± 1.5) specimens with the highest under- and over-expression
respectively presentation. Thus, the plot is divided into 9 areas (see insert).
Selected loci are highlighted.
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6.4.3. HLA ligand pools derived from tumour and normal
tissue
For approximately 75% of all identified HLA ligands we could not detect signifi-
cant changes neither in their HLA presentation ratio nor in their corresponding
mRNA expression levels (Fig. 6.4, area V). Regarding mRNA expression this
might have been expected as it indicates on a transcriptional basis that the tu-
mour tissue still resembles its corresponding normal tissue. As to the HLA level
this is more surprising as gene chip analysis shows upregulation of interferon
gamma inducible proteins in the antigen processing machinery (Tab. 6.2).
Table 6.2.: Gene Chip analysis of gene transcripts involved in antigen processing. Analy-
sis comprised constitutive proteasomal subunits (PSMB1, 2 and 5), immuno-
proteasomal subunits (LMP7, 2 and MECL1), subunits of the immunopro-
teasomal regulator PA28 (PSME1-3), proteins of the HLA peptide loading
complex (TAP1 and 2, tapasin, calreticulin, calnexin and PDIA3), HLA class
I and II (HLA-A, -B, -C, -DR, -DP and -DQ), the endoplasmic reticulum
aminopeptidase associated with antigen processing (ERAAP) and proteins of
the SEC61 translocon which can be involved in peptide export from the ER.
Proteins inducible by interferon gamma are highlighted in bold.
Gene
Symbol Gene Title
RCC099
2log
mRNA
ratio
RCC100
2log
mRNA
ratio
RCC110
2log
mRNA
ratio
PSMB1 proteasome subunit beta 1 0.4 0.4 0.6
PSMB2 proteasome subunit beta 2 0.3 0.1 0.5
PSMB5 proteasome subunit beta 5 0.0 -0.2 0.2
LMP7 proteasome subunit beta 8 2.5 2.1 2.5
LMP2 proteasome subunit beta 9 1.8 1.7 3.5
MECL1 proteasome subunit beta 10 1.3 0.8 2.4
PSME1 proteasome activator subunit 1 0.2 0.2 0.7
PSME2 proteasome activator subunit 2 0.1 -0.3 1.4
PSME3 proteasome activator subunit 3 -0.1 -0.9 -0.6
CALR calreticulin 0.0 0.0 0.1
CANX calnexin 1.5 0.8 2.0
TAP1 transp. 1, ATP-bind.cass. 1.5 1.8 2.6
TAP2 transp. 2, ATP-bind.cass. 0.3 1.1 2.6
TAPBP Tapasin 1.4 1.1 1.6
HLA-A m.histocomp.complex I A 0.8 0.3 1.1
HLA-B m.histocomp.complex I B 1.3 0.8 2.1
HLA-C m.histocomp.complex I C 0.9 0.5 1.6
HLA-DP m.histocomp.complex II DP 1.4 0.6 2.5
HLA-DQ m.histocomp.complex II DQ 2.0 1.3 3.5
continued on next page
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Table 6.2 – contiuned
Gene
Symbol Gene Title
RCC099
2log
mRNA
ratio
RCC100
2log
mRNA
ratio
RCC110
2log
mRNA
ratio
HLA-DR m.histocomp.complex II DR 1.1 0.6 2.4
PDIA3 prot. disulfide isomerase A3 0.2 0.1 0.7
SEC61A1 Sec61 alpha 1 subunit 0.6 -0.5 0.5
SEC61A2 Sec61 alpha 1 subunit 0.0 -0.9 -1.2
SEC61B Sec61 alpha 1 subunit -0.1 -0.2 0.6
SEC61G Sec61 alpha 1 subunit 1.9 0.9 1.2
ERAP1 ER aminopep.assoc.AG.process. 0.7 0.7 0.8
In all tumour tissues analysed, immunoproteasomal subunits were clearly over-
expressed (up to 11-fold for LMP2 in RCC110). Although immunoproteasomal
activity is thought to change the HLA bound peptide repertoire [31] and although
it has been shown that both normal and immunoproteasomes are capable of de-
stroying each other’s epitopes [32, 33], we could not detect major differences in
the HLA ligandome of tumour versus normal tissue.
6.4.4. Multiple HLA ligands from one source protein
Tab. 6.3 lists mRNA and HLA presentation ratios of proteins which are high-
lighted in Fig. 6.4 and discussed below. Analysis of individual peptide pairs
indicated tumour associated changes in HLA presentation ratios (Tab. 6.4).
Table 6.3.: Diversity of peptide and RNA ratios highlighted by 11 examples. Genes
were sorted according to the area classification introduced in Fig. 6.4.
HLA ligand ratios and mRNA ratios were calculated between tumour
and autologous normal tissue. Gene Symbol and Title can be found at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene.
Area GeneSymbol Gene Title Sequence
2log
HLA
ligand
ratio
2log
mRNA
ratio
Source
II PLXNB2 plexin B2 TYTDRVFFL 9.58 −0.50 RCC110
ADFP adip.diff.-related prot. VRLGSLSTK 4.22 −0.08 RCC099
CD24 CD24 antigen RAMVARLGL 5.32 0.71 RCC100
III ANXA4 annexin A4 DEVKFLTV 3.52 1.41 RCC100
ADFP adip.diff.-related prot. SLLTSSKGQLQK 2.32 1.71 RCC100
ANXA4 annexin A4 DEVKFLTV 1.95 2.20 RCC110
HMOX1 heme oxygenase 1 KIAQKALDL 2.30 3.70 RCC110
VI ADFP adip.diff.-related prot. VRLGSLSTK −0.81 3.60 RCC110
VII UMOD uromodulin RAFSSLGLLK −5.49 −7.19 RCC100
VIII UGT1A6 UDP glucuron.transfer.1-A6 ALGKIPQTV −4.55 1.12 RCC099
IX PIGR polymeric Ig receptor FSVVINQLR −4.73 1.72 RCC099
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Table 6.4.: Multiple peptides from one source protein identified in one tumour and normal
tissue pair. HLA presentation ratios were calculated between a corresponding
tumour and normal tissue pair. Peptides which were identified also in N-
terminally trimmed forms are marked in bold. Gene Symbol and Title can
be found at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene.
Gene
Symbol Gene Title Sequence
2log
HLA
ligand
ratio
2log
mRNA
ratio
HLA
restrict.
Source
ALDOA aldolase A ALSDHHIYL 3.38 2.72 A02 RCC099
ALDOA aldolase A RTVPPAVTGITF 2.63 2.72 B57 RCC099
CCNI cyclin I LLDRFLATV −0.93 −0.18 A02 RCC099
CCNI cyclin I SLLDRFLATV 0.01 −0.18 A02 RCC099
EEF2 euk.transl.elongat.fact. 2 ILTDITKGV −0.91 0.42 A02 RCC099
EEF2 euk.transl.elongat.fact. 2 RRWLPAGDAL 0.37 0.42 B27 RCC099
FLNA filamin A GTHKVTVLF 0.06 1.02 B57 RCC099
FLNA filamin A GTHTVSVKY 1.01 1.02 B57 RCC099
FLNA filamin A GVHTVHVTF −0.24 1.02 B57 RCC099
GNB2L1 guan.nucleot.bind.prot. b2-L 1 KTIKLWNTL 1.06 1.02 A02 RCC099
GNB2L1 guan.nucleot.bind.prot. b2-L 1 YTDNLVRVW 0.24 1.02 B57 RCC099
HLA-A/G m.histocomp.complex I A/G VMAPRTLLL −0.23 1.60 A02 RCC110
HLA-A m.histocomp.complex I A VMAPRTLVL 0.40 1.60 A02 RCC110
HLA-B m.histocomp.complex I B AAQITQRKW 1.84 1.29 B57 RCC099
HLA-B m.histocomp.complex I B TAAQITQRKW 1.61 1.29 B57 RCC099
HNRPM heterogen.nucl.rib.prot. M KSRGIGTVTF −0.74 0.47 B57 RCC099
HNRPM heterogen.nucl.rib.prot. M LLFDRPMHV 0.43 0.47 A02 RCC099
LMNA lamin A/C KAGQVVTIW 0.29 0.07 B57 RCC099
LMNA lamin A/C MRARMQQQL −0.60 0.07 B27 RCC099
PPP1CA/B/C prot. phosphatase 1 alpha/b/c KYPENFFLL 6.20 0.35 C RCC110
PPP1CA prot. phosphatase 1 alpha SIIGRLLEV 0.47 0.35 A02 RCC110
RBBP4/7 retinoblastoma bind.prot. 4/7 HTAKISDFSW −0.13 0.14 B57 RCC099
RBBP4/7 retinoblastoma bind.prot. 4/7 TAKISDFSW 0.43 0.14 B57 RCC099
RPS16 ribosomal prot. S16 ISKALVAYY 1.12 0.82 B57 RCC099
RPS16 ribosomal prot. S16 KLLEPVLLL 1.09 0.82 A02 RCC099
SCD stearoyl-CoA desaturase ARLPLRLFL 3.96 1.52 B27 RCC099
SCD stearoyl-CoA desaturase ITAGAHRLW 1.50 1.52 B57 RCC099
SSR1 signal sequence receptor VLFRGGPRGLLAVA −2.00 0.70 A02 RCC110
SSR1 signal sequence receptor VLFRGGPRGSLAVA −2.42 0.70 A02 RCC110
SSR1 signal sequence receptor VLFRGGPRGLLAVA 0.89 0.37 A02 RCC099
SSR1 signal sequence receptor VLFRGGPRGSLAVA −1.35 0.37 A02 RCC099
STAT3 s.transd.activ.transcript.3 EERIVELF 0.10 −0.80 B18 RCC110
STAT3 s.transd.activ.transcript.3 EELQQKVSY 0.38 −0.80 B18 RCC110
TMED10 transmemb.traff.prot. 10 FLLGPRLVLA −0.91 −0.08 A02 RCC099
TMED10 transmemb.traff.prot. 10 LLGPRLVLA 1.49 −0.08 A02 RCC099
TMEM66 transmembrane prot. 66 KGWDGYDVQW 0.39 0.72 B57 RCC099
TMEM66 transmembrane prot. 66 RRLDPIPQL −3.55 0.72 B27 RCC099
TNS1 tensin 1 HAKVLEFGW 0.81 0.32 B57 RCC099
TNS1 tensin 1 FLIETGPRGV 0.45 0.32 A02 RCC099
VIM vimentin ARLDLERKV 1.13 1.82 B27 RCC099
VIM vimentin NLAEDIMRL 0.27 1.82 A02 RCC099
VIM vimentin NYIDKVRFL 1.02 1.82 C RCC099
For 20% of all proteins with several identified HLA ligands, HLA presentation
ratios differed between the individual peptides more than 4-fold. For four pep-
tides, N-terminally trimmed forms were identified (CCNI, HLA-B, RBBP4 and
TMED10). The presentation ratios of these peptide variants changed up to 5-fold.
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This might indicate tumour associated changes in antigen processing [34] and es-
pecially alterations in trimming by the endoplasmic reticulum aminopeptidase
associated with antigen processing (ERAAP) [35].
6.4.5. HLA ligands identified only in one tissue specimen
Several HLA ligands were found to be presented exclusively on one tissue speci-
men (Tab. 6.5), although mRNA ratios changed only marginally in most cases.
Peptides derived from UDP glucuronosyltransferase 1 family, polypeptide A6
(UGT1A6), uromodulin (UMOD) and from the polymeric Ig receptor (PIGR)
were presented uniquely on normal tissue (Fig. 6.4, areas VII-IX); peptides de-
rived from annexin A4 (ANXA4), plexin B2 (PLXNB2), decycling heme oxy-
genase 1 (HMOX1) and ADFP, as well as from the small cell lung carcinoma
cluster 4 antigen CD24, were presented solely on tumour tissue (Fig. 6.4, areas
II and III). Peptides presented specifically on one tissue specimen might reflect
both differences in antigen processing between one tumour/ normal tissue pair
and patient specific variations: identical peptides from ANXA4 and ADFP were
identified in different tumours but without being presented uniquely.
Table 6.5.: HLA ligands exclusively identified in either tumour or normal tis-
sue. Values were calculated against background and sorted ac-
cording to their HLA presentation ratio between tumour and autol-
ogous normal tissue. Gene Symbol and Title can be found at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene.
Gene
Symbol Gene Title Sequence
2log
HLA
ligand
ratio
2log
mRNA
ratio
HLA
restrict.
Source
PLXNB2 plexin B2 TYTDRVFFL 9.58 0.00 C RCC110
PPP1CA/B/C prot. phosphatase 1 alpha/b/c KYPENFFLL 6.20 0.35 C RCC110
CD24 CD24 antigen RAMVARLGL 5.32 0.71 n/a RCC100
SLC17A3 solute carrier family 17, member 3 ARYGIALVL 4.86 0.62 B27 RCC099
ADFP adip.diff.-related prot. VRLGSLSTK 4.22 −0.08 B27 RCC099
MAT1A/2A met.adenosyltransf. Ia/Iia RRVLVQVSY 4.08 0.50 B27 RCC110
SCD stearoyl-CoA desaturase ARLPLRLFL 3.96 1.52 B27 RCC099
ANXA4 annexin A4 DEVKFLTV 3.52 1.41 B18 RCC100
POLR2C polymerase II pol.pep.C,33kDa KLSDLQTQL 3.52 0.10 A02 RCC110
HMOX1 heme oxygenase 1 KIAQKALDL 2.30 3.70 A02 RCC110
CXCL14 chemokine ligand 14 RLLAAALLL 2.09 0.47 A02 RCC099
OGG1 8-oxoguan.DNA glycosyl. VLADQVWTL −3.07 0.17 A02 RCC099
MYL6 myosin, light pol.pep. 6 FVRHILSG −3.45 0.12 n/a RCC099
GNB5 guan.nucleot.bind.prot. b5 ILFGHENRV −3.72 −0.78 A02 RCC099
HLA-B/C m.histocomp.complex I B/C DTAAQITQR −4.41 1.58 A68 RCC110
RPL15 ribosomal prot. L15 EVILIDPFHK −4.51 −0.75 A68 RCC110
UGT1A6 UDP glucuron.transfer.1-A6 ALGKIPQTV −4.55 1.12 A02 RCC099
PIGR polymeric Ig receptor FSVVINQLR −4.73 1.72 A03 RCC099
UMOD uromodulin RAFSSLGLLK −5.49 −7.19 A03 RCC100
MYO1C myosin IC FLDHVRTSF −5.69 0.36 A03 RCC100
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For 60% of all source proteins in the group of the top 5% over-presented pep-
tides (Fig. 6.4, area I-III), tumour association has been reported and this number
actually increases to nearly 80% for peptides presented exclusively on tumour tis-
sue (Supplementary Tab. A.5). As far as tumour immunotherapy is concerned,
these uniquely presented peptides are excellent targets but they also underline
the importance of patient specific adaptations in such an approach [9].
6.4.6. HLA ligands without corresponding mRNA
The fact that there are differences between the transcriptome and HLA ligandome
becomes even more obvious when one considers that several peptides could be
identified for which no mRNA was detectable in the respective tissues (Tab.
6.6). In RCC100, for example, the mRNA for the EH-domain containing protein
2 (EHD2) was detectable neither in tumour nor in normal tissue. Nevertheless,
the EHD2-derived peptide ALASHLIEA was identified on tumour as well as on
normal tissue (Fig. 6.2-B to D). These HLA ligands are presumably derived from
long-lived proteins from which the mRNA has already been degraded [36], or
represent mutated peptides for which the correct allocation to the correct mRNA
was not possible any more.
Table 6.6.: HLA ligands identified from RCC099, RCC100 and RCC110 with no de-
tectable mRNA in tumour and/ or normal tissue.Values were calculated
against background; mRNA detection categorized by GCOS software in
present (P), marginal present (M) or absent (A). Gene Symbol and Title
can be found at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene.
Gene
Symbol Gene Title Sequence
2log
HLA
ligand
ratio
2log
mRNA
ratio
Detect.
mRNA
Tumor
vs.
Normal
Source
CLIC5 Cl- intracell.chan. 5 NLLPKLHVV 3.00 -2.75 A / P RCC099
ACVRL1 activin A receptor type II-L 1 SPRKGLLML −0.65 3.01 P / A RCC100
EHD2 EH-domain containing 2 ALASHLIEA 1.07 3.32 P / A RCC099
EHD2 EH-domain containing 2 ALASHLIEA 1.82 3.41 P / A RCC100
LSP1 lymphocyte-specific prot. 1 KLIDRTESL 0.39 1.90 P / A RCC110
PLVAP plasmalem.vesic.assocc.prot. KVKTLEVEI 0.50 0.52 P / A RCC099
SRXN1 sulfiredoxin 1 homolog TLSDLRVYL 0.43 0.32 P / M RCC099
WDR78 WD repeat domain 78 TSVVYDVAW 0.32 0.52 P / A RCC099
ATOX1 ATX1 antiox.prot. 1 homol. RVLNKLGGVK −1.01 n/a A / A RCC100
CCDC21 coiled-coil dom.cont. 21 RLQMEQMQL −1.14 n/a A / A RCC100
CYHR1 cysteine/histidine-rich 1 HLGPEGRSV −1.21 n/a M / A RCC099
DHX38 DEAH box pol.pep. 38 VLFGLLREV 0.81 n/a A / A RCC099
FLJ32206 hypothetical protein FLJ32206 GSHFISHLS −0.89 n/a A / A RCC099
GBP4 guanylate binding prot. 4 KRLGTLVVTY −0.60 n/a A / A RCC099
KIAA1305 KIAA1305 TLADIIARL −0.10 n/a A / A RCC099
RASL11A RAS-L, family 11, member A YLLPKDIKL −0.37 n/a A / A RCC099
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6.4.7. HLA ligands identified in several patient samples
Peptides identified in more than one patient allowed the evaluation of patient
specific variations in mRNA expression ratios and HLA presentation ratios (Sup-
plementary Tab. A.4). More than 12% of the HLA presented peptides exhibit a
change in the presentation level in different patients that is greater than 4-fold
and includes many of the significantly over- or under-presented peptides. The
peptide VRLGSLSTK derived from the tumour associated antigen adipophilin
(ADFP) [37] is under-presented on RCC110 but mRNA levels are clearly up-
regulated in the tumour tissue (Fig. 6.4, area VI). Yet the same peptide is
presented exclusively on RCC099 although the mRNA levels of ADFP remain
unchanged between tumour and normal tissue (Fig. 6.4, area II). Another dif-
ferent ADFP-derived peptide (SLLTSSKGQLQK) is presented on RCC100 by
HLA-A*03 with an mRNA ratio that matches its HLA presentation ratio (Fig.
6.4, area III). HLA peptide ratios exhibit stronger patient individual changes
than mRNA ratios might indicate. This is due to the fact that changes in the
HLA ligandome reflect not only mRNA ratio alterations, but also changes in the
degradome, which to some extent is conserved in the HLA ligandome [38].
6.5. Discussion
6.5.1. Stable isotope labeling of ex vivo isolated MHC
molecules
Stable isotope labeling is the method of choice for protein quantification and
is widely used in proteomics. For ex vivo prepared MHC peptide samples the
standard isotope labeling methods are either not feasible or are not applicable
to the majority of MHC bound peptides due to their amino acid composition.
To overcome these impediments we have established the differential N-terminal
isotope coding (dNIC) strategy; to our knowledge this is the first study using
an isotope-based quantitative MS-method for a large scale ex vivo comparison
of the HLA ligandome of two tissue specimen. Patient samples were chosen for
analysis according to two criteria: Categorization of the RCCs into the clear cell
type by histology and the broadest possible overlap of the MHC alleles between
the different patients. Tumour samples were taken from its central area, control
samples from renal cortex assessed as ‘normal’ and as distant as possible from
the tumour.
6.5.2. Individual variances in antigen processing
In the three RCC tissue pairs analysed in this study, each sample displays to
some extent individual features regarding antigen processing. Apart from HLA
mismatches, the activity of enzymes involved in antigen processing also varied.
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We found, for example, varying mRNA levels of immunoproteasome subunits in
the different samples (Tab. 6.2). All individual variances in antigen process-
ing summarize at the level of the MHC ligandome. For example, we detected
ADFP-derived peptides ranging in their presentation from exclusive presentation
on tumour tissue to equal presentation on tumour and normal tissue. These in-
dividual variances in MHC:peptide levels are one of the reasons why for example
tumour vaccination studies can vary extremely in their outcome.
6.5.3. Four major hypotheses
The HLA ligandome is more complex in its variations than mRNA but it is
of far greater immunological relevance; it reflects a particularly complex aspect
of systems biology that is exemplified here by a naturally occurring change in
tissue (tumour genesis). The long and complex path from mRNA transcription
to HLA presentation is reflected in our observation of a generally weak mRNA-
HLA-ligand correlation. Four hypotheses can thus be deduced from Fig. 6.4:
First, HLA ligand generation implies that one mRNA species is able to account
for several different peptides which differ in their presentation ratios and which
are potentially presented by different HLA allotypes (Tab. 6.4).
Second, for more than 75% of all identified HLA ligands, we could detect no ma-
jor differences in the HLA peptide repertoire [39] (Fig. 6.4, areas IV-VI), although
immunoproteasomes were up-regulated on a transcriptional level. Assuming tran-
scription of immunoproteasomal mRNA and activity of the immunoproteasomal
subunits, this would limit the implication of the proteasome composition on the
HLA ligandome in our ex vivo setting [36].
Third, several HLA ligands could be identified although no corresponding
mRNA was detectable. In these cases HLA ligands might be derived either from
long-lived proteins or from mutated proteins for which the correct peptide-mRNA
allocation was not possible.
Fourth, strong differences in HLA presentation without mRNA changes (Fig.
6.4, area II and VIII) are due to altered peptide generation which can be triggered
by several scenarios [40]: Higher translation efficiency leads to a larger number
of defective ribosomal products (DRiPs) which are known to be a major source
for HLA ligands [41]. The amount of DRiPs from certain source mRNAs might
also be elevated due to mutations in some of the mRNAs, distorting transcription
and thus increasing DRiP formation [17]. On the other hand, enhanced protein
turnover increases the total amount of substrates for proteases such as the pro-
teasome. Moreover, proteolytic activity in the cytosol or ER can vary for some
peptides when tumour and normal tissue are compared.
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6.5.4. Context and limitations of the chosen experimental
setting
The exact molecular mechanism responsible for alterations in the level of our ex
vivo isolated MHC:peptide complex levels could not be deduced. This is due to
the fact that these alterations are most probably not caused by one single change
in the peptide generation pathway or in the antigen processing machinery but
are rather complex, multifactorial changes established during tumour genesis.
Defining molecular mechanisms in a complex interaction network such as the
antigen processing machinery is in many cases not possible. In a recent study by
Milner et al. [38], the turnover kinetics of MHC pepides was determined in a cell
culture setting. Not even in this plain setting could the ‘simple’ discrimination
between short-lived proteins and DRiPs clearly be made. In these experiments
the only strong indication for MHC:peptide complexes derived from DRiPs was
a biphasic turnover kinetics in pulse chase experiments using incorporation of
isotope labeled amino acids.
In 1999 and 2003 the first quantitative experiments were carried out to compare
the yeast transcriptome with its proteome [2, 4]. Here, the authors showed only a
weak correlation between transcriptome and proteome (R = 0.45). In our study,
the correlation between transcriptome and HLA ligandome was even weaker (R
= 0.32) which might reflect that the generation of HLA ligands is a pathway
that begins only after mRNA transcription. At the present time, large-scale
data regarding the extent of correlation between proteome and HLA ligandome
are not available. Taking into consideration that a major portion of the HLA
ligandome is supposed to be derived from the transient proteome – that is short-
lived proteins and DRiPs – one could expect an even weaker correlation between
the HLA ligandome and the well quantifiable permanent proteome.
6.6. Summary and outlook
mRNA-based identification of tumour associated antigens is well established and
widely used. As we could show in this study that mRNA levels alone do not
adequately reflect cellular reality at the HLA level, our results have a direct im-
pact on T-cell based immunotherapy. We conclude that for the rational selection
of appropriate tumour specific T-cell targets, quantitative HLA ligand analysis
contributes greatly to the benefits of quantitative transcriptome analysis; a com-
bination of both strategies enables the identification of new target candidates and
helps to avoid false positive targets. In summary, comparing changes in the tran-
scriptome to those in the HLA ligandome of renal tumour versus normal tissue
without further reflection is like comparing apples to oranges. Conveying this
finding to RNA based vaccination, which was shown to be a potent vaccine also
against cancer [42], one cannot take for granted that every mRNA leads to actual
75
Results III: mRNA vs. MHC lingands
peptide presentation on HLA molecules. Thus for each mRNA that is designed
for vaccination, intensive individual in vitro tests are advisable. Our findings pro-
vide insight into tumour associated changes in translation efficiency and protein
turnover and provide immunologically relevant tumour information to a depth
that could not be achieved before with hitherto existing standard techniques.
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7.1. Summary
The vascular endothelial growth factor A (VEGF) is involved in various physi-
ological processes, such as angiogenesis or wound healing, but is also crucial in
pathological events such as tumor growth. Thus, clinical anti-VEGF treatments
have been developed which could already demonstrate beneficial effects for can-
cer patients. In this article we describe the first VEGF-derived CD8+ T cell
epitope. The natural HLA ligand SRFGGAVVR was identified by differential
mass spectrometry in two primary renal cell carcinomas (RCC) and was signif-
icantly over-presented on both tumor tissues. SRFGGAVVR is derived from a
cryptic translated region of VEGF presumably by initiation of translation at the
non-classical start codon CUG499. SRFGGAVVR specific T cells were generated
in vitro using peptide loaded dendritic cells or artificial antigen presenting cells.
SRFGGAVVR specific CD8+ T cells – identified by HLA tetramer analysis after
in vitro stimulation – were fully functional T-effector cells, which were able to
secrete IFN-gamma upon stimulation and killed tumor cells in vitro. Addition-
ally, we have quantitatively analyzed VEGF mRNA and protein levels in RCC
tumor and normal tissue samples by gene chip analysis, qRT-PCR, in situ hy-
bridization, and bead based immunoassay. In the future, T cells directed against
VEGF as a tumor associated antigen may represent a possible way of combin-
ing peptide-based anti-VEGF immunotherapy with already existent anti-VEGF
cancer therapies.
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7.2. Introduction
The vascular endothelial growth factor A (VEGF), also known as vascular per-
meability factor, is a mitogen with high specificity for vascular endothelial cells.
Its biological activities range from angiogenesis [1, 2], endothelial cell growth [3],
and expression of anti-apoptotic proteins like Bcl-2 in endothelial cells [4] to in-
duction of vascular leakage [5] by activation of MMP activity [6] . Thus, VEGF
is crucial in various physiological and pathological states such as the formation
of new blood vessels, wound healing, and tumor growth (for reviews see Refs. [7]
and [8]).
The human vegf gene is organized in eight exons which can be spliced alter-
natively into four major isoforms (VEGF121, VEGF165, VEGF189 and VEGF206)
[9, 10] and into two minor isoforms (VEGF145 and VEGF183) [7]. With increas-
ing length of the VEGF isoform, the ability to bind to heparin also increases.
VEGF189 and VEGF206 are highly basic and almost completely bound to the ex-
tracellular matrix. VEGF121 is acidic, does not bind heparin and thus is freely
diffusible [11]. VEGF165 has intermediate properties regarding its secretion. As
the mitogenic potency of VEGF decreases upon loss of the heparin binding region,
VEGF165 is twice as active as VEGF121 [12] and thus has optimal bioavailability
and biological activity [13–15]. It has been demonstrated that translation of the
VEGF mRNA may not only be initiated at its presumed start codon at nucleotide
1039 (AUG1039) but also at an in–frame CUG codon at nucleotide 499 (CUG499).
Utilization of CUG499 has been described for VEGF121, VEGF165, and VEGF189.
Although the exact extent of CUG499 usage differs between reports [16, 17], one
can assume that transcription of VEGF121 and VEGF165 starts at CUG499 in
more than 50% of the cases.
VEGF is in the spotlight of cancer therapy as its presence is crucial for neo-
angiogenesis. A tumor growing beyond a volume of 1-2 mm3 requires its own
blood vessels for a sufficient supply of nutrition and oxygen [18]. Therefore sev-
eral strategies have been developed to hamper tumor vascularization by tackling
VEGF signaling or levels of secreted VEGF. Several small molecules that inter-
fere with VEGF signaling are being incorporated at present in clinical phase II
trials. VEGF binds to two receptor tyrosine kinases (VEGFR-1 and VEGFR-
2) present at the surface of most blood endothelial cells. VEGF binding leads
to receptor dimerization, subsequent autophosphorylation, and activation of in-
tracellular signaling cascades [19]. VEGFR-1 expressing cells can be selectively
killed by a recombinant fusion construct of VEGF121 with the toxin gelonin [20].
VEGFR-2, the major mediator of the mitogenic, angiogenic, and permeability
enhancing effects of VEGF [7], can be blocked by several kinase inhibitors such
as sunitinib, sorafenib, [21, 22] KRN951 [23] and AMG706 [24]. In order to pre-
vent VEGF from binding to its receptors, the monoclonal antibody bevacizumab
has been developed. Bevacizumab is a humanized neutralizing VEGF antibody
[25] that binds all biologically active forms of VEGF. In 2004 it was approved
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by the FDA e.g. for treatment of metastatic colorectal cancer. To summarize,
various anti-VEGF based cancer therapies have been developed, several of which
have a substantial clinical impact.
7.3. Materials and Methods
7.3.1. Materials
The HPLC reagents, trifluoroacetic acid, acetonitrile, formic acid, and HPLC
water were purchased from Merck (Darmstadt, Germany). Peptide modification
reagent O-Methyl isourea hemisulfate was purchased from Acros Organics (Geel,
Belgium), 1-([1H4/2D4] nicotinoyloxy)succinimide (light or heavy dNIC-NHS)
was synthesized as described elsewhere [26].
7.3.2. Elution of HLA presented peptides
HLA presented peptides were obtained by immune precipitation of HLAmolecules
from solid tissues using an adapted protocol [27]. One volume of 2x lysis buffer
containing PBS, 0.6% 3-[(3-Cholamidopropyl)-dimethylammonio]-2-hydroxy-
propanesulfonate (CHAPS) and complete protease inhibitor (Roche, Mannheim,
Germany) was added to shock frozen tissue samples. Subsequently, the samples
were homogenized using a blender and afterwards by a potter. One volume of
1x lysis buffer was added and the lysate was stirred for 1 h at 4℃A˙fter 4x 30
seconds of sonication, the sample was centrifuged at 3,000 g, 4℃ for 20 min and
afterwards at 150,000 g, 4℃ for 1 h to remove cell debris. Finally, the sample
was passed through a 0.2 µm filter (Sartorius, Göttingen, Germany). For im-
mune precipitation this lysate was applied for at least 12 h to a CNBr-activated
sepharose 4B column (GE Healthcare, Freiburg, Germany; 40 mg sepharose /
mg tissue) to which the HLA-A, -B and -C specific antibody W6/32 had been
coupled (1 mg antibody / mg tissue) as described by the manufacturer. After
binding, the column was rinsed with 250 ml PBS and subsequently with 500
ml ddH2O. For elution and dissociation of bound HLA-peptide complexes, the
column was shaken at least four times in one bed volume of 0.1% TFA for 20
min at room temperature. The four TFA-eluates were subsequently collected and
combined. Finally, the HLA presented peptides were isolated by ultrafiltration
through a centricon 10 kD cut-off membrane (Millipore, Schwalbach, Germany).
For LC-MS analysis samples were freeze-dried and resuspended in 0.1% formic
acid or 0.1% TFA for modification.
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7.3.3. Peptide modification and analysis
Modification of peptides was carried out as follows. Isolated and freeze-dried HLA
ligands were resuspended in 500 µl 0.1% TFA. Lysine side chains of peptides were
guanidinated at pH 11 at 65℃ for 10 min using 90 µl 2.5 M O-methyl isourea
hemisulfate. The reaction was halted adjusting the pH to 3 with formic acid
and peptides were desalted using Peptide Cleanup C18 Spin Tubes (Agilent,
Palo Alto, CA, USA) as described in the manual. Peptides were nicotinylated on
column for 15 min at room temperature using a 20 mM light or heavy dNIC-NHS
solution in 50 mM phosphate buffer pH = 8.5. Aminolysis of undesired Tyrosine-
dNIC esters was carried out by treatment with 500 µl 50% hydroxylamine for 10
min at room temperature. Subsequently, peptides were eluted using four times
50 µl of 50% acetonitrile, 1% formic acid. Peptide analysis was carried out as
described elsewhere [26] using an Ultimate HPLC system (Dionex, Sunnyvale,
CA, USA) with a gradient ranging from 15-55% solvent B within 170 minutes.
For quantification, tumor and normal samples were mixed in a total peptide
ratio of 1:1 and recorded in a single LC-MS experiment without fragmentation
using a hybrid quadrupol orthogonal acceleration time of flight MS/MS (Q-TOF,
Micromass, Manchester, UK), equipped with a micro-ESI source. For sequence
analysis tumor and normal samples were analysed separately in individual LC-
MS/MS experiments. Interpretation of MS/MS fragmentation spectra was done
as described elsewhere in detail [28].
7.3.4. Database searches
BLAST searches for SRFGGAVVR peptide sequence were performed using the
PAM30 matrix and an expect value of less than 1000
(http://www.ncbi.nlm.nih.gov/BLAST/). Protein versus protein searches (pblast)
were done in 245,584 sequences deposited in the swissprot database; all species
were included in the search. Translated protein versus nucleotide searches (tblastn)
were done for all species using the NCBI non-redundant database (4,934,654 se-
quences), EST sequences were excluded.
7.3.5. Histology and ISH
Cells expressing VEGF mRNA were detected by radioactive in situ hybridization
using single-stranded 35S-labeled RNA probes which were synthesized from hu-
man VEGF121 cloned into pBluescript II SK (Stratage, La Jolla, CA, USA). This
pBSK-hVEGF121 plasmid was generously provided by Georg Breier (Institute of
Pathology, Dresden, Germany). Pretreatment, hybridization, and washing pro-
cedures of 5 µm paraffin tissue sections were performed as described previously
[29]. Slide preparations were subjected to autoradiography, exposed for 3 weeks
at 4℃ and counterstained with hematoxylin-eosin.
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7.3.6. RT-PCR and qRT-PCR
RNA from cells was isolated using TRIzol reagent (Invitrogen, Karlsruhe, Ger-
many) according to the manufacturer’s recommendations. cDNA was synthesized
from 1 µg total RNA as described elsewhere [30]. Real-time quantitative PCR
(qRT-PCR) was performed using the ABI PRISM 7000 Sequence Detection Sys-
tem (Applied Biosystems, Darmstadt, Germany). SYBR Green PCR Master
Mix (Applied Biosystems, Darmstadt, Germany) was used for PCR amplifica-
tion and real-time detection of PCR products. Primers (biomers.net, Ulm, Ger-
many) specific for VEGF121 and VEGF165 were designed to have a melting tem-
perature of 60℃ (forward primer VEGF121: 5’-AACATCACCATGCAGATTA
TGC-3’, reverse primer VEGF121: 5’-GGCTTGTCACATTTTTCTTGTC-3’, for-
ward primer VEGF165: 5’-GTGAATGCAGACCAAAGAAAG-3’, reverse primer
VEGF165: 5’-TTTTTGCAGGAACATTTACACG-3’). 18S RNA was chosen as
a reference for normalizations (forward primer: 5’-CGGCTACCACATCCAA
GGAA-3’, reverse primer: 5’-GCTGGAATTACCGCGGCT-3’). PCR reactions
were carried out in 20 µl with 400 nM of each primer. All samples were amplified
in duplicate. Formation of undesired side products during PCR that contribute to
fluorescence was excluded by melting curve analysis after PCR. Expression differ-
ences between tumor and normal tissue samples for different genes were calculated
from PCR amplification curves by relative quantification using the comparative
threshold cycle (CT ) method (http://docs.appliedbiosystems.com/pebiodocs/
04303859.pdf). For absolute quantification standard curves of VEGF121 and
VEGF165 were prepared using plasmids coding for the respective VEGF. Linear
ranges of standard curves ranged from 10 fg to 10 ng of VEGF coding DNA.
In order to calculate absolute VEGF copy numbers per cell, CT values of the
VEGF standard curve were allocated to CT values of 18S RNA isolated from
2000 JY-BLCL cells.
7.3.7. Gene expression analysis by high-density
oligonucleotide microarrays
RNA isolation from tumor and autologous normal kidney specimens as well as
gene expression analysis by Affymetrix Human Genome U133 Plus 2.0 oligonu-
cleotide microarrays (Affymetrix, Santa Clara, CA, USA) were performed as de-
scribed previously [31]. Data were analysed with the GeneChip Operating Soft-
ware (GCOS, Affymetrix, Santa Clara, CA, USA). Pairwise comparisons between
tumor and autologous normal kidney were calculated using the respective nor-
mal array as baseline. Microarray data are available from the Gene Expression
Omnibus repository (www.ncbi.nih.gov/geo) with the accession no. GSE8050.
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7.3.8. VEGF protein quantification
Prior to the VEGF protein quantification, anti-VEGF beads were generated by
covalent coupling of the anti-VEGF capture antibody to xMAP COOH-Microspheres
(Luminex, Austin, TX, USA). To do so, we used a standard carbodiimide/
succinimide-based activation procedure where the bead carboxyls formed an
acylamino ester that reacted with the primary amines of the antibody, yield-
ing a stable amide bond. VEGF protein quantification was done as described
elsewhere [32]. In brief 40 to 80 mg of tissue or 1.107 X63-B*2705 cells were
pulverized in a Mikro-Dismembrator U (Braun/Satorius, Melsungen, Germany)
at full speed for 1 min Proteins were extracted with a 10-fold excess of solubi-
lization buffer: 50 mM Tris pH 7.5 / 400 mM NaCl / 1 mM CaCl2 / 1 mM
MgCl2 / 1% Triton X-100 / 1x complete protease inhibitor (Roche Diagnostics,
Mannheim, Germany). After 1 h incubation on ice, cellular debris was removed
by centrifugation at 16,000 g for 5 min The total amount of solubilized protein
was determined by Bradford assay. 10 µg of total solubilized protein were diluted
in 30 µl assay buffer (ELISA blocking reagent, Roche Diagnostics, Mannheim,
Germany) and mixed with 30 µl bead suspension in a 96-well filter plate. After an
overnight incubation at 4℃ in a plate shaker, unbound proteins were washed out
and beads were resuspended in 30 µl of biotinylated detection antibody (R&D
Systems, Wiesbaden, Germany). Excessive antibodies were removed after 2 h in-
cubation at room temperature and beads were washed twice. Bound biotinylated
antibodies were detected by R-phycoerythrin labeled streptavidin (S-PE). Before
the beads were analyzed in a Luminex100 IS (Luminex, Austin, TX, USA), they
were washed twice and finally resuspended in 100 µl assay buffer. At least 100
beads were analyzed and the median fluorescence intensities were taken as the
read out signals. As a standard, a dilution series of recombinant human VEGF165
(R&D Systems, Wiesbaden, Germany) from 0.3 to 300 pg/ml was used.
7.3.9. Transfection of eukaryotic cells
The mouse myeloma cell line X63-B2705 (X63-Ag8.653 transfected with human
HLA-B*2705 and human beta-2-microglobulin), generously provided by Elisa-
beth Weiss [33], was maintained in RPMI 1640 (C.C.Pro, Neustadt, Germany)
medium containing 10% FCS (Pan, Aidenbach, Germany) and supplemented
with 1 mg/ml G418S (Biochrom AG, Berlin, Germany). In the case of VEGF
transfected cell clones 0.4 mg/ml hygromycin (Roche, Mannheim, Germany) was
added. Stable VEGF transfectants were generated by electroporation of X63-
B2705 cells (260 V, 925 µF; Gene Pulser II, Bio-Rad, München, Germany) fol-
lowed by cloning using the limiting dilution method. For transfection a VEGF
construct containing the complete mRNA of VEGF165 including the ‘untrans-
lated’ region was used (VEGF-UTR165). Furthermore a VEGF165 construct
containing only the protein coding nucleotides from ATG1039 was used (VEGF-
86
Results IV: A cryptic VEGF T cell epitope
165). All VEGF constructs used for transfection experiments were generously
provided by Ben-Zion Levi (Technion Haifa, Israel).
7.3.10. Peptides, recombinant HLA molecules and
fluorescent tetramers
Peptides derived from VEGF (SRFGGAVVR) and HCMV pp65 (NLVPMVATV)
were synthesized by standard Fmoc chemistry using an Economy Peptide Synthe-
sizer EPS 221 (ABIMED, Langen, Germany). Peptides were checked by MALDI
and HPLC for identity and purity. Afterwards they were dissolved at 10 mg/ml
in DMSO (Merck, Darmstadt, Germany), diluted 1:10 in ddH2O, and aliquots
stored at –20℃B˙iotinylated recombinant HLA class I molecules and fluorescent
HLA tetramers for CD8+ T cell analysis were produced as described earlier [34].
Briefly, fluorescent tetramers were generated by co-incubating biotinylated HLA
monomers with streptavidin-PE or streptavidin-APC (Molecular Probes, Leiden,
the Netherlands) at a 4:1 molar ratio. The HLA-B*2705 tetramers used had a
cysteine-to-serine mutation in position 67.
7.3.11. In vitro stimulation of human CD8+T cells using
dendritic cells
PBMCs from healthy blood donors were isolated by standard Ficoll (PAA Labo-
ratories, Cölbe, Germany) centrifugation. PBMCs (12x107 cells/10 ml per flask)
were incubated in tissue culture flasks (CELLSTAR, Greiner Bio-One GmbH,
Frickenhausen, Germany) with serum-free X-VIVO 20 medium (Lonza, Verviers,
Belgium). After 2 hours of incubation at 37℃ non-adherent cells were removed
and adherent cells (12%-19% of the incubated cells) were cultured in T cell
culture medium supplemented with 20 ng/ml IL-4 (R&D Systems, Wiesbaden,
Germany), 100 ng/ml human recombinant GM-CSF (Leukine, Berlex Labora-
tories, Richmond, USA). T cell culture medium consisted of RPMI 1640, 25
mM HEPES, 2 mM L-glutamine (all from Invitrogen, Karlsruhe, Germany), 10%
heat-inactivated human AB serum (CC pro, Neustadt/W., Germany), 50 U/ml
penicillin, 50 µg/ml streptomycin and 20 µg/ml gentamycin (all from Lonza,
Verviers, Belgium). Cultures were fed with fresh medium and cytokines every
2 to 3 days. After 7 days, DCs were activated with 10 ng/ml human TNF-
α (R&D Systems, Wiesbaden, Germany) and 1 µg/ml human PGE-2 (Sigma-
Aldrich, Taufkirchen, Germany). Mature DCs were predominantly CD14high,
CD40high, CD80high, CD83high, CD86high and HLA-DRhigh (data not shown).
DCs were pulsed for 2 hours with 25 µg/ml of SRFGGAVVR peptide in T cell
culture medium and washed 3 times with PBS prior to subsequent usage. In vitro
stimulations were initiated in 24-well plates with 25x105 responder cells (autolo-
gous PBMCs, in vitro cultured for one week) plus 5x105 DCs per well in 1.5 ml
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of T cell culture medium. Cryopreserved, peptide–loaded irradiated autologous
PBMC were used for restimulation after priming with DCs.
7.3.12. In vitro stimulation of human CD8+ T cells using
artificial antigen presenting cells (aAPCs)
Untouched CD8+ T cells were MACS enriched by negative depletion of PBMCs
(Miltenyi Biotec, Bergisch Gladbach, Germany). Stimulations were initiated in
96-well plates with 1x106 responder cells in 250 µl of T cell culture medium com-
plemented with 5 ng/ml human IL-12 (PromoKine, Heidelberg, Germany) plus
2x105 microbeads coated with HLA-B*2705-SRFGGAVVR-complexes,
HLA-A*0201-NLVPMVATV-complexes plus anti-CD28 and anti-4-1BB antibod-
ies as costimulatory signals [35]. After 3 to 4 days of incubation at 37℃ fresh
medium with 80 U/ml human IL-2 (Chiron, Emeryville, CA) was added and cells
were incubated for another 3 to 4 days [36]. This stimulation cycle was performed
two or three times.
7.3.13. Tetramer staining
Tetramer analyses were performed with SRFGGAVVR-tetramer-APC,
NLVPMVATV-tetramer-PE, and antibody CD8-PerCP clone SK1 (BD Biosciences,
Heidelberg, Germany). Cells were incubated with the antibody at 4℃ for 20 min
in the dark, followed by 30 min incubation with fluorescent HLA tetramers in
the dark at room temperature. After resuspending with PBS containing 1%
paraformaldehyde, 0.5% BSA, 2mM EDTA and 0.02% NaN3, cells were analyzed
by flow cytometry on a four-color FACSCalibur cytometer (BD Biosciences, Hei-
delberg, Germany).
7.3.14. Intracellular IFN-γ staining
After two and three rounds of stimulation, autologous PBMCs were thawed,
washed twice in X-VIVO 20 medium (Lonza, Verviers, Belgium), resuspended
at 1x107 cells/ml in T cell culture medium, and cultured overnight. On the
next day, PBMCs pulsed with 10 µg/ml peptide were incubated with effector
cells in a ratio of 1:1 for 6 hours. Golgi-Stop (BD Biosciences, Heidelberg, Ger-
many) was added for the final 5 hours of incubation. Cells were analyzed us-
ing a Cytofix/Cytoperm Plus kit (BD Biosciences, Heidelberg, Germany) and
CD8-PerCP clone SK1 (BD Biosciences, Heidelberg, Germany), IFN-γ-PE (BD
Biosciences, Heidelberg, Germany). For negative controls, cells were incubated
either with irrelevant peptide or without peptide, respectively. Stimulation with
phorbol-12-myristate-13-acetate/Ionomycin was used as positive control. Cells
were analyzed on a four-color FACSCalibur (BD Biosciences, Heidelberg, Ger-
many).
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7.3.15. 51Cr-release assay
For the cytolytic assays, CD8+ T cells were stained with a SRFGGAVVR-PE
tetramer. Tetramer-positive cells were incubated with anti-PE MACS beads (Mil-
tenyi Biotec, Bergisch Gladbach, Germany) and then sorted using magnetic cell
separation according to the manufacturer’s recommendations. Cells were sub-
sequently cultured in the presence of 5x105 cells/ml irradiated fresh allogenic
PBMCs, 5x104 cells/ml irradiated LG2-EBV cells, 150 U/ml IL-2, and 0.5 µg/ml
PHA-L (Roche Diagnostics, Mannheim, Germany). Cells were further expanded
in T cell culture medium containing 150 U/ml IL-2. Target cells were labeled with
100 µCi Na2 51CrO4 (Hartmann Analytic, Braunschweig, Germany). Per well,
10000 target cells were used at different effector-to-target cell ratios in a standard
6 h 51Chromium release assay. Spontaneous (target cells in medium alone) and
maximal (target cells in 1% Triton X-100) 51Cr release was determined and %
specific lysis was calculated as follows: (cpm experimental release – cpm spon-
taneous release)/(cpm total release – cpm spontaneous release) x 100. Varying
between different cell types, spontaneous releases ranged from 800 to 1.400 cpm,
maximal releases were in the range between 8.000 and 15.000 cpm.
7.4. Results and Discussion
7.4.1. A cryptic VEGF derived HLA-ligand identified by
mass spectrometry
Renal cell carcinoma of the clear cell type (RCC) is a frequent genitourinary
tumor which is very resistant to standard therapy. In order to discover poten-
tial targets for T cell based tumor immunotherapy, we have analyzed the HLA
ligandome of several RCCs and their autologous normal kidney tissue in detail
[28, 31]. Therefore, we isolated HLA-presented peptides from tumor and normal
tissue, labeled the peptides with a stable isotope tag [26], and subjected them to
liquid chromatography coupled to an electrospray ionization mass spectrometer
(ESI-LC-MS): All normal tissue derived peptides were labeled N-terminally with
nicotinic acid (H4-NIC); all peptides derived from tumor tissue were labeled in
exactly the same manner but with a nicotinic acid bearing four deuterium atoms
(D4-NIC). The introduced isotope labels allowed – due to the isotopic mass shift
– an accurate allocation of peptide signals to tumor or normal tissue after mixing
of the two samples in a total peptide ratio of 1:1. Comparing the signal intensity
of a heavy D4-NIC peptide with its light H4-NIC counterpart allowed peptide
quantification between tumor and autologous normal tissue in one ESI-LC-MS
experiment [28]. In such an analysis of RCC099 a very prominent tumor de-
rived peptide with a mass to charge ratio (m/z) of 529.3 attracted attention (Fig.
7.1-A).
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Figure 7.1.: The SRFGGAVVR peptide is over-presented on HLA molecules of RCC099
and RCC110. HLA-presented peptides isolated from RCC099 and RCC110
were analyzed by mass spectrometry. For analysis samples were differen-
tially labeled with an isotope tag. Tumor samples were modified with
deuterated nicotinic acid (D4-NIC), normal tissue samples with normal nico-
tinic acid (H4-NIC). A, Mass chromatogram of m/z 529.3 corresponding to
D4-NIC-SRFGGAVVR. B, Ratio analysis of SRFGGAVVR presented on
tumor (D4-NIC-SRFGGAVVR, m/z = 529.3) and normal tissue (H4-NIC-
SRFGGAVVR, m/z = 527.3). After normalization to the average presenta-
tion ratio, SRFGGAVVR appeared over-presented by 6.5-fold on RCC099
and 5.4-fold on RCC110. C, Fragment spectra of differentially nicotinylated
SRFGGAVVR derived from RCC099 tumor and normal tissue, respectively
synthetic D4-NIC-SRFGGAVVR.
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Figure 7.2.: SRFGGAVVR is located in the ‘untranslated’ region of VEGF. The trans-
lated protein sequence of VEGF mRNA (NCBI RefSeq Database ID
NM_003376) starting at CUG499 is shown. VEGF protein sequence as
deposited in swissprot (primary accession number P15692) is highlighted
in bold. VEGF121 is composed of amino acids shaded in light grey. The
protein sequence of VEGF165 contains additionally the amino acids shaded
in dark grey. In frame SRFGGAVVR is highlighted in bold italics and is
underlined.
After normalization to the average peptide presentation ratio [28], the quanti-
tative analysis of this peptide showed a more than sixfold over-presentation of the
peptide in tumor (D4-NIC) compared to normal tissue (H4-NIC; Fig. 7.1-b, left
panel). In RCC110 the same peptide appeared more than fivefold over-presented
on tumor tissue (Fig. 7.1-B, right panel). The corresponding peptide sequence
(SRFGGAVVR) was identified by de novo sequencing using tandem mass spec-
trometry (MS/MS; Fig. 7.1-c). Furthermore, SRFGGAVVR fragmentation spec-
tra from RCC samples were identical with fragmentation spectra of synthetic
SRFGGAVVR (Fig. 7.1-C, lower panel). The peptide matched the HLA mo-
tif of HLA-B*2705 (www.syfpeithi.de, score = 30) for which both RCC099 and
RCC110 were positive.
In order to identify the source protein from which the peptide SRFGGAVVR
was derived, BLAST searches were performed against protein and translated
nucleotide databases. Using the swissprot protein database, no protein in any
species was found containing the peptide SRFGGAVVR. However, searching
in a translated nucleotide database, the SRFGGAVVR peptide was found in
the ‘untranslated’ region of VEGF in humans, chimpanzee, and rhesus mon-
key. SRFGGAVVR is in frame with the actual VEGF protein sequence and
can be transcribed using the non-classical CUG499 [16, 17] as start codon, thus
being cryptic (Fig. 7.2). Furthermore, the C-terminus of the peptide is pre-
dicted to be generated very efficiently by the proteasome (netchop 3.0 soft-
ware http://www.cbs.dtu.dk/services/NetChop, score = 0.97). Integrated bioin-
formatical approaches, assessing the whole antigen processing pathway, rank
SRFGGAVVR at least in the top 2% of all HLA-B*27 presented peptides of
VEGF (WAPP score MHC 1.05, TAP -48.58, proteasome 3.31, http://www-
bs.informatik.uni-tuebingen.de/WAPP ; NetCTL score 1.68,
http://www.cbs.dtu.dk/services/NetCTL/; EpiJen score 1.498,
http://www.jenner.ac.uk/EpiJen/).
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7.4.2. Analysis of VEGF expression by in situ hybridization
Figure 7.3.: VEGF mRNA is expressed in tumor but not in autologous normal tissue
as revealed by radioactive in situ hybridization. RCC135, RCC180 and
RCC190 tumor (A, B, C) and autologous normal tissue (D, E, F) sections
were stained with hematoxylin-eosin. VEGF mRNA expressing cells were
detected by in situ hybridized, radioactively labeled VEGF121 RNA. VEGF
positive cells are exemplarily marked with arrows. No VEGF mRNA ex-
pression is detectable in normal tissue and renal tubuli of healthy kidneys.
bv, blood vessels; if, infiltrating cells.
In order to further characterize the cellular origin of VEGF leading to presen-
tation of the SRFGGAVVR peptide in RCC tissue, in situ hybridization (ISH)
experiments with radioactively labeled VEGF RNA probes were performed in
RCC tumors and autologous normal tissues. Lacking appropriate paraffin em-
bedded sample material for RCC099 and RCC110, this analysis was performed
using three other clear cell RCCs (RCC135, RCC180 and RCC190) and their
autologous normal tissues. In all analyzed samples VEGF transcripts were only
detected in tumor cells (Fig. 7.3 A, B, C), thus being responsible for VEGF
protein expression and subsequent presentation of the VEGF-derived peptide
SRFGGAVVR. All autologous normal tissues (Fig. 7.3 D, E, F), inflammatory
cells (Fig. 7.3 D, if) as well as endothelial cells of blood vessels within the tumor
tissues (Fig. 7.3 A, B, C, bv) were negative for VEGF mRNA.
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7.4.3. Expression profile of VEGF variants in RCCs
Table 7.1.: VEGF ratios of tumor vs. normal tissue are increased on various cellular
levels. Protein, gene chip, and qRT-PCR refer to an average of VEGF121
and VEGF165 levels with potential minor contributions of VEGF145 and
VEGF189;HLA-peptide ratio refers to presentation differences of the cryp-
tic SRFGGAVVR peptide on HLA-B*2705.
VEGF ratios tumor vs. Normal tissue
sample HLA peptide protein gene chip qRT PCR
RCC099 6.5 4.5 2.0 1.3
RCC110 5.4 42.1 4.7 12.9
Gene chip analysis of RCC099 and RCC110 showed a 2-4-fold over-expression of
VEGF in tumor tissue (Tab. 7.1). However, the gene chip probe set detecting
VEGF did not allow determination of the variant of VEGF was expressed in
tumor, respectively normal tissue. Similarily, the ISH probe allowed no specific
detection of any VEGF variant because it had a minimum of 90% sequence overlap
with each VEGF variant. A RT-PCR was therefore set up using primers covering
the VEGF sequence from the classical ATG1039 start codon to the TGA1686 stop
codon. VEGF121 (459 nt) and VEGF165 (591 nt) could subsequently be identified
as the major transcript variants of VEGF in all analyzed samples (Fig. 7.4-
A). Moreover, minor amounts of VEGF145 (531 nt) and VEGF189 (663 nt) could
also be detected. In the same samples, VEGF amounts were analyzed by qRT-
PCR in an absolute manner using defined amounts of reference plasmids coding
for VEGF121 and VEGF165. Thus, VEGF121 specific qRT-PCR primers were
designed. In the case of VEGF165, no specific qRT-PCR primer pair could be
defined which did not also recognize VEGF189. Due to the very low amount of
VEGF189 expression (Fig. 7.4-A), its contribution to VEGF165 derived signals in
qRT-PCR was put aside. VEGF165 was expressed in RCC099 threefold higher
amounts than in VEGF121 and in RCC110 sevenfold (Fig. 7.4-B), respectively.
Comparing tumor versus normal tissue, RCC099 showed only minor differences
of mRNA expression levels for both VEGF variants. In contrast, RCC110 showed
a minimum of 12-fold over-expression of VEGF in tumor tissue.
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Figure 7.4.: VEGF is over-expressed in RCC099 and RCC110 both on mRNA and pro-
tein level. A, VEGF variants expressed in tumor and normal tissue were
analyzed by RT-PCR by amplification of VEGF mRNA from nt 1021 to nt
1689. VEGF121 and VEGF165 coding plasmids were used as reference sam-
ples. VEGF145 and VEGF189 are observable as faint bands in RCC099 and
RCC110 samples. B, Absolute quantification of VEGF121 and VEGF165 by
qRT-PCR. Plasmids coding for VEGF121 and VEGF165 were used as stan-
dards. Samples were normalized to 18S RNA isolated from 2000 JY-BLCL
cells. C and D, Protein quantification of VEGF by bead based sandwich
immuno assay. C, Four tumor and autologous tissues were analyzed. D,
Transfection efficiency of different VEGF constructs was determined in X63-
B*2705 cells. In untransfected X63-B*2705 cells VEGF was not detectable.
All error bars represent standard errors of the mean.
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7.4.4. Quantitative analysis of VEGF protein levels in RCCs
Correlation of mRNA with protein levels [37] and HLA ligand levels [28] has been
shown to be weak. Thus, protein levels of VEGF were assessed by a bead-based
sandwich immunoassay [32] in RCC099 and RCC110 (Fig. 7.4-C, left panel).
Additionally two other RCCs (RCC147 and RCC160), for which protein samples
were available, were tested for VEGF protein expression. In all samples analyzed,
VEGF protein expression was more than fourfold higher in tumor compared to
normal tissue. Protein ratios in both RCC099 and RCC110 were about four times
higher as their corresponding mRNA ratios. This is in agreement with reports
showing enhanced VEGF translation under hypoxic conditions [38].
7.4.5. Assessment of VEGF on various cellular levels
We analyzed VEGF on mRNA, protein, and HLA ligand levels (Tab. 7.1). Ex-
pression of VEGF mRNA in RCC tumor tissue has been described in several
reports [39, 40]. It is induced under hypoxic conditions mediated by the hypoxia
inducible factor-1 (HIF-1). In RCCs in particular, it has been demonstrated that
inactivation of the von Hippel-Lindau tumor suppressor gene leads to excessive
VEGF production [41] due to constitutive HIF-1 [42] and HIF-2 [43] activation.
In 16 gene chip experiments (data not shown) we compared the expression of
VEGF in primary RCC tissue and autologous normal kidney tissue and found
VEGF over-expression (more than 3-fold) in about 70% of all cases. In 25%
of all cases, over-expression was greater than 9-fold. For RCC099 and RCC110,
over-expression in tumor tissue was 2.0-fold respectively 4.7-fold. These gene chip
data were confirmed by qRT-PCR. VEGF121 and VEGF165 were the predominant
VEGF variants expressed in RCC, both being significantly over-expressed in tu-
mor tissue. On the protein level, VEGF over-expression in tumor tissue was even
more prominent. Here, differences ranged from 4- to 40-fold. Furthermore, the
VEGF-derived peptide SRFGGAVVR was over-presented on HLA-molecules in
both tumor tissues. The extent of HLA-peptide over-presentation did not match
its corresponding mRNA-levels; this observation has been described previously
for other gene products [28].
7.4.6. Generation of VEGF expressing cell lines
For subsequent T cell experiments, the mouse myeloma cell line X63-B*2705 –
X63-Ag8 cells stably transfected with human HLA-B*2705 and β2-microglobulin
– was used in order to circumvent contamination due to endogenous expression
of human VEGF, which we could observe in human cell lines (see below). X63-
B*2705 were stably transfected with two different VEGF constructs: VEGF-
UTR165 was transfected with VEGF165 containing the ‘untranslated’ region and
thus also containing the SRFGGAVVR peptide. VEGF-165 was transfected with
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VEGF165 lacking the ‘untranslated’ region and thus the SRFGGAVVR peptide.
Surface expression of HLA-B*2705 was confirmed by FACS analysis (data not
shown), VEGF protein expression was tested as described above (Fig. 7.4-D).
7.4.7. Generation of VEGF specific T cells
The VEGF derived peptide SRFGGAVVR is presented by HLA-B*2705. In or-
der to investigate whether the HLA-bound peptide can be recognized by func-
tional cytotoxic T cells, CD8+ T cells from healthy blood donors were stimulated
in vitro for four weeks with dendritic cells (DCs) or artificial antigen present-
ing cells (aAPCs). All blood donors were HLA-A*0201 and -B*2705 positive
as well as seropositive for human cytomegalovirus (HCMV). For stimulation ex-
periments, DCs were loaded with SRFGGAVVR peptide; aAPCs were loaded
with costimulatory antibodies, HLA-B*2705-SRFGGAVVR-complexes and HLA-
A*0201-NLVPMVATV-complexes. The immunodominant HCMV derived pep-
tide NLVPMVATV served as positive control. After four weeks of stimulation,
cells were stained with fluorescence labeled B*2705-SRFGGAVVR- or A*0201-
NLVPMVATV-tetramers and assayed in a FACS experiment. Both the HCMV
derived peptide and the VEGF derived SRFGGAVVR were able to induce a
specific T cell population (Fig. 7.5-A).
7.4.8. Functional analysis of VEGF-specific T cells
In order to assess the functionality of SRFGGAVVR-specific T cells, their abil-
ity to secrete cytokines and their cytolytic potential were analyzed. For these
functional experiments only DC stimulations were used because it has been re-
ported that strong and rapid T cell expansion using aAPCs bears the risk of
inducing dysfunctional T cells [44]. Upon co-culture with autologous PBMCs
loaded with SRFGGAVVR-peptide, CD8+ T cells were able to secrete IFN-γ.
This confirmed that the effector T cells were functional and specific for VEGF
(Fig. 7.5-B). Furthermore, the cytolytic potential of these cells was analyzed in
a chromium release assay. Therefore, in vitro stimulated SRFGGAVVR specific
tetramer positive T cells were MACS-sorted and expanded. Autologous PBMCs
loaded with an irrelevant peptide remained unlysed. Human C1R-B*2705 trans-
fected with VEGF-UTR165 were lysed efficiently; however, the parental cell line
C1R-B*2705 was lysed due to endogenous VEGF expression as well (data not
shown). Mouse X63-B*2705 cells were recognized only after transfection with
VEGF-UTR165 containing the cryptic SRFGGAVVR peptide sequence, whereas
VEGF-165 transfected X63-B*2705 cells were not lysed – although VEGF-165
protein levels were 10-fold higher than in VEGF-UTR165 cells (Fig. 7.4-D). Fi-
nally, a cell line generated from RCC110 tumor tissue was specifically recognized
by these T cells.
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Figure 7.5.: SRFGGAVVR specific T cells are functional cytotoxic effector T cells. A,
Tetramer staining of CD8+ T cells that were stimulated with aAPCs loaded
with HLA-A*0201-NLVPMVATV (HCMV), HLA-B*2705-SRFGGAVVR
(VEGF) and with co-stimulating antibodies. The respective tetramer used
for staining is indicated in each plot. Percentages are calculated from total
CD8+ cells. B and C, CD8+ T cells, stimulated in vitro using dendritic
cells, were used for functional assays. Stimulated T cells were tested for
IFN-γ secretion upon co-culture with autologous PBMCs loaded with SR-
FGGAVVR. C, 51Cr-cytotoxicity assay of SRFGGAVVR stimulated CD8+
T cells. Two X63-B*2705 transfectants, a RCC110 tumor cell line as well
as peptide loaded autologous PBMCs were used as target cells. Error bars
represent standard deviations. D, Combined tetramer-IFN-γ analysis of
PBMCs isolated from RCC160 and RCC294. Cells were stained ex vivo re-
spectively after one week of in vitro stimulation with SRFGGAVVR peptide.
Irrelevant peptide stimulations resulted in identical percentages regarding
the IFN-γ staining. Stimulation with PMA/Ionomycin resulted in IFN-γ
secretion of 70-90% of all CD8+ T cells. Data are representative for PBMC
samples from 10 other RCC patients.
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7.4.9. Absence of VEGF specific T cells in blood of RCC
patients
Using PBMCs from healthy blood donors, SRFGGAVVR specific T cells were in-
ducible in vitro. In order to asses whether such SRFGGAVVR specific T cells were
induced in vivo in RCC patients, we analyzed PBMC samples of 12 HLA-B*27
positive RCC patients by tetramer analysis and by intracellular IFN-γ staining.
In none of the samples – including RCC110 – were tetramer positive or IFN-γ
producing cells detectable, neither in an ex vivo analysis nor upon 7 days of in
vitro peptide stimulation (Fig. 7.5-D). This suggests that SRFGGAVVR may not
be spontaneously recognized by T cells from RCC patients and this may indicate
a possibility for a therapeutic utilization of VEGF specific T cells.
7.5. Summary
Several anti-VEGF based tumor therapies have already been shown to have a
substantial clinical impact. We have identified a cryptic HLA ligand derived
from the ‘untranslated’ region of VEGF by mass spectrometry. The peptide is
derived most probably from the VEGF variants VEGF121 or VEGF165, which are
highly over-expressed on mRNA and on the protein level in RCC tumors (sum-
marized in Tab. 7.1). Furthermore, the HLA-bound peptide SRFGGAVVR is
highly over-presented on RCC tumor tissue and can be directly recognized by
cytotoxic effector T cells. Therefore, our findings define VEGF as a T cell tar-
getable tumor associated antigen. A peptide-based immunotherapeutic approach
directed against HLA-presented VEGF epitopes may amend other anti-VEGF
based therapies in the future.
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8. Summary
Molecularly defined approaches in tumour immunotherapy require the identifi-
cation of appropriate tumour (associated) antigens. Therefore, a quantitative
mass spectrometric approach based on the differential N-terminal isotope coding
(dNIC) strategy was chosen for analysis of various HLA-bound peptide pools. In
a first step, we could show that the systemic variations in the dNIC approach are
low enough that biological differences in two samples can be detected reliably.
In a TAP-deficient cell line we have identified several over-presented peptides,
which share some common features: Most of these peptides had a reduced binding
affinity to MHC-I molecules and were derived from signal sequences. However,
several of the TAP-independently presented peptides were presumably generated
by the proteasome and transported into the ER via alternative pathways.
Using primary tumour tissue and autologous normal tissue, we were able
to show that the correlation of over-presented peptides to their corresponding
mRNA levels was very weak. This result emphasized the importance of quanti-
tative MHC ligand analysis for a fast and reliable identification of tumour (asso-
ciated) antigens.
Finally, we took an HLA ligand which was identified as being majorly over-
presented in our tumour vs. normal tissue comparison and demonstrated that
this VEGF-derived ligand can be used as a CTL epitope derived from the tumour
associated antigen VEGF.
Concluding, the dNIC strategy is a powerful MS-based approach for the identi-
fication of differences in the HLA ligandome of two samples. This can be utilised
for a broad spectrum of applications ranging from quantitative HLA ligandome
comparisons to the identification of tumour associated CTL epitopes.
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9. Zusammenfassung
Molekular definierte Ansätze in der Tumorimmuntherapie setzen die Identifika-
tion geeigneter Tumor (assoziierter) Antigene voraus. Deshalb wurde ein massen-
spektrometrischer Ansatz, basierend auf der differentiellen N-terminalen Isotopen-
codierungs (dNIC) Strategie, gewählt um diverse Vergleiche von HLA-gebundenen
Peptidpools durchzuführen. In einem ersten Schritt konnten wir zeigen, dass die
systemischen Variationen der dNIC-Methode klein genug sind, um biologische
Unterschiede zwischen zwei Proben verlässlich zu identifizieren.
In einer TAP-defizienten Zelllinie konnten wir mehrere überpräsentierte Pep-
tide identifizieren, die einige Gemeinsamkeiten teilten: Die meisten dieser Pep-
tide hatten eine verminderte Bindungsaffinität zu MHC-I Molekülen und kamen
aus Signalsequenzen. Einige der TAP-unabhängig präsentierten Peptide wurden
jedoch wahrscheinlich durch das Proteasom erzeugt und gelangten durch einen
alternativen Weg in das ER.
Bei einem Vergleich von Tumor- und autologem Normalgewebe konnten wir
zeigen, dass die Korrelation von überpräsentierten Peptiden mit ihren korre-
spondierenden mRNA-Verhältnissen nur sehr gering war. Dieses Ergebnis be-
tont die Bedeutung der quantitativen MHC-Ligandenanalyse für eine schnelle
und verlässliche Identifizierung von Tumor (assoziierten) Antigenen.
Zuletzt verwendeten wir einen HLA-Liganden, der in unserem Tumor versus
Normalgewebsvergleich als besonders überpräsentiert identifiziert wurde. Für
diesen Liganden aus VEGF konnten wir zeigen, dass er als CTL-Epitop des
Tumor-assoziierten Antigens VEGF verwendet werden kann.
Schlussfolgernd betrachtet ist die dNIC-Strategie ein MS-basierter Ansatz mit
großem Potential für die Identifizierung von Unterschieden im HLA-Ligandom
von zwei Proben. Dies kann für ein breites Anwendungsspektrum eingesetzt
werden, welches von den quantitativen HLA-Ligandomanalysen bis hin zur Iden-
tifizierung von Tumor-assoziierten Antigenen reicht.
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10. Abbreviations
2D-GE two-dimensional gel electrophoresis
AAF-CMK Ala-Ala-Phe-chloromethylketone
ADFP adipophilin
ALICE acid-labile isotope-coded extractants
ANXA4 annexin A4
AQUA absolute quantification
CCNI cyclin I
CD24 small cell lung carcinoma cluster 4 antigen
CDK4 cyclin-dependent kinase 4
CEA carcinoembryonic antigen
cICAT cleavable isotope coded affinity tag
CML chronic myeloid leukemia
CNBr cyanogen bromide activated
CTL cytotoxic T lymphocyte
DCs dendritic cells
DDF differential detergent fractionation
DIGE difference gel electrophoresis
dNIC differential N-terminal isotope coding
DRiPs defective ribosomal products
EDT ethanedithiol
EHD2 EH-domain containing protein 2
ERAAP endoplasmic reticulum aminopeptidase associated with antigen
processing
EST expressed sequence tag
FARSLA homologue to the phenylalanine-tRNA synthetase alpha unit
HHV human herpes virus
HIF hypoxia inducible factor
HLA human leukocyte antigen
HLA-B*2705 human leukocyte antigen B*2705
HMOX1 decycling heme oxygenase 1
ICAT isotope coded affinity tag
ICPL isotope coded protein labels
ICROC isotope-coded reduction off of a chromatographic support
IDO indoleamine 2,3-dioxygenase
IFNγ interferon gamma
IL interleukin
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Abbreviations
LC liquid chromatography
LCL721.174 lymphoblastoid B-cell line 721.174
LCL721.45 lymphoblastoid B-cell line 721.45
LC-MS liquid chromatography - mass spectrometry
LMP2/7 proteasome subunit beta 9/8
MAGE melanoma antigen
MAGE1 melanoma antigen 1
MALDI-TOF matrix assisted laser desorption ionization - time of flight
MHC major histocompatibility complex
MHC-I or II major histocompatibility complex class I or II
MS mass spectrometry
MS/MS tandem mass spectrometry
MUC1 mucin 1
NHS nicotinoyloxysuccinimide
NIC nicotinic acid
NIC-NHS nicotinoyloxy-succinimide
OD optical density
PhIAT phosphoprotein isotope-coded affinity tags
PIGR polymeric Ig receptor
PLXNB2 plexin B2
PSMA prostate-specific membrane antigen
pVHL von Hippel-Lindau gene product
qRT-PCR quantitative real time PCR
RBBP4 retinoblastoma binding protein 4
RCC renal cell carcinoma
SILAC stabile isotope labeling by amino acids in cell culture
SPP signal peptide peptidase
TAA tumour associated antigen
TAP transporter associated with antigen processing
TMAB 4-trimethyl-ammoniumbutyryl
TMED10 transmembrane trafficking protein 10
TPP2 tripeptidyl peptidase II
UGT1A6 UDP glucuronosyltransferase 1 family, polypeptide A6
UMOD uromodulin
VEGF vascular endothelial growth factor
ZF zonal zentrifugation
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A. Supplementary Tables
Table A.1.: Peptides identified in RCC099 for which MS/MS spectra were compared
to MS/MS spectra of synthetic peptides For 16 randomly chosen pep-
tides from RCC099 synthetic peptides were produced. Synthetic pep-
tides were modified using the dNIC strategy and peptide fragmenta-
tion spectra were recorded. Fragmentation spectra of synthetic peptides
were compared to fragmentation spectra of the naturally occurring pep-
tide. Peptides which were also used in MASCOT searches of Supple-
mentary Tab. A.3 are marked in bold. A comparison of the frag-
mentation spectra for each peptide can be found at http://www.uni-
tuebingen.de/uni/kxi/PaperSupplements/Weinzierl_MCP2006/.
Sequence m/z charge
state
MS/MS spectra natural and
synthetic peptide match
ALASHLIEA 517.28 2 yes
ALLNIKVKL 602.89 2 yes
ALSDHHIYL 589.30 2 yes
FLLDKKIGV 613.37 2 yes
GRVFIIKSY 617.36 2 yes
ILMEHIHKL 642.86 2 yes
LLAAWTARA 541.31 2 yes
LLFDRPMHV 618.83 2 yes
QLIDKVWQL 647.37 2 yes
QLVDIIEKV 604.35 2 yes
RLASYLDRV 601.33 2 yes
RLLDYVVNI 607.35 2 yes
SLLDIIEKV 590.85 2 yes
SLLDKIIGA 540.82 2 yes
SLSEKTVLL 570.83 2 yes
YLLPAIVHI 574.34 2 yes
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Table A.2.: Presentation ratios and mRNA expression ratios were calculated between tumour and autologous normal tissue.
# indicates that no corresponding MS/MS spectrum was recorded. Gene Symbol and Title can be found at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene. Fragmentation spectra for each peptide can be found at
http://www.uni-tuebingen.de/uni/kxi/PaperSupplements/Weinzierl_MCP2006/.
Gene
Symbol Gene Title Sequence
2log HLA
ligand
ratio
2log
mRNA
ratio
HLA
restrict.
Source
m/z
H4-
NIC
m/z
D4-
NIC
charge
state
SEPT2 septin 2 RLYPWGVVEV 0.33 0.32 A02 RCC099 661.86 663.93 2
ACVRL1 activin A receptor type II-L 1 SPRKGLLML -0.65 3.01 B07 RCC100 581.36 583.37 2
ADFP adip.diff.-related prot. VRLGSLSTK 4.22 -0.08 B27 RCC099 554.38 556.38 2
ADFP adip.diff.-related prot. SLLTSSKGQLQK 2.32 1.71 A03 RCC100 # 741.96 2
ADFP adip.diff.-related prot. VRLGSLSTK -0.81 3.60 B27 RCC110 554.37 556.37 2
ADPRHL2 ADP-ribosylhydrolase L 2 EGLARPLPL -2.10 0.61 n/a RCC100 535.83 # 2
AKR1C1 aldo-keto reductase family 1C1 RPELVRPAL 1.97 0.29 B07 RCC100 # 580.37 2
ALDH1L1 aldeh.dehyd. 1L1 RVKTVTFEY 4.04 -0.38 B57 RCC099 # 647.38 2
ALDOA aldolase A ALSDHHIYL 3.38 2.72 A02 RCC099 587.31 589.31 2
ALDOA aldolase A RTVPPAVTGITF 2.63 2.72 B57 RCC099 # 684.44 2
ALDOA aldolase A ALSDHHIYL 2.11 1.01 A02 RCC100 # 589.31 2
ALDOA aldolase A ALSDHHIYL 2.23 0.60 A02 RCC110 587.28 589.38 2
ANKRD25 ankyrin repeat domain 25 RLLDYVVNI -0.06 -0.08 A02 RCC099 # 607.37 2
ANXA4 annexin A4 DEVKFLTV 3.52 1.41 B18 RCC100 549.39 551.38 2
ANXA4 annexin A4 DEVKFLTV 1.95 2.20 B18 RCC110 # 551.37 2
APOL1 apolipoprot. L1 ALADGVQKV 0.78 1.52 A02 RCC099 524.29 526.31 2
APOL1 apolipoprot. L1 ALADGVQKV 0.20 1.90 A02 RCC110 526.38 524.36 2
APP amyloid beta precursor prot. LLAAWTARA 0.93 -0.38 A02 RCC099 # 541.35 2
ARF1 ADP-ribosylation factor 1 KLGEIVTTI -0.62 -0.21 A02 RCC099 560.84 562.88 2
ASCC3L1 activ.signal coint. 1-3-L 1 DEHLITFF 0.88 0.71 B18 RCC100 # 565.87 2
ASCC3L1 activ.signal coint. 1-3-L 1 DEHLITFF 0.23 0.20 B18 RCC110 563.77 # 2
ATOX1 ATX1 antiox.prot. 1 homol. RVLNKLGGVK -1.01 n/a A03 RCC100 636.92 638.92 2
ATP1B1 ATPase, Na+/K+ transp. b1 GRTGGSWFK -0.07 -0.93 B27 RCC099 # 573.87 2
AUP1 ancient ubiquitous prot. 1 TLAQRVKEV -1.00 -0.08 A02 RCC099 595.85 # 2
BSG basigin RVRSHLAALW 0.58 0.12 B57 RCC099 # 659.41 2
C10orf10 chrom. 10 ORF 10 RPSSVLRTL 2.96 3.01 B07 RCC100 # 569.36 2
C1QG complement component 1q RSGVKVVTF 0.96 2.02 B57 RCC099 # 572.37 2
C2orf24 chrom. 2 ORF 24 GRWRGWYTY 0.49 0.72 B27 RCC099 675.37 677.33 2
C2orf24 chrom. 2 ORF 24 GRWRGWYTY 0.42 1.10 B27 RCC110 # 677.38 2
CALD1 caldesmon 1 DEAAFLERL -0.52 1.20 B18 RCC110 584.80 # 2
continued on next page
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Table A.2 – contiuned
Gene
Symbol Gene Title Sequence
2log HLA
ligand
ratio
2log
mRNA
ratio
HLA
restrict.
Source
m/z
H4-
NIC
m/z
D4-
NIC
charge
state
CCDC21 coiled-coil dom.cont. 21 RLQMEQMQL -1.14 n/a A02 RCC100 641.35 643.38 2
CCNI cyclin I LLDRFLATV -0.93 -0.18 A02 RCC099 576.87 578.83 2
CCNI cyclin I SLLDRFLATV 0.01 -0.18 A02 RCC099 620.34 622.34 2
CCT2 chap.cont.TCP1, subun.2 FLLDKKIGV 0.41 0.42 A02 RCC099 611.38 613.37 2
CCT3 chap.cont.TCP1, subun.3 ITTKAISRW 1.22 0.52 B57 RCC099 611.85 613.86 2
CD24 CD24 antigen RAMVARLGL 5.32 0.71 A02 RCC100 # 548.43 2
CD59 CD59 antigen SLSEKTVLL -1.04 -0.78 A02 RCC099 568.85 570.85 2
CD59 CD59 antigen SLSEKTVLL -0.32 -0.44 A02 RCC100 # 570.91 2
CD59 CD59 antigen SLSEKTVLL -1.17 -0.20 A02 RCC110 # 570.90 2
CIB1 Ca2+integrin bind. 1 FLTKQEILL 2.55 0.42 A02 RCC099 626.37 628.44 2
CIRBP cold induc.RNA bind.prot. RSRGFGFVTF 0.13 -0.46 B57 RCC099 # 641.84 2
CLIC1/4 Cl- intracell.chan. 1/4 NLLPKLHIV -1.34 0.65 A02 RCC099 597.44 599.40 2
CLIC1/4 Cl- intracell.chan. 1/4 NLLPKLHIV 1.18 0.41 A02 RCC100 597.39 599.42 2
CLIC1/4 Cl- intracell.chan. 1/4 NLLPKLHIV -0.82 0.95 A02 RCC110 597.36 599.48 2
CLIC4 Cl- intracell.chan. 4 FLDGNEMTL -0.02 0.17 A02 RCC099 572.76 574.83 2
CLIC5 Cl- intracell.chan. 5 NLLPKLHVV 3.00 -2.75 A02 RCC099 590.37 # 2
CLTC clathrin, heavy pol.pep. SRVNIPKVLR -1.47 -0.28 B27 RCC099 664.92 666.91 2
COL18A1 collagen, type XVIII, alpha 1 RLLDVLAPL -0.17 -1.28 A02 RCC099 557.85 559.89 2
COL6A2 collagen, type VI, alpha 2 KTRVFAVVI 0.60 -0.58 A02 RCC099 # 592.41 2
COPG coatom.prot.complex, g AIVDKVPSV 0.77 1.02 A02 RCC099 537.82 539.84 2
COPG coatom.prot.complex, g AIVDKVPSV 1.32 0.40 A02 RCC110 537.81 539.89 2
COPG/G2 coatom.prot.complex, g DEFKVVVV 0.39 0.01 A02 RCC100 541.41 # 2
COPS7A COP9 const.photom. 7A ALATLIHQV -0.21 -0.08 A02 RCC099 535.82 537.85 2
CREB3L1/2 cAMP resp.bind.3-L 1/2 KRTLIAEGY 0.09 0.30 B27 RCC110 599.34 601.41 2
CREB3L1/2 cAMP resp.bind.3-L 1/2 KRTLIAEGY 0.78 0.02 B27 RCC099 599.34 # 2
CSPG4 chondr.sulf.proteoglyc. 4 TMLARLASA 3.38 2.81 A02 RCC100 # 521.81 2
CTNNB1 catenin beta 1 TTSRVLKVL -0.66 -0.67 A02 RCC099 582.38 584.37 2
CXCL14 chemok.(C-X-C motif)lig. 14 RLLAAALLL 2.09 0.47 A02 RCC099 # 531.90 2
CYHR1 cysteine/histidine-rich 1 HLGPEGRSV -1.21 n/a A02 RCC099 528.77 # 2
CYP2J2 cytochrome P450, family 2J2 KLLDEVTYL 4.78 2.32 A02 RCC099 # 622.90 2
DDX48 DEAD box pol.pep. 48 GRKGVAINF 2.48 -0.28 B27 RCC110 554.81 556.81 2
DDX5/17 DEAD box pol.pep. 5/17 YLLPAIVHI 0.55 -0.61 A02 RCC099 572.35 574.38 2
DDX5/17 DEAD box pol.pep. 5/17 YLLPAIVHI 0.18 -0.40 A02 RCC110 572.34 # 2
DHX38 DEAH box pol.pep. 38 VLFGLLREV 0.81 n/a A02 RCC099 575.82 577.86 2
DNCL2A dynein, cytoplasmic, light 2A SLMHSFILK 0.57 -0.09 A03 RCC100 611.85 613.87 2
continued on next page
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Table A.2 – contiuned
Gene
Symbol Gene Title Sequence
2log HLA
ligand
ratio
2log
mRNA
ratio
HLA
restrict.
Source
m/z
H4-
NIC
m/z
D4-
NIC
charge
state
DNM2 dynamin 2 TLIDLPGITKV -0.62 -1.68 A02 RCC099 658.90 660.91 2
DST/MACF1 dyst.microt.actin crossl. fact. 1 SRWEKVVQR -0.22 -0.78 B27 RCC099 667.88 669.93 2
DST/MACF1 dyst.microt.actin crossl. fact. 1 SRWEKVVQR -0.21 0.13 B27 RCC110 667.87 # 2
EEF2 euk.transl.elongat.fact. 2 ILTDITKGV -0.91 0.42 A02 RCC099 553.81 # 2
EEF2 euk.transl.elongat.fact. 2 RRWLPAGDAL 0.37 0.42 B27 RCC099 # 632.41 2
EEF2 euk.transl.elongat.fact. 2 ILTDITKGV -1.27 0.50 A02 RCC110 553.82 # 2
EFHD1 EF-hand domain family D1 KLSEIDVAL -0.77 -3.18 A02 RCC099 567.81 569.87 2
EFHD1 EF-hand domain family D1 KLSEIDVAL 0.15 -2.99 A02 RCC100 # 569.85 2
EFHD1 EF-hand domain family D1 KLSEIDVAL 0.37 -2.30 A02 RCC110 567.82 # 2
EHD2 EH-domain containing 2 ALASHLIEA 1.07 3.32 A02 RCC099 515.31 517.29 2
EHD2 EH-domain containing 2 ALASHLIEA 1.82 3.41 A02 RCC100 # 517.31 2
EHD2 EH-domain containing 2 ALASHLIEA -0.21 1.00 A02 RCC110 515.28 # 2
EIF3S6 euk.transl.elongat.fact. 3-6 KRTTVVAQL -0.10 0.52 B27 RCC099 # 583.88 2
EIF3S8 euk.transl.elongat.fact. 3-8 ISKQFHHQL 0.20 0.59 B57 RCC099 # 644.86 2
EIF4A2 euk.transl.elongat.fact. 4A2 GRKGVAINF -0.71 0.00 B27 RCC099 554.81 556.85 2
EPAS1 endoth.PAS dom.prot. 1 HSMDMKFTY -0.94 -0.68 B57 RCC099 # 655.84 2
EPAS1 endoth.PAS dom.prot. 1 HELPLPHSV -1.18 1.01 B18 RCC100 567.32 # 2
EXOSC6 exosome component 6 ALMPVLNQV -0.08 -0.08 A02 RCC099 545.32 547.32 2
FBXL5 F-box leu-rich rep.prot. 5 SLFEKGLKNV -0.65 -0.18 A02 RCC099 662.35 664.38 2
FLJ14803 hypothetical prot. FLJ14803 YLFERIKEL 1.11 0.52 A02 RCC099 # 681.42 2
FLJ21439 hypothetical prot. FLJ21439 KVANIILSY 0.20 -0.26 A03 RCC100 584.36 586.38 2
FLJ32206 hypothetical prot. FLJ32206 GSHFISHLS -0.89 n/a n/a RCC099 545.23 547.32 2
FLNA filamin A GTHKVTVLF 0.06 1.02 B57 RCC099 574.92 576.84 2
FLNA filamin A GTHTVSVKY 1.01 1.02 B57 RCC099 569.80 # 2
FLNA filamin A GVHTVHVTF -0.24 1.02 B57 RCC099 551.33 553.32 2
FOLH1 folate hydrolase ALFDIESKV -1.69 -2.58 A02 RCC099 584.85 586.85 2
G3BP Ras-GTPase-activating prot. RRFMQTFVL 0.88 0.47 B27 RCC099 651.92 653.94 2
G3BP Ras-GTPase-activating prot. RRFMQTFVL 0.65 0.10 B27 RCC110 651.83 653.93 2
GAPDH glyc.aldeh.-3-phosph.dehydr. GRIGRLVTR 1.35 0.32 B27 RCC099 # 568.85 2
GBP4 guanylate binding prot. 4 KRLGTLVVTY -0.60 n/a B27 RCC099 648.88 # 2
GNB1 guan.nucleot.bind.prot. B1 HAIPLRSSW 0.15 0.31 B57 RCC099 586.33 588.37 2
GNB2L1 guan.nucleot.bind.prot. b2-L 1 KTIKLWNTL 1.06 1.02 A02 RCC099 # 655.39 2
GNB2L1 guan.nucleot.bind.prot. b2-L 1 YTDNLVRVW 0.24 1.02 B57 RCC099 # 637.85 2
GNB5 guan.nucleot.bind.prot. B5 ILFGHENRV -3.72 -0.78 A02 RCC099 595.33 # 2
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Gene
Symbol Gene Title Sequence
2log HLA
ligand
ratio
2log
mRNA
ratio
HLA
restrict.
Source
m/z
H4-
NIC
m/z
D4-
NIC
charge
state
GPX1 glutathione peroxidase 1 LLIENVASL 1.06 1.02 A02 RCC099 538.82 540.83 2
GRHPR glyoxylate reductase GRIGQAIAR 0.28 -0.28 B27 RCC099 523.83 525.83 2
GTF2I gen.transcript.fact. II, i NRIKFVIKR -0.52 0.52 B27 RCC099 681.98 456.31 2,3
HCA112 hep.cell.carc.assoc.ag. 112 SSRLLVASW 0.66 1.02 B57 RCC099 541.79 # 2
HDAC1/2 histone deacetylase 1/2 RMLPHAPGV -0.07 -0.38 A02 RCC099 541.79 # 2
HDAC1/2 histone deacetylase 1/2 RMLPHAPGV -0.47 0.21 A02 RCC100 541.81 543.82 2
HDAC1/2 histone deacetylase 1/2 RMLPHAPGV -0.35 -0.05 A02 RCC110 # 543.87 2
HECTD1 HECT domain containing 1 MPRGVVVTL -0.13 -0.49 B07 RCC100 538.83 540.85 2
HLA-A m.histocomp.complex I A HRVDLGTLR 0.93 0.77 B27 RCC099 # 588.40 2
HLA-A m.histocomp.complex I A VMAPRTLVL 0.40 1.60 A02 RCC110 # 555.39 2
HLA-A/G m.histocomp.complex I A/G VMAPRTLLL -0.23 1.60 A02 RCC110 # 561.92 2
HLA-B m.histocomp.complex I B AAQITQRKW 1.84 1.29 B57 RCC099 # 626.88 2
HLA-B m.histocomp.complex I B TAAQITQRKW 1.61 1.29 B57 RCC099 675.37 677.40 2
HLA-B/C m.histocomp.complex I B/C DTAAQITQR -4.41 1.85 A68 RCC110 554.77 # 2
HLA-DPA1 m.histocomp.complex II DPA1 EEFGQAFSF -0.34 0.66 B18 RCC100 583.77 585.97 2
HLA-DRB1/5 m.histocomp.complex II DPB1/5 LGRPDAEYW -0.49 1.01 B57 RCC099 606.32 608.38 2
HMGB1 high-mobility group box 1 VAKKLGEMW -1.05 0.32 B57 RCC099 # 625.84 2
HMOX1 heme oxygenase 1 KIAQKALDL 2.30 3.70 A02 RCC110 # 596.88 2
HNRPC heterogen.nucl.rib.prot. C SLLENLEKI 1.14 -0.19 A02 RCC100 603.50 605.47 2
HNRPC heterogen.nucl.rib.prot. C SLLENLEKI 0.18 0.00 A02 RCC110 603.34 605.38 2
HNRPM heterogen.nucl.rib.prot. M KSRGIGTVTF -0.74 0.47 B57 RCC099 # 608.88 2
HNRPM heterogen.nucl.rib.prot. M LLFDRPMHV 0.43 0.47 A02 RCC099 616.85 618.87 2
HNRPUL1 heterogen.nucl.rib.prot. U-L1 VGLPAAGKTTW 0.68 0.72 B57 RCC099 624.40 626.37 2
HSPA5 heat shock 70kDa prot. 5 TRIPKIQQL 0.24 0.12 B27 RCC099 # 624.43 2
HSPG2 hep.sul.prot.glyc. 2 ALADLDELLIRA 1.56 -0.08 A02 RCC099 # 711.39 2
IFI30 IFN-g-inducib.prot. 30 LLDVPTAAV -0.34 1.42 A02 RCC099 # 504.34 2
IFI30 IFN-g-inducib.prot. 30 LLDVPTAAV -0.03 1.80 A02 RCC110 502.29 # 2
IL32 interleukin 32 LVHAVQALW 2.17 1.82 B57 RCC099 # 573.33 2
IMP3 U3 small nucl.ribonuc.prot. ALLDKLYAL 1.59 0.91 A02 RCC100 # 586.42 2
ITPR1 inosit. 1,4,5-triphos.recpt.1 TLLNVIKSV -0.53 -0.83 A02 RCC099 567.36 # 2
KIAA0152 KIAA0152 gene product TAVALLRLL 0.85 0.12 A02 RCC099 # 539.87 2
KIAA0738 KIAA0738 gene product KLGSVPVTV -0.20 0.32 A02 RCC099 523.83 525.83 2
KIAA1305 KIAA1305 gene product TLADIIARL -0.10 n/a A02 RCC099 545.85 547.87 2
KLHL24 kelch-L 24 VLLGKVYVV -0.11 0.57 A02 RCC099 568.88 # 2
KPNA1 karyopherin alpha 1 VMDSKIVQV -0.51 -0.46 A02 RCC099 583.37 585.37 2
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Symbol Gene Title Sequence
2log HLA
ligand
ratio
2log
mRNA
ratio
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restrict.
Source
m/z
H4-
NIC
m/z
D4-
NIC
charge
state
KRT18 keratin 18 ALLNIKVKL 2.06 1.22 A02 RCC099 # 602.93 2
KRT18 keratin 18 RLASYLDRV -0.14 1.22 A02 RCC099 599.34 601.34 2
KRT18 keratin 18 RLASYLDRV 1.00 0.91 A02 RCC100 # 601.45 2
KRT18 keratin 18 RLASYLDRV -0.51 -0.20 A02 RCC110 599.34 601.41 2
KRT8 keratin 8 KLSELEAAL 0.56 0.62 A02 RCC099 # 562.82 2
LMNA lamin A/C KAGQVVTIW 0.29 0.07 B57 RCC099 574.83 576.90 2
LMNA lamin A/C MRARMQQQL -0.60 0.07 B27 RCC099 633.85 635.85 2
LMO4 LIM domain only 4 KIADRFLLY -0.86 -0.49 A03 RCC100 643.37 645.37 2
LSP1 lymphocyte-specific prot. 1 KLIDRTESL 0.39 1.90 A02 RCC110 611.35 # 2
LYPLA2 lysophospholipase II FLEKLLPPV -0.10 -0.08 A02 RCC099 601.86 603.87 2
MACF1 microt.-actin crossl fact.1 SRWEKVVQR -0.22 -0.58 B27 RCC099 667.88 669.93 2
MAF v-maf fibrosarc.oncogene ALISNSHQL 0.40 2.80 A02 RCC110 # 546.37 2
MAT1A/2A met.adenosyltransf. Ia/Iia RRVLVQVSY 0.48 -0.48 B27 RCC099 # 614.92 2
MAT1A/2A met.adenosyltransf. Ia/Iia RRVLVQVSY 4.08 0.50 B27 RCC110 612.85 614.96 2
MYH10 myosin, heavy pol.pep. 10 YLLEKSRAV -0.57 -1.38 A02 RCC099 613.33 # 2
MYL6 myosin, light pol.pep. 6 FVRHILSG -3.45 0.12 n/a RCC099 517.29 # 2
MYL6 myosin, light pol.pep. 6 DEMNVKVL 0.28 -0.80 B18 RCC110 547.77 549.88 2
MYO1C Myosin IC FLDHVRTSF -5.69 0.36 A03 RCC100 627.89 # 2
NAT8 N-acetyltransferase 8 ILDTGTIQL 1.65 -1.28 A02 RCC099 539.81 541.82 2
NCSTN nicastrin RRSSIQSTF 0.09 0.22 B27 RCC099 593.82 595.88 2
NCSTN nicastrin RRSSIQSTF 0.99 0.70 B27 RCC110 595.90 # 2
NDRG1 N-myc downstr.regul.gene 1 KLDPTKTTL 2.75 0.62 A02 RCC099 603.36 605.36 2
NDRG1 N-myc downstr.regul.gene 1 KLDPTKTTL 3.03 1.90 A02 RCC110 603.33 605.41 2
NEDD9 neur.prec.cell devel.downreg. 9 ALQEMVHQV -0.49 0.42 A02 RCC099 580.30 582.32 2
NPL N-acet.neuram.pyruv.lyase KLDQVIIHV -0.74 -0.48 A02 RCC099 606.38 608.38 2
NYREN18 NEDD8 ultimate buster-1 RSKIAETF 0.29 0.92 B57 RCC099 549.80 # 2
ODC1 ornithine decarboxylase 1 ILDQKINEV -0.18 0.32 A02 RCC099 609.84 611.85 2
OGG1 8-oxoguan.DNA glycosyl. VLADQVWTL -3.07 0.17 A02 RCC099 575.35 # 2
ORMDL3 ORM1-L 3 VLIPKLPQL -0.07 -0.98 A02 RCC099 584.37 586.40 2
PDCD6IP progr.cell death 6 interac. prot. SLFGGSVKL -0.07 -0.78 A02 RCC099 527.81 # 2
PFN1 profilin 1 RTKSTGGAPTF -0.38 0.92 B57 RCC099 635.38 637.40 2
PGCP plasm.glutam.carboxypeptidase ALASLIRSV -0.08 -1.08 A02 RCC099 # 519.87 2
PGK1 phosphoglycerate kinase 1 VTRAKQIVW 0.50 1.27 B57 RCC099 624.36 626.40 2
PHGDHL1 phosph.glyc.dehydrogen. L1 RLFPPLRQR 0.19 0.41 A03 RCC100 644.41 646.42 2
PIGR polymeric Ig receptor FSVVINQLR -4.73 1.72 A03 RCC099 590.43 # 2
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PLS3 plastin 3 KSSDIAKTF -0.90 -0.68 B57 RCC099 # 595.40 2
PLVAP plasmalem.vesic.assocc.prot. KVKTLEVEI 0.50 0.52 A02 RCC099 624.36 626.40 2
PLXNB2 plexin B2 TYTDRVFFL 9.58 -0.50 C RCC110 # 635.48 2
POLR2C polymerase II pol.pep.C,33kDa KLSDLQTQL 3.52 0.10 A02 RCC110 # 598.93 2
PPHLN1 periphilin 1 KTKEIEQVY -0.37 -0.28 B57 RCC099 663.88 665.90 2
PPP1CA prot. phosphatase 1 alpha SIIGRLLEV -3.83 0.02 A02 RCC099 552.85 # 2
PPP1CA prot. phosphatase 1 alpha SIIGRLLEV 0.47 0.35 A02 RCC110 552.83 # 2
PPP1CA/B/C prot. phosphatase 1 alpha/b/c KYPENFFLL 6.20 0.35 C RCC110 # 661.40 2
PPP1R3C prot. phosphatase 13C GRMENLASYR -0.78 0.92 B27 RCC099 # 653.40 2
PRKDC prot. kinase, DNA-activated DEFKIGELF 0.50 0.31 B18 RCC100 # 624.92 2
PSMB1 proteasome subun. b type, 1 RRFFPYYVY 0.66 0.37 B27 RCC099 708.43 710.44 2
PSMB1 proteasome subun. b type, 1 RRFFPYYVY 0.23 0.55 B27 RCC110 708.36 # 2
PSME3 proteasome acti. subun.3 QLVDIIEKV 1.43 -0.75 A02 RCC110 602.36 # 2
PSME3 proteasome acti. subun.3 QLVDIIEKV -0.12 -0.05 A02 RCC099 # 604.38 2
PTGFRN prostgland.F2 recept.neg.regul. RLASRPLLL -0.17 -0.29 A02 RCC100 572.46 574.46 2
PTRF polym. I transcript.rel.fact. SLLDKIIGA -0.07 0.82 A02 RCC099 538.86 540.86 2
PTRF polym. I transcript.rel.fact. DEVKLPAKL -0.04 0.81 B18 RCC100 601.35 603.39 2
PTRF polym. I transcript.rel.fact. SLLDKIIGA 0.99 0.81 A02 RCC100 538.84 540.85 2
PTRF polym. I transcript.rel.fact. DEVKLPAKL -0.18 0.90 B18 RCC110 601.44 603.47 2
PTRF polym. I transcript.rel.fact. SLLDKIIGA -0.54 0.90 A02 RCC110 # 540.90 2
RAMP2 recept.activ.modif.prot. 2 RPAALRLLL -1.45 0.56 B07 RCC100 564.37 566.40 2
RASL11A RAS-L, family 11, member A YLLPKDIKL -0.37 n/a A02 RCC099 646.45 648.46 2
RBBP4/7 retinoblastoma bind.prot. 4/7 HTAKISDFSW -0.13 0.14 B57 RCC099 # 671.85 2
RBBP4/7 retinoblastoma bind.prot. 4/7 TAKISDFSW 0.43 0.14 B57 RCC099 601.34 603.39 2
RBM4/30 RNA binding motif prot. 4/30 KLHGVNINV -0.07 -0.73 A02 RCC099 570.89 572.88 2
RBM4/30 RNA binding motif prot. 4/30 KLHGVNINV -0.10 -0.03 A02 RCC110 570.82 572.87 2
RBPMS RNA bind.prot.mult.splicing TSKQPVGF 0.63 0.42 B57 RCC099 # 507.81 2
RCN1 reticulocalbin 1 RRLGLALGL 1.71 0.42 B27 RCC099 # 539.38 2
RCN1 reticulocalbin 1 RRLGLALGL 0.73 0.70 B27 RCC110 537.33 539.39 2
RPA2 replication prot. A2, 32kDa GRAPISNPGM 0.66 0.42 B27 RCC099 # 554.82 2
RPL15 ribosomal prot. L15 EVILIDPFHK -4.51 -0.05 A68 RCC110 679.37 # 2
RPL19 ribosomal prot. L19 ILMEHIHKL 0.45 0.92 A02 RCC099 640.89 642.89 2
RPL19 ribosomal prot. L19 ILMEHIHKL 1.07 0.41 A02 RCC100 # 642.89 2
RPL19 ribosomal prot. L19 ILMEHIHKL -0.34 0.70 A02 RCC110 640.86 642.97 2
RPL8 ribosomal prot. L8 GRIDKPILK 0.39 1.02 B27 RCC099 614.86 616.91 2
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RPL8 ribosomal prot. L8 GRIDKPILK 0.85 0.70 B27 RCC110 614.87 616.98 2
RPS11 Ribosomal prot. S11 GRILSGVVTK 0.31 0.12 B27 RCC099 588.88 590.89 2
RPS16 ribosomal prot. S16 ISKALVAYY 1.12 0.82 B57 RCC099 587.82 589.83 2
RPS16 ribosomal prot. S16 KLLEPVLLL 1.09 0.82 A02 RCC099 # 594.94 2
RPS25 ribosomal prot. S25 HRAQVIYTR 0.11 0.52 B27 RCC099 # 626.91 2
RPS4X ribosomal prot. S4 GRIGVITNR 0.05 0.02 B27 RCC099 545.86 547.87 2
RPS4X ribosomal prot. S4 GRIGVITNR -0.90 0.30 B27 RCC110 545.81 # 2
RPS8 ribosomal prot. S8 KTRIIDVVY 0.81 1.02 B57 RCC099 627.35 629.39 2
RSL1D1 ribosomal L1 dom.cont. 1 HIIENIVAV 0.47 1.30 A02 RCC110 # 558.90 2
SBLF stoned B-L factor SVAGKIHTV -2.19 -0.28 A02 RCC099 529.80 531.87 2
SCAP2 src assoc.phosphoprot. 2 KRGDVIYIL -0.05 0.16 n/a RCC100 612.37 614.39 2
SCAP2 src assoc.phosphoprot. 2 KRGDVIYIL -0.79 -0.90 B27 RCC110 612.36 614.47 2
SCD stearoyl-CoA desaturase ARLPLRLFL 3.96 1.52 B27 RCC099 # 604.46 2
SCD stearoyl-CoA desaturase ITAGAHRLW 1.50 1.52 B57 RCC099 # 567.31 2
SCOC short coiled-coil prot. KTRLINQVL -0.51 -0.58 B27 RCC099 # 618.43 2
SDCBP syndecan binding prot. LMDHTIPEV 0.00 0.92 A02 RCC099 580.36 582.32 2
SEC14L1 SEC14-L 1 QLIDKVWQL -0.24 -0.53 A02 RCC099 645.40 647.41 2
SEC14L1 SEC14-L 1 QLIDKVWQL -1.25 -0.20 A02 RCC110 645.37 647.43 2
SF3B3 splic.fact.3b, subun.3 GRVLIGVGK -0.29 0.62 B27 RCC099 523.32 # 2
SKP1A S-phase kin.assoc.prot.1A AILKKVIQW 0.68 0.02 A02 RCC099 # 646.45 2
SLC17A3 solute carrier family 17-3 ARYGIALVL 4.86 0.62 B27 RCC099 # 542.89 2
SNRPG small nucl.ribon.prot. G IMLEALERV 0.32 0.80 A02 RCC110 589.83 # 2
SPTBN1 spectrin b, non-erythroc. 1 DEMKVLVL -0.87 0.86 B18 RCC100 547.30 549.33 2
SPTBN1 spectrin b, non-erythroc. 1 DEMKVLVL -0.69 0.30 B18 RCC110 547.30 549.38 2
SRXN1 sulfiredoxin 1 homolog TLSDLRVYL 0.43 0.32 A02 RCC099 # 594.85 2
SSR1 signal sequence receptor VLFRGGPRGLLAVA 0.89 0.37 A02 RCC099 765.99 767.98 2
SSR1 signal sequence receptor VLFRGGPRGSLAVA -1.35 0.37 A02 RCC099 752.93 754.97 2
SSR1 signal sequence receptor VLFRGGPRGLLAVA -2.00 0.70 A02 RCC110 765.95 # 2
SSR1 signal sequence receptor VLFRGGPRGSLAVA -2.42 0.70 A02 RCC110 752.94 # 2
SSR2 signal sequence receptor b DVSHTVVLR 0.50 0.60 A68 RCC110 565.80 # 2
STAT3 s.transd.activ.transcript.3 EERIVELF -0.25 -0.09 B18 RCC100 570.32 572.34 2
STAT3 s.transd.activ.transcript.3 EERIVELF 0.10 -0.80 B18 RCC110 570.30 # 2
STAT3 s.transd.activ.transcript.3 EELQQKVSY 0.38 -0.80 B18 RCC110 635.81 # 2
SYNCRIP syn.tagm.bind.RNA interact.prot. RLFVGSIPK -0.34 0.31 A03 RCC100 582.35 584.39 2
TAGLN transgelin TGYGRPRQI -0.44 0.02 n/a RCC099 576.79 # 2
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TCF3 transcription factor 3 RVRDINEAF -0.42 -0.25 B57 RCC099 # 614.83 2
TCN2 transcobalamin II MRHLGAFLF 0.89 0.12 B27 RCC099 # 600.85 2
TEGT testis enhanced gene transcript KRLGLLAGF 0.49 -0.10 B27 RCC110 561.34 563.43 2
TLN1 talin 1 LLDHVLLTL 0.82 0.02 A02 RCC099 571.33 573.36 2
TMED10 transmemb.traff.prot. 10 FLLGPRLVLA -0.91 -0.08 A02 RCC099 602.41 604.38 2
TMED10 transmemb.traff.prot. 10 LLGPRLVLA 1.49 -0.08 A02 RCC099 528.86 530.87 2
TMED10 transmemb.traff.prot. 10 LLGPRLVLA -1.21 -0.40 A02 RCC110 528.84 # 2
TMEM16F transmembrane prot. 16F VLDDKLVFV -0.05 0.02 A02 RCC099 # 599.86 2
TMEM16F transmembrane prot. 16F VLDDKLVFV 0.28 0.61 A02 RCC100 # 599.91 2
TMEM16F transmembrane prot. 16F VLDDKLVFV 0.38 0.40 A02 RCC110 597.84 # 2
TMEM41B transmembrane prot. 41B HLINYIIFL -0.10 -1.23 A02 RCC099 # 628.35 2
TMEM66 transmembrane prot. 66 KGWDGYDVQW 0.39 0.72 B57 RCC099 700.83 702.86 2
TMEM66 transmembrane prot. 66 RRLDPIPQL -3.55 0.72 B27 RCC099 606.87 608.94 2
TMEM66 transmembrane prot. 66 RRLDPIPQL 1.35 0.40 B27 RCC110 606.86 608.95 2
TNIK TRAF2-NCK interact.kinase ITKDVVLQW 0.16 0.10 B57 RCC099 # 626.93 2
TNS1 tensin 1 HAKVLEFGW 0.81 0.32 B57 RCC099 617.40 619.34 2
TNS1 tensin 1 FLIETGPRGV 0.45 0.32 A02 RCC099 # 599.40 2
TRIM22 tripartite motif-containing 22 HLANIVERV 0.55 1.60 A02 RCC110 # 580.34 2
TRRAP transcript.dom.assoc.prot. TLADLVHHV 0.08 0.47 A02 RCC099 555.32 557.30 2
TRRAP transcript.dom.assoc.prot. TLADLVHHV 0.48 -0.04 A02 RCC100 555.35 557.33 2
TRRAP transcript.dom.assoc.prot. TLADLVHHV -1.05 -0.05 A02 RCC110 555.30 # 2
TSC2 tuberous sclerosis 2 SLLDIIEKV 0.13 -1.08 A02 RCC099 # 591.40 2
TXNIP thioredoxin interacting prot. KIKSFEVVF -0.89 0.05 A03 RCC099 643.37 645.40 2
UBB ubiquitin B QIFVKTLTGK 1.04 0.16 A03 RCC100 662.42 664.46 2
UGT1A6 UDP glucuron.transfer.1-A6 ALGKIPQTV -4.55 1.12 A02 RCC099 537.32 # 2
UMOD uromodulin RAFSSLGLLK -5.49 -7.19 A03 RCC100 619.85 # 2
UNC84B unc-84 homolog B RIRPTAVTL -0.58 0.11 A02 RCC100 566.36 568.37 2
USMG5 upregul.skelet.musc.grow.5 YQFTGIKKY -0.69 -0.28 B27 RCC099 668.89 670.94 2
USP9X ubiquit.specif.peptidase 9 RLWGEPVNL -0.23 -0.10 A02 RCC110 # 596.88 2
UTRN utrophin KLLDPEDVAVQL -0.66 -0.48 A02 RCC099 743.93 746.00 2
VIM vimentin ARLDLERKV 1.13 1.82 B27 RCC099 623.93 625.93 2
VIM vimentin NLAEDIMRL 0.27 1.82 A02 RCC099 # 592.29 2
VIM vimentin NYIDKVRFL 1.02 1.82 C RCC099 657.88 659.86 2
VIM vimentin LERKVESL 1.61 1.90 B18 RCC110 560.91 562.89 2
WDR78 WD repeat domain 78 TSVVYDVAW 0.32 0.52 B57 RCC099 572.83 574.83 2
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XPO1 exportin 1 VLIDYQRNV 0.09 0.32 A02 RCC099 # 614.86 2
YTHDF1/2/3 YTH dom.fam. 1/2/3 GRVFIIKSY 0.91 -0.01 B27 RCC099 615.38 617.38 2
YTHDF1/2/3 YTH dom.fam. 1/2/3 GRVFIIKSY -0.45 0.20 B27 RCC110 # 617.45 2
ZA20D2 zinc finger A20 dom.cont.2 IRKENPVVV 0.62 -0.08 B27 RCC099 600.86 # 2
ZFR zinc finger RNA binding prot. DEGKVIRF 0.23 -0.07 B18 RCC110 # 557.87 2
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Table A.3.: MASCOT search results for 50 randomly chosen peptides identified in RCC099. With 50 randomly chosen sequence tags
derived from HLA peptides found in RCC099 MASCOT searches were performed against a database containing the EBI IPI
database in a normal and a reversed format. Peptides with only one MASCOT hit are marked in bold, peptides resulting in
MASCOT hits with a significant score (>63) are highlighted in bold and italic.
Sequence [M-H]
+
calc.
MASCOT searched sequence tag No. hits
IPI
No. hits
rIPI
max.
MASCOT
score IPI
max.
MASCOT
score rIPI
RLLAAALLL 1062.78 1062.90 seq(n-R[IL][IL]AAA[IL][IL][IL]) 1 0 90 n.a.
LVHAVQALW 1145.72 1145.76 seq(c-AVQALW) 1 0 78 n.a.
KLHGVNINV 1144.73 1144.86 seq(n-K) tag(530.41,GVN[IL],913.64) 1 1 77 67
LLDRFLATV 1156.75 1156.76 seq(n-[IL][IL]DRF[IL]A) 1 0 72 n.a.
KLDQVIIHV 1215.80 1215.86 seq(n-K) tag(508.4,QV[IL][IL],961.78) 1 0 72 n.a.
HAKVLEFGW 1237.72 1237.78 seq(n-H) seq(c-EFGW) 1 0 70 n.a.
SLLDKIIGA 1080.72 1080.82 seq(n-S[IL][IL]D) tag(708.5,[IL][IL],934.66) 1 0 69 n.a.
LGRPDAEYW 1215.65 1215.76 seq(n-[IL]) seq(c-AEYW) 1 0 68 n.a.
RLLDYVVNI 1213.77 1213.84 seq(n-R) seq(c-YVVN[IL]) 1 0 67 n.a.
KLLDEVTYL 1244.76 1244.90 seq(n-K) tag(621.48,EVT,950.7) comp(*[Y]) 1 0 67 n.a.
FLEKLLPPV 1206.80 1206.92 seq(n-F[IL]EK[IL][IL]) 1 0 65 n.a.
ARYGIALVL 1084.73 1084.88 seq(n-A) seq(c-[IL]A[IL]V[IL]) 1 0 63 n.a.
KLSELEAAL 1124.71 1124.74 seq(n-K) seq(c-[IL]EAA[IL]) 1 0 63 n.a.
GRVFIIKSY 1233.79 1233.86 seq(n-GRVF[IL][IL]) 1 0 63 n.a.
KTRLINQVL 1235.83 1235.86 seq(n-K) seq(c-NQV[IL]) 1 0 63 n.a.
TAVALLRLL 1078.77 1078.84 seq(n-TAVA[IL][IL]) 2 0 62 n.a.
RSGVKVVTF 1143.74 1143.84 seq(n-R) seq(c-VVTF) 1 0 62 n.a.
TLADIIARL 1094.73 1094.84 seq(n-T[IL]AD[IL][IL]) 1 0 61 n.a.
ILMEHIHKL 1284.80 1284.78 seq(n-[IL][IL]MEH) 1 0 61 n.a.
RLLDVLAPL 1118.77 1118.88 seq(n-R[IL][IL]DV[IL]) 2 0 60 n.a.
KAGQVVTIW 1152.73 1152.90 seq(c-VVT[IL]W)/1152.9 seq(c-VVT[IL][ADGEVS][ADGEVS]) 1 0 60 n.a.
FLLGPRLVLA 1207.83 1207.86 seq(n-F[IL][IL]) seq(c-[IL]V[ILAPS][ILAPS]) 1 0 60 n.a.
HLINYIIFL 1254.80 1254.80 seq(n-H[IL][IL]NY) 1 0 59 n.a.
KTKEIEQVY 1330.79 1330.90 seq(c-[IL]EQVY) 1 1 59 60
RRLGLALGL 1077.76 1077.86 seq(n-R) seq(c-[IL]A[IL]G[IL]) 1 0 58 n.a.
RRSSIQSTF 1190.70 1190.86 seq(c-[IL]QSTF) 1 0 58 n.a.
SLLDIIEKV 1180.77 1180.90 seq(n-S[IL][IL]D[IL][IL]) 2 0 57 n.a.
ARLPLRLFL 1207.84 1208.02 seq(n-AR) seq(c-LFL) 1 0 57 n.a.
LLGPRLVLA 1060.76 1060.84 seq(n-[IL][IL]) seq(c-[IL]V[IL]A) 1 0 56 n.a.
LLAAWTARA 1081.69 1081.80 seq(n-[IL][IL]AAW) 2 0 55 n.a.
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ALFDIESKV 1172.71 1172.80 seq(n-A[IL]FD) seq(c-V) 1 0 55 n.a.
TLSDLRVYL 1188.74 1188.80 seq(n-T[IL]SD[IL]) 3 0 55 n.a.
ILTDITKGV 1106.70 1106.72 seq(n-[IL][IL]TD) seq(c-V) 2 2 55 50
VLFGLLREV 1154.77 1154.82 seq(n-V[IL]FG[IL][IL]) 1 0 54 n.a.
QLVDIIEKV 1207.78 1207.86 seq(n-Q[IL]VD[IL]) 2 0 54 n.a.
NLAEDIMRL 1183.69 1183.68 seq(n-N[IL]AED) 1 1 54 51
GRIGQAIAR 1050.69 1050.76 seq(n-G) seq(c-A[IL]AR) 1 1 53 46
ILFGHENRV 1189.69 1189.66 seq(n-[IL][IL]FG) seq(c-V) 1 0 52 n.a.
ITKDVVLQW 1252.78 1252.96 seq(c-V[IL]QW) 2 0 52 n.a.
ALADLDELLIRA 1421.88 1421.88 seq(n-A[IL]AD[IL]D) 1 0 52 n.a.
ALADGVQKV 1051.67 1051.72 seq(n-A[IL]ADG) 1 0 51 n.a.
VLDDKLVFV 1198.76 1198.82 seq(n-V[IL]) tag(722.5,[IL]V,934.66) comp(*[F]) 1 2 51 54
VGLPAAGKTTW 1251.76 1251.84 seq(n-VG[IL]PA) 1 0 50 n.a.
LLDHVLLTL 1145.77 1145.82 seq(c-V[IL][IL]T[IL]) 3 0 47 n.a.
KIKSFEVVF 1289.81 1289.90 seq(c-EVVF) 1 0 47 n.a.
QLIDKVWQL 1293.81 1293.92 seq(n-Q[IL][IL]D) comp(*[W]) 1 0 47 n.a.
FLIETGPRGV 1197.74 1197.90 seq(n-F[IL][IL]ET) 1 0 46 n.a.
ISKALVAYY 1178.73 1178.84 seq(n-[IL]SKA) 2 1 46 45
ITAGAHRLW 1133.70 1133.72 seq(n-[IL]TAG) 7 2 46 44
KRTTVVAQL 1166.78 1166.86 seq(c-VAQ[IL]) 4 2 44 40
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Table A.4.: HLA ligands identified in more than one RCC patient. 31 HLA ligands were identified in two tumour and normal tissue
pairs, 11 ligands in all analysed samples. Thus in total 64 HLA ligand comparisons were drawn. Gene Symbol and Title can
be found at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene.
Gene
Symbol Gene Title Sequence
2log HLA
ligand ratio
2log mRNA
ratio
HLA
restrict.
Source
ADFP adip.diff.-related prot. VRLGSLSTK −0.81 3.60 B27 RCC110
ADFP adip.diff.-related prot. VRLGSLSTK 4.22 −0.08 B27 RCC099
ALDOA aldolase A ALSDHHIYL 2.11 1.01 A02 RCC100
ALDOA aldolase A ALSDHHIYL 2.23 0.60 A02 RCC110
ALDOA aldolase A ALSDHHIYL 3.38 2.72 A02 RCC099
ANXA4 annexin A4 DEVKFLTV 3.52 1.41 B18 RCC100
ANXA4 annexin A4 DEVKFLTV 1.95 2.20 B18 RCC110
APOL1 apolipoprot. L1 ALADGVQKV 0.20 1.90 A02 RCC110
APOL1 apolipoprot. L1 ALADGVQKV 0.78 1.52 A02 RCC099
ASCC3L1 activ.signal coint. 1-3-L 1 DEHLITFF 0.88 0.71 B18 RCC100
ASCC3L1 activ.signal coint. 1-3-L 1 DEHLITFF 0.23 0.20 B18 RCC110
C2orf24 chrom. 2 ORF 24 GRWRGWYTY 0.42 1.10 B27 RCC110
C2orf24 chrom. 2 ORF 24 GRWRGWYTY 0.49 0.72 B27 RCC099
CD59 CD59 antigen SLSEKTVLL −0.32 −0.44 A02 RCC100
CD59 CD59 antigen SLSEKTVLL −1.17 −0.20 A02 RCC110
CD59 CD59 antigen SLSEKTVLL −1.04 −0.78 A02 RCC099
CLIC1/4 Cl- intracell.chan. 1/4 NLLPKLHIV 1.18 0.41 A02 RCC100
CLIC1/4 Cl- intracell.chan. 1/4 NLLPKLHIV −0.82 0.95 A02 RCC110
CLIC1/4 Cl- intracell.chan. 1/4 NLLPKLHIV −1.34 0.65 A02 RCC099
COPG coatom.prot.complex, g AIVDKVPSV 1.32 0.40 A02 RCC110
COPG coatom.prot.complex, g AIVDKVPSV 0.77 1.02 A02 RCC099
CREB3L1 cAMP respons.element binding 3-L 1 KRTLIAEGY 0.09 0.30 B27 RCC110
CREB3L1 cAMP respons.element binding 3-L 1 KRTLIAEGY 0.78 0.02 B27 RCC099
DDX5/17 DEAD box pol.pep. 5/17 YLLPAIVHI 0.55 −0.61 A02 RCC099
DDX5/17 DEAD box pol.pep. 5/17 YLLPAIVHI 0.18 −0.40 A02 RCC110
DST/MACF1 dyst.microt.actin crossl. fact. 1 SRWEKVVQR −0.21 0.13 B27 RCC110
DST/MACF1 dyst.microt.actin crossl. fact. 1 SRWEKVVQR −0.22 −0.78 B27 RCC099
EEF2 eukaryotic translation elongat. factor 2 ILTDITKGV −1.27 0.50 A02 RCC110
EEF2 eukaryotic translation elongat. factor 2 ILTDITKGV −0.91 0.42 A02 RCC099
EFHD1 EF-hand domain family D1 KLSEIDVAL 0.15 −2.99 A02 RCC100
EFHD1 EF-hand domain family D1 KLSEIDVAL 0.37 −2.30 A02 RCC110
EFHD1 EF-hand domain family D1 KLSEIDVAL −0.77 −3.18 A02 RCC099
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EHD2 EH-domain containing 2 ALASHLIEA 1.82 3.41 A02 RCC100
EHD2 EH-domain containing 2 ALASHLIEA −0.21 1.00 A02 RCC110
EHD2 EH-domain containing 2 ALASHLIEA 1.07 3.32 A02 RCC099
G3BP Ras-GTPase-activating prot. RRFMQTFVL 0.65 0.10 B27 RCC110
G3BP Ras-GTPase-activating prot. RRFMQTFVL 0.88 0.47 B27 RCC099
HDAC1/2 histone deacetylase 1/2 RMLPHAPGV −0.47 0.21 A02 RCC100
HDAC1/2 histone deacetylase 1/2 RMLPHAPGV −0.35 −0.05 A02 RCC110
HDAC1/2 histone deacetylase 1/2 RMLPHAPGV −0.07 −0.38 A02 RCC099
HNRPC heterogen. nuclear ribonucleoprot. C SLLENLEKI 1.14 −0.19 A02 RCC100
HNRPC heterogen. nuclear ribonucleoprot. C SLLENLEKI 0.18 0.00 A02 RCC110
IFI30 IFN-g-inducib.prot. 30 LLDVPTAAV −0.03 1.80 A02 RCC110
IFI30 IFN-g-inducib.prot. 30 LLDVPTAAV −0.34 1.42 A02 RCC099
KRT18 keratin 18 RLASYLDRV 1.00 0.91 A02 RCC100
KRT18 keratin 18 RLASYLDRV −0.51 −0.20 A02 RCC110
KRT18 keratin 18 RLASYLDRV −0.14 1.22 A02 RCC099
MAT1A/2A met.adenosyltransf. Ia/Iia RRVLVQVSY 4.08 0.50 B27 RCC110
MAT1A/2A met.adenosyltransf. Ia/Iia RRVLVQVSY 0.48 −0.48 B27 RCC099
NCSTN nicastrin RRSSIQSTF 0.99 0.70 B27 RCC110
NCSTN nicastrin RRSSIQSTF 0.09 0.22 B27 RCC099
NDRG1 N-myc downstr.regul.gene 1 KLDPTKTTL 3.03 1.90 A02 RCC110
NDRG1 N-myc downstr.regul.gene 1 KLDPTKTTL 2.75 0.62 A02 RCC099
PPP1CA prot. phosphatase 1 alpha SIIGRLLEV 0.47 0.35 A02 RCC110
PPP1CA prot. phosphatase 1 alpha SIIGRLLEV −3.83 0.02 A02 RCC099
PSMB1 proteasome subun. b type, 1 RRFFPYYVY 0.23 0.55 B27 RCC110
PSMB1 proteasome subun. b type, 1 RRFFPYYVY 0.66 0.37 B27 RCC099
PSME3 proteasome acti. subun.3 QLVDIIEKV −0.12 −0.05 A02 RCC099
PSME3 proteasome acti. subun.3 QLVDIIEKV 1.43 −0.75 A02 RCC110
PTRF polym. I transcript.rel.fact. DEVKLPAKL −0.04 0.81 B18 RCC100
PTRF polym. I transcript.rel.fact. DEVKLPAKL −0.18 0.90 B18 RCC110
PTRF polym. I transcript.rel.fact. SLLDKIIGA 0.99 0.81 A02 RCC100
PTRF polym. I transcript.rel.fact. SLLDKIIGA −0.54 0.90 A02 RCC110
PTRF polym. I transcript.rel.fact. SLLDKIIGA −0.07 0.82 A02 RCC099
RBM4 RNA binding motif prot. 4 KLHGVNINV −0.10 −0.03 A02 RCC110
RBM4 RNA binding motif prot. 4 KLHGVNINV −0.07 −0.73 A02 RCC099
RCN1 reticulocalbin 1 RRLGLALGL 0.73 0.70 B27 RCC110
RCN1 reticulocalbin 1 RRLGLALGL 1.71 0.42 B27 RCC099
continued on next page
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Table A.4 – contiuned
Gene
Symbol Gene Title Sequence
2log HLA
ligand ratio
2log mRNA
ratio
HLA
restrict.
Source
RPL19 ribosomal prot. L19 ILMEHIHKL 1.07 0.41 A02 RCC100
RPL19 ribosomal prot. L19 ILMEHIHKL −0.34 0.70 A02 RCC110
RPL19 ribosomal prot. L19 ILMEHIHKL 0.45 0.92 A02 RCC099
RPL8 ribosomal prot. L8 GRIDKPILK 0.85 0.70 B27 RCC110
RPL8 ribosomal prot. L8 GRIDKPILK 0.39 1.02 B27 RCC099
RPS4X ribosomal prot. S4 GRIGVITNR −0.90 0.30 B27 RCC110
RPS4X ribosomal prot. S4 GRIGVITNR 0.05 0.02 B27 RCC099
SCAP2 src assoc.phosphoprot. 2 KRGDVIYIL −0.05 0.16 n/a RCC100
SCAP2 src assoc.phosphoprot. 2 KRGDVIYIL −0.79 −0.90 B27 RCC110
SEC14L1 SEC14-L 1 QLIDKVWQL −1.25 −0.20 A02 RCC110
SEC14L1 SEC14-L 1 QLIDKVWQL −0.24 −0.53 A02 RCC099
SPTBN1 spectrin b, non-erythroc. 1 DEMKVLVL −0.87 0.86 B18 RCC100
SPTBN1 spectrin b, non-erythroc. 1 DEMKVLVL −0.69 0.30 B18 RCC110
SSR1 signal sequence receptor VLFRGGPRGLLAVA −2.00 0.70 A02 RCC110
SSR1 signal sequence receptor VLFRGGPRGLLAVA 0.89 0.37 A02 RCC099
SSR1 signal sequence receptor VLFRGGPRGSLAVA −2.42 0.70 A02 RCC110
SSR1 signal sequence receptor VLFRGGPRGSLAVA −1.35 0.37 A02 RCC099
STAT3 s.transd.activ.transcript.3 EERIVELF −0.25 −0.09 B18 RCC100
STAT3 s.transd.activ.transcript.3 EERIVELF 0.10 −0.80 B18 RCC110
TMED10 transmemb.traff.prot. 10 LLGPRLVLA −1.21 −0.40 A02 RCC110
TMED10 transmemb.traff.prot. 10 LLGPRLVLA 1.49 −0.08 A02 RCC099
TMEM16F transmembrane prot. 16F VLDDKLVFV 0.28 0.61 A02 RCC100
TMEM16F transmembrane prot. 16F VLDDKLVFV 0.38 0.40 A02 RCC110
TMEM16F transmembrane prot. 16F VLDDKLVFV −0.05 0.02 A02 RCC099
TMEM66 transmembrane prot. 66 RRLDPIPQL 1.35 0.40 B27 RCC110
TMEM66 transmembrane prot. 66 RRLDPIPQL −3.55 0.72 B27 RCC099
TRRAP transcript.dom.assoc.prot. TLADLVHHV 0.48 −0.04 A02 RCC100
TRRAP transcript.dom.assoc.prot. TLADLVHHV −1.05 −0.05 A02 RCC110
TRRAP transcript.dom.assoc.prot. TLADLVHHV 0.08 0.47 A02 RCC099
YTHDF1/2/3 YTH dom.fam. 1/2/3 GRVFIIKSY −0.45 0.20 B27 RCC110
YTHDF1/2/3 YTH dom.fam. 1/2/3 GRVFIIKSY 0.91 −0.01 B27 RCC099
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Table A.5.: The majority of HLA ligands significantly over-presented on tumour tissue
derived from tumour associations antigens. Out of the 30 redundant source
proteins (Figure 4, area I-III) 19 were described to be tumour associated.
10 HLA ligands were found uniquely presented on tumour tissue (marked in
bold). 8 of their source proteins were reported to be tumour associated.
Gene
Symbol Gene Title Sequence
2log
HLA
ligand
ratio
2log
mRNA
ratio
Source Literature
ADFP adip.diff.-related prot. SLLTSSKGQLQK 2.32 1.71 RCC100 [1]
ADFP adip.diff.-related prot. VRLGSLSTK 4.22 −0.08 RCC099 [1]
AKR1C1 aldo-keto reductase family 1C1 RPELVRPAL 1.97 0.29 RCC100 [2]
ALDH1L1 aldeh.dehyd. 1L1 RVKTVTFEY 4.04 −0.38 RCC099 [3]
ALDOA aldolase A ALSDHHIYL 2.11 1.01 RCC100 -
ALDOA aldolase A ALSDHHIYL 2.23 0.60 RCC110 -
ALDOA aldolase A RTVPPAVTGITF 2.63 2.72 RCC099 -
ALDOA aldolase A ALSDHHIYL 3.38 2.72 RCC099 -
ANXA4 annexin A4 DEVKFLTV 1.95 2.20 RCC110 [4]
ANXA4 annexin A4 DEVKFLTV 3.52 1.41 RCC100 [4]
C10orf10 chrom. 10 ORF 10 RPSSVLRTL 2.96 3.01 RCC100 -
CD24 CD24 antigen RAMVARLGL 5.32 0.71 RCC100 [5]
CIB1 Ca2+integrin bind. 1 FLTKQEILL 2.55 0.42 RCC099 [6]
CLIC5 Cl- intracell.chan. 5 NLLPKLHVV 3.00 −2.75 RCC099 -
CSPG4 chondr.sulf.proteoglyc. 4 TMLARLASA 3.38 2.81 RCC100 [7]
CXCL14 chemok.(C-X-C motif)lig. 14 RLLAAALLL 2.09 0.47 RCC099 [8]
CYP2J2 cytochrome P450, family 2J2 KLLDEVTYL 4.78 2.32 RCC099 -
DDX48 DEAD box pol.pep. 48 GRKGVAINF 2.48 −0.28 RCC110 [9]
EHD2 EH-domain containing 2 ALASHLIEA 1.82 3.41 RCC100 -
HLA-B m.histocomp.complex I B TAAQITQRKW 1.61 1.29 RCC099 -
HLA-B m.histocomp.complex I B AAQITQRKW 1.84 1.29 RCC099 -
HMOX1 heme oxygenase 1 KIAQKALDL 2.30 3.70 RCC110 [10]
HSPG2 hep.sul.prot.glyc. 2 ALADLDELLIRA 1.56 −0.08 RCC099 [11]
IL32 interleukin 32 LVHAVQALW 2.17 1.82 RCC099 -
IMP3 U3 small nucl.ribonuc.prot. ALLDKLYAL 1.59 0.91 RCC100 -
KRT18 keratin 18 ALLNIKVKL 2.06 1.22 RCC099 [12]
MAT1A/2A met.adenosyltransf. Ia/Iia RRVLVQVSY 4.08 0.50 RCC110 -
NAT8 N-acetyltransferase 8 ILDTGTIQL 1.65 −1.28 RCC099 [13]
NDRG1 N-myc downstr.regul.gene 1 KLDPTKTTL 2.75 0.62 RCC099 [14]
NDRG1 N-myc downstr.regul.gene 1 KLDPTKTTL 3.03 1.90 RCC110 [14]
PLXNB2 plexin B2 TYTDRVFFL 9.58 −0.50 RCC110 [15]
POLR2C polymerase II pol.pep.C,33kDa KLSDLQTQL 3.52 0.10 RCC110 [16]
PPP1CA/B/C prot. phosphatase 1 alpha/b/c KYPENFFLL 6.20 0.35 RCC110 [17]
RCN1 reticulocalbin 1 RRLGLALGL 1.71 0.42 RCC099 -
SCD stearoyl-CoA desaturase ITAGAHRLW 1.50 1.52 RCC099 [18]
SCD stearoyl-CoA desaturase ARLPLRLFL 3.96 1.52 RCC099 [18]
SLC17A3 solute carrier family 17-3 ARYGIALVL 4.86 0.62 RCC099 -
VIM vimentin LERKVESL 1.61 1.90 RCC110 [19]
[1] S. M. Schmidt, K. Schag, M. R. Muller, T. Weinschenk, S. Appel, O. Schoor,
M. M. Weck, F. Grunebach, L. Kanz, S. Stevanovic, H. G. Rammensee, and
P. Brossart. Induction of adipophilin-specific cytotoxic T lymphocytes using
a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res.,
64(3):1164–1170, 2004.
[2] C. Y. Chen, C. P. Hsu, N. Y. Hsu, C. S. Shih, T. Y. Lin, and K. C. Chow.
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Expression of dihydrodiol dehydrogenase in the resected stage I non-small
cell lung cancer. Oncol. Rep., 9(3):515–519, 2002.
[3] S. A. Krupenko and N. V. Oleinik. 10-formyltetrahydrofolate dehydrogenase,
one of the major folate enzymes, is down-regulated in tumor tissues and
possesses suppressor effects on cancer cells. Cell Growth Differ., 13(5):227–
236, 2002.
[4] U. Zimmermann, S. Balabanov, J. Giebel, S. Teller, H. Junker, D. Schmoll,
C. Protzel, C. Scharf, B. Kleist, and R. Walther. Increased expression and
altered location of annexin IV in renal clear cell carcinoma: a possible role
in tumour dissemination. Cancer Lett., 209(1):111–118, 2004.
[5] S. Schindelmann, J. Windisch, R. Grundmann, R. Kreienberg, R. Zeillinger,
and H. Deissler. Expression profiling of mammary carcinoma cell lines: cor-
relation of in vitro invasiveness with expression of CD24. Tumour. Biol., 23
(3):139–145, 2002.
[6] H. Lee, E. C. Yi, B. Wen, T. P. Reily, L. Pohl, S. Nelson, R. Aebersold, and
D. R. Goodlett. Optimization of reversed-phase microcapillary liquid chro-
matography for quantitative proteomics. J. Chromatogr. B Analyt. Technol.
Biomed. Life Sci., 803(1):101–110, 2004.
[7] J. Yang, M. A. Price, C. L. Neudauer, C. Wilson, S. Ferrone, H. Xia, J. Iida,
M. A. Simpson, and J. B. McCarthy. Melanoma chondroitin sulfate proteo-
glycan enhances FAK and ERK activation by distinct mechanisms. J. Cell
Biol., 165(6):881–891, 2004.
[8] S. R. Schwarze, J. Luo, W. B. Isaacs, and D. F. Jarrard. Modulation of
CXCL14 (BRAK) expression in prostate cancer. Prostate, 64(1):67–74, 2005.
[9] Q. Xia, X. T. Kong, G. A. Zhang, X. J. Hou, H. Qiang, and R. Q. Zhong.
Proteomics-based identification of DEAD-box protein 48 as a novel autoanti-
gen, a prospective serum marker for pancreatic cancer. Biochem. Biophys.
Res. Commun., 330(2):526–532, 2005.
[10] P. O. Berberat, Z. Dambrauskas, A. Gulbinas, T. Giese, N. Giese, B. Kunzli,
F. Autschbach, S. Meuer, M. W. Buchler, and H. Friess. Inhibition of heme
oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer
treatment. Clin. Cancer Res., 11(10):3790–3798, 2005.
[11] E. M. Gonzalez, M. Mongiat, S. J. Slater, R. Baffa, and R. V. Iozzo. A novel
interaction between perlecan protein core and progranulin: potential effects
on tumor growth. J. Biol. Chem., 278(40):38113–38116, 2003.
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[12] U. Woelfle, G. Sauter, S. Santjer, R. Brakenhoff, and K. Pantel. Down-
regulated expression of cytokeratin 18 promotes progression of human breast
cancer. Clin. Cancer Res., 10(8):2670–2674, 2004.
[13] C. Lilla, E. Verla-Tebit, A. Risch, B. Jager, M. Hoffmeister, H. Brenner,
and J. Chang-Claude. Effect of NAT1 and NAT2 genetic polymorphisms on
colorectal cancer risk associated with exposure to tobacco smoke and meat
consumption. Cancer Epidemiol. Biomarkers Prev., 15(1):99–107, 2006.
[14] H. Cangul, K. Salnikow, H. Yee, D. Zagzag, T. Commes, and M. Costa.
Enhanced expression of a novel protein in human cancer cells: a potential
aid to cancer diagnosis. Cell Biol. Toxicol., 18(2):87–96, 2002.
[15] P. Conrotto, S. Corso, S. Gamberini, P. M. Comoglio, and S. Giordano.
Interplay between scatter factor receptors and B plexins controls invasive
growth. Oncogene, 23(30):5131–5137, 2004.
[16] R. J. White. RNA polymerases I and III, growth control and cancer. Nat.
Rev. Mol. Cell Biol., 6(1):69–78, 2005.
[17] M. Fujita, C. Seta, J. Fukuda, S. Kobayashi, and T. Haneji. Induction of
apoptosis in human oral squamous carcinoma cell lines by protein phos-
phatase inhibitors. Oral Oncol., 35(4):401–408, 1999.
[18] N. Scaglia, J. M. Caviglia, and R. A. Igal. High stearoyl-CoA desaturase
protein and activity levels in simian virus 40 transformed-human lung fi-
broblasts. Biochim. Biophys. Acta, 1687(1-3):141–151, 2005.
[19] S. Singh, S. Sadacharan, S. Su, A. Belldegrun, S. Persad, and G. Singh.
Overexpression of vimentin: role in the invasive phenotype in an androgen-
independent model of prostate cancer. Cancer Res., 63(9):2306–2311, 2003.
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Table A.6.: HLA ligands identified from LCL721.174 and LCL721.45. HLA presentation ratios, protein and mRNA expression
ratios were calculated between LCL721.174 and LCL721.45. Signal sequence prediction was performed with Sig-
nalP (http://www.cbs.dtu.dk/services/SignalP/). SYFPEITHI and BIMAS scores were calculated using web based
software (http://www.syfpeithi.de, http://www-bimas.cit.nih.gov/molbio/hla_bind). Gene Symbol can be found at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene.
2log (721.174 vs. 721.45)
Sequence GeneSymbol position signal seq. HLA
SYFP-
EITHI
score
Bimas
score
HLA protein mRNA
LLSAEPVPA CD79B 20-28 28 | 29 A*0201 18 8 9.12 n.s.d. 0.30
LLGPRLVLA TMP21 22-31 31 | 32 A*0201 24 19 7.98 n.d. -0.80
SLWGQPAEA COL4A5 18-26 26 | 27 A*0201 23 41 6.96 n.a. -0.10
VLAPRVLRA RCN1 21-29 29 | 30 A*0201 24 19 6.91 -0.04 -0.40
ALVVQVAEA HEXB 34-42 42 | 43 A*0201 24 11 6.86 n.d. -0.70
HGVFLPLV KIAA0247 21-28 39 | 40 B*5101 26 n.a. 6.53 n.d. -0.10
LLAAWTARA APP 9-17 17 | 18 A*0201 22 8 6.52 n.d. 0.00
VLLKARLVPA KIAA1946 19-28 28 | 29 or 33 | 34 A*0201 23 72 5.58 n.d. -1.10
KMDASLGNLFA FAM3C 30-40 24 | 25 A*0201 23 6 5.19 n.d. 0.40
LLFSHVDHVIA SLC8A1 25-35 35 | 36 A*0201 22 27 4.81 n.d. 721.174 only
FLGPWPAAS LRPAP1 22-30 28 | 29 or 32 | 33 A*0201 16 0 4.57 n.d. -0.40
SLYALHVKA VKORC1 23-31 31 | 32 A*0201 16 16 4.53 n.d. n.d.
LLLSAEPVPA CD79B 19-28 28 | 29 A*0201 20 31 4.48 n.d. 0.30
AMAPPSHLLL PELP1 473-482 21 | 22 A*0201 25 15 4.19 n.d. 721.174 only
MAPLALHLL IL4I1 1-9 21 | 22 B*5101 21 n.a. 4.17 n.s.d. n.d.
FLLGPRLVLA TMP21 22-31 31 | 32 A*0201 27 149 4.16 n.s.d. -0.80
LLLDVPTAAV IFI30 15-24 26 | 27 A*0201 30 128 4.15 n.s.d. -0.20
LLLDVPTAAVQA IFI30 15-26 26 | 27 A*0201 20 128 3.89 n.s.d. -0.20
LLLDVPTAA IFI30 15-23 26 | 27 A*0201 20 128 3.88 n.s.d. -0.20
LLDVPTAAV IFI30 16-24 26 | 27 A*0201 28 47 3.85 n.s.d. -0.20
VLFRGGPRGLLAVA SSR1 19-32 20 | 21 A*0201 23 0 3.68 n.s.d. -1.57
ALLSSLNDF NIF3L1 5-13 no A*0201 19 1 3.68 n.d. 0.10
IITKEVLAP EST sequence frame 3 n.a. A*0201 15 0 3.68 n.d. n.d.
QLQEGKNVIGL TAGLN2 166-176 no A*0201 23 18 2.98 0.25 -0.10
ILAPAGSLPKI TERE1 328-338 no A*0201 n.a. n.a. 2.63 n.d. 0.60
MASRWGPLIG Cab45 8-17 36 | 37 B*5101 21 260 2.19 n.d. -0.10
AVLALVLAPAGA NRP1 10-21 21 | 22 A*0201 23 19 2.11 n.d. n.d.
LAPRVLRA RCN1 22-29 29 | 30 A*0201 n.a. n.a. 2.08 -0.04 -0.40
continued on next page
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Table A.6 – contiuned
2log (721.174 vs. 721.45)
Sequence GeneSymbol position signal seq. HLA
SYFP-
EITHI
score
Bimas
score
HLA protein mRNA
AALLDVRSVP GDF5 275-284 27 | 28 A*0201 24 2 1.94 n.d. n.d.
SLPKKLALL HSPC023 72-80 no A*0201 29 49 1.70 n.d. 0.40
KAPVTKVAA PDLIM1 241-249 no n.a. n.a. n.a. 0.81 1.32 1.60
NPLPSKETI TMSB4X 27-35 no B*5101 26 586 0.29 -0.32 n.d.
MFPLVKSAL COX7B 1-9 no B*5101 18 n.a. -0.15 n.d. 0.00
MAPRTLVL HLA-A 4-11 24 | 25 B*5101 24 n.a. -0.93 n.d. -0.80
TLLGHEFVL CDC27 605-613 no A*0201 24 188 -1.29 n.d. 0.70
LPHVPLGVI AUP1 374-382 yes B*5101 26 629 -1.74 n.d. 0.50
YLTAEILEL HIST1H2AJ 58-66 61 | 62 A*0201 28 226 -1.86 0.49 n.d.
LPREILNLI LOC116064 259-267 no B*5101 26 692 -1.87 n.d. 0.65
LLDRFLATV CCNI 72-80 no A*0201 31 413 -2.25 n.d. 0.20
GSHSMRYF HLA-A, -B, -C, -G 25-32 24 | 25 n.a. n.a. n.a. -2.34 n.d. n.d.
HLINYIIFL TMEM41B 240-248 no A*0201 27 9 -2.54 n.d. n.d.
YVPRAILV TUBB3 59-66 no B*5101 14 n.a. -2.81 n.a. n.d.
TLAEIAKVEL NONO 120-129 no A*0201 28 88 -2.86 0.41 0.70
RIIEETLAL ARPC2 9-17 no A*0201 26 12 -3.04 -0.04 -0.15
DGLVVLKI EIF3S3 42-49 no B*5101 27 n.a. -3.07 n.s.d. 0.20
MAPRTLLL HLA-C 4-11 24 | 25 B*5101 22 n.a. -3.12 n.d. -0.98
VMAPRTLVL HLA-A 3-11 24 | 25 A*0201 24 n.a. -3.23 n.d. -0.80
IPPIQVTKV NCOR2 973-981 no B*5101 26 286 -3.42 n.d. -0.20
KLWEMDNMLI PP784 56-65 no A*0201 25 2544 -3.49 n.d. n.d.
YAYDGKDYLAL HLA-A, -B, -C 140-150 24 | 25 B*5101 23 173 -3.51 n.d. n.d.
IPPLIKSV DSCAM 1573-1580 17 | 18 B*5101 25 n.a. -3.52 n.d. n.d.
QLDDLKVEL RPL35 20-28 no A*0201 26 35 -3.53 n.s.d. 0.90
YAYDGKDYL HLA-G 140-148 24 | 25 B*5101 23 173 -3.79 n.d. -1.15
IARVLTVI RPL35 54-61 no B*5101 25 n.a. -3.91 n.s.d. 0.90
DALDVANKIGII RPL23A 145-156 no B*5101 33 484 -3.97 0.25 0.00
LPFRVLLV WDR54 80-87 no B*5101 30 n.a. -3.98 n.d. n.d.
IPYQDLPHL MGLL 14-22 no B*5101 24 286 -4.01 n.d. -0.70
TIIDTKGVTAL PAF53 174-184 no A*0201 25 4 -4.01 n.d. 1.45
FLTKQEILL CIB1 21-29 no A*0201 20 98 -4.10 n.d. 0.20
VPYPLPKI NPEPPS 254-261 no B*5101 28 n.a. -4.13 -0.3 0.07
SLLDRFLATV CCNI 71-80 no A*0201 33 9221 -4.21 n.d. 0.20
LLIDDKGTIKL CDC2 134-144 no A*0201 25 8 -4.30 0.34 0.55
ILHEIAVLEL STK17B 77-86 no A*0201 31 342 -4.35 n.d. -0.10
continued on next page
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Table A.6 – contiuned
2log (721.174 vs. 721.45)
Sequence GeneSymbol position signal seq. HLA
SYFP-
EITHI
score
Bimas
score
HLA protein mRNA
DALDKIRLI TRA1 110-118 yes B*5101 30 532 -4.35 -0.38 -0.70
HLANIVERV TRIM22 73-81 no A*0201 26 3 -4.39 n.d. -0.30
ASPSSIRSL MCM5 132-140 no n.a. n.a. n.a. -4.45 0.03 1.00
LLATLAAAML C16orf30 177-186 25 | 26 A*0201 26 36 -4.47 n.d. n.d.
HIIENIVAV RSL1D1 225-233 no A*0201 29 3 -4.48 0.36 n.d.
FLIRESETL LYN 153-161 no A*0201 25 48 -4.48 n.s.d. 0.00
QSPVALRPL FLJ22875 n.a. n.a. B*5101 19 n.a. -4.51 n.d. 0.20
VLPKLYV RPS26 63-69 no B*5101 n.a. n.a. -4.64 -0.05 0.90
DAKQLTTTI NEDD9 541-549 no B*5101 27 440 -4.66 n.d. -2.60
YPFKPPKI UBE2L3 61-68 no B*5101 35 n.a. -4.76 -0.18 0.68
MAPRSLLL HLA-F 1-8 21 | 22 B*5101 22 n.a. -4.78 -2.13 -1.30
LPRSTVINI IFITM1 19-27 no B*5101 26 572 -4.79 721.45 only -0.80
DAYLPLRL POLD1 515-522 no B*5101 26 n.a. -4.84 n.d. 1.10
DAYLVHLI DDX49 232-239 no B*5101 29 n.a. -5.03 n.d. 0.80
AIVDKVPSV COPG 147-155 no A*0201 29 90 -5.04 n.s.d. -0.70
YPPPEVRNI SF3A1 44-52 no B*5101 26 572 -5.06 -0.46 0.70
IMLEALERV SNRPG 68-76 no A*0201 28 1460 -5.10 n.s.d. 0.40
YPFKPPKV UBE2E2 114-121 no B*5101 33 n.a. -5.11 n.d. n.d.
KMDPIISRV BTG2 73-81 28 | 29 A*0201 25 162 -5.14 n.d. -0.40
DPYKVYRIV IRF4 120-128 no B*5101 30 1065 -5.38 0.12 0.05
DALGKLISI GCN1L1 692-700 no B*5101 30 484 -5.42 n.s.d. 0.30
DPYEVSYRI BTG2 105-113 28 | 29 B*5101 33 1936 -5.65 n.d. -0.40
ALSDHHIYL ALDOA 216-224 no A*0201 23 482 -5.70 0.09 -0.23
DAWKLPKI CYBB 378-385 25 | 26 or 34 | 35 B*5101 33 n.a. -5.72 n.d. 0.00
IANHQVLII DHX16 412-420 no B*5101 25 260 -5.78 n.d. -0.80
DAFTIKTV IFIH1 514-521 no B*5101 29 n.a. -5.86 n.d. n.d.
TLFDYEVRL UHRF1 57-65 no A*0201 25 324 -6.07 n.d. 1.40
VLAVLGAVVAV HLA-C ca. >280 24 | 25 A*0201 27 52 -6.21 n.s.d. -0.98
LAPLIQVI HIP1 222-229 no B*5101 29 n.a. -6.36 n.d. n.d.
DAFRQPSLFY MAP3K5 158-167 no B*5101 29 n.a. -6.41 n.d. 0.40
RMLPHAPGV HDAC1 371-379 no A*0201 24 186 -6.44 -0.41 0.50
DAPHPPLKI OAZ1 69-77 no B*5101 29 400 -6.44 n.d. n.d.
DALLKFSHI TEGT 11-19 45 | 46 B*5101 29 400 -6.44 n.d. 0.10
KLLDPEDISV SPTBN1 249-258 no A*0201 26 3693 -6.46 n.a. 0.45
DAHIYLNHI TYMS 254-262 no B*5101 28 484 -6.50 721.45 only 0.20
continued on next page
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Table A.6 – contiuned
2log (721.174 vs. 721.45)
Sequence GeneSymbol position signal seq. HLA
SYFP-
EITHI
score
Bimas
score
HLA protein mRNA
RLLEVPVML ISOC2 49-57 no A*0201 26 324 -6.51 n.d. n.d.
DAAAKALRI STAU 70-78 no B*5101 29 400 -6.51 n.s.d. -0.55
DALRSILTI MARS 703-711 24 | 25 B*5101 31 532 -6.52 721.45 only -0.80
SAPYGRITL CYFIP2 832-840 no B*5101 18 n.a. -6.57 n.s.d. -0.20
IPPHVVKV G3BP 270-277 no B*5101 27 n.a. -6.60 n.a. 0.70
DGLRDLPSI LPIN1 456-464 no B*5101 23 176 -6.86 n.d. -0.93
VPYLFKKV L3MBTL2 411-418 no B*5101 23 n.a. -6.92 n.d. 1.20
KLIDRTESL LSP1 135-143 no A*0201 28 150 -6.94 n.a. -0.60
NLLPKLHIV CLIC1 179-187 no A*0201 30 243 -7.02 -1.76 -1.30
IAPTGHSL SEPT6 155-162 no B*5101 20 n.a. -7.02 -0.03 0.10
DGVAVLKV HSPD1 399-406 no B*5101 25 n.a. -7.06 0.59 0.10
ILMEHIHKL RPL19 137-145 no A*0201 32 1267 -7.07 0.71 0.20
YLLPAIVHI DDX5 148-156 no A*0201 30 408 -7.08 -0.05 -0.20
KIADFGWSV AURKC 181-189 no A*0201 25 3911 -7.09 n.d. n.d.
NPYDSVKKI UBD 25-33 no B*5101 32 1065 -7.11 n.d. -3.10
KILEDVVGV TPX2 465-473 no A*0201 30 1168 -7.28 n.d. 1.10
LPHHRVIEV NOMO3 1030-1038 no B*5101 23 260 -7.29 n.d. n.d.
FPLDPQLAKMVI DHX15 565-576 no A*0201 21 0 -7.46 n.s.d. 0.30
DAYVLPKLY RPS26 60-68 no B*5101 23 7 -7.55 -0.05 0.90
QLIDKVWQL SEC14L1 593-601 no A*0201 28 1511 -7.59 n.s.d. -0.47
DGPRVFRV FARSLA 121-128 no B*5101 25 n.a. -7.60 721.45 only n.d.
LPEDKPRLI QTRTD1 243-251 no B*5101 26 629 -7.61 n.d. 0.50
DAMKYTIVV ATP5A1 217-225 no B*5101 28 220 -7.62 -1.85 0.30
KLLEPVLLL RPS16 50-58 no A*0201 31 2609 -7.67 n.a. 0.40
ALIEKLVEL POLA2 22-30 no A*0201 35 201 -7.74 0.47 0.90
ALAEIAKAEL SFPQ 343-352 no A*0201 30 88 -7.76 n.d. -0.20
ALADGVQKV APOL1 160-168 27 | 28 A*0201 33 656 -7.80 n.d. 721.45 only
LPHLLPLL TNPO2 392-399 no B*5101 23 n.a. -7.84 n.d. -0.20
LLIENVASL GPX1 40-48 18 | 19 A*0201 34 342 -7.87 n.d. 0.30
ALSNLEVKL URP2 326-334 no A*0201 27 21 -7.92 -0.05 0.00
TSPKALVI CDYL 148-155 no B*5101 17 n.a. -7.95 n.d. -1.10
DAARFPII HM13 74-81 no B*5101 30 n.a. -8.21 721.45 only 0.00
IPNRIPKI KIAA1430 111-118 no B*5101 33 n.a. -8.28 n.d. 0.00
VPLDKQITI GNL3 295-303 no B*5101 28 692 -8.31 n.s.d. n.d.
ALLDKLYAL C15orf12 78-86 no A*0201 32 745 -8.41 n.d. 0.50
continued on next page
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Table A.6 – contiuned
2log (721.174 vs. 721.45)
Sequence GeneSymbol position signal seq. HLA
SYFP-
EITHI
score
Bimas
score
HLA protein mRNA
LPPEVNRI SF3B14 13-20 no B*5101 26 n.a. -8.50 n.s.d. n.d.
ALTELLAKI CCND2 227-235 no A*0201 30 98 -8.51 n.d. -1.03
TGYLNTVTV GNB2L1 192-200 no B*5101 22 88 -8.62 n.a. 0.40
TLIDLPGITRV MX1 or MX2 175-185/222-232 no A*0201 24 15 -8.64 -1.13 n.d.
ALATLIHQV COPS7A 26-34 no A*0201 30 160 -8.66 n.d. 0.30
VLFHNLPSL CD53 42-50 24 | 25 or 29 | 30 A*0201 29 309 -8.73 n.d. 0.10
SIIGRLLEV PPP1CA 11-19 no A*0201 31 22 -8.81 721.45 only 0.00
HPDSHQLFI G3BP 336-344 no B*5101 21 440 -8.85 n.a. 0.70
HLPETKFSEL AIM1 942-951 no A*0201 24 6 -8.92 n.d. -0.60
KLHGVNINV RBM4 59-67 no A*0201 23 243 -8.93 -0.02 0.25
HPYRLILTV TYK2 479-487 40 | 41 B*5101 26 484 -9.01 n.d. -0.20
YPFHVPLL LTA 142-149 34 | 35 B*5101 27 n.a. -9.02 n.d. -1.70
YAFNMKATV HSPA8 545-553 no B*5101 24 315 -9.09 0.2 0.30
IPYHIVNIV SARS 357-365 no B*5101 27 572 -9.10 -0.19 -0.70
DAYSFSRKI CNAP1 626-634 no B*5101 31 880 -9.12 n.d. 0.80
DANPYDSVKKI UBD 23-33 no B*5101 32 1065 -9.26 n.d. -3.10
VLIPKLPQL ORMDL3 134-142 38 | 39 A*0201 31 84 -9.44 n.d. n.d.
QLVDIIEKV PSME3 114-122 no A*0201 27 321 -9.97 0.17 0.85
IPYPRPIHL LOC57149 79-87 no B*5101 25 260 -10.11 n.d. 0.00
LPAPIEKTI IGHG3 402-410 19 | 20 B*5101 25 692 -10.49 0.81 0.40
DVANKIGII RPL23A 148-156 no B*5101 26 n.a. n.a. 0.25 0.00
LDVPTAAVQA IFI30 17-26 26 | 27 A*0201 10 0 n.a. n.s.d. -0.20
VLIDYQRNV XPO1 784-792 no A*0201 25 97 n.a. n.d. 0.25
RVFENIVAV TRAF1 195-203 no A*0201 24 212 n.a. 721.45 only -0.20
DAFKIWVI SWAP70 114-121 no B*5101 34 n.a. n.a. n.d. -0.80
MAPARLFAL SDC4 1-9 18 | 19 B*5101 20 72 n.a. n.d. 721.45 only
LPLRLFLII SCD 132-140 no B*5101 26 520 n.a. n.d. 0.23
VLIGEFLEKV RNMT 182-191 no A*0201 31 506 n.a. n.d. -0.20
SLAQYLINV PCBP2 346-354 no A*0201 29 160 n.a. -0.02 n.d.
RLIPIIVLL MYO1G 708-716 no A*0201 30 49 n.a. n.d. -0.65
SLYREILFL MYCPBP 1800-1808 no A*0201 28 865 n.a. n.d. n.d.
DGLTVHLVI UBQLN1 98-106 no B*5101 29 176 n.a. n.a. 0.00
QLLEKVIEL ECHDC1 79-87 no A*0201 31 745 n.a. n.d. 0.05
n.d. not detected, n.s.d. no significant detection (n < 3) , n.a. no definite ratio available
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Table A.7.: 21-25 aa precursors of HLA ligands presented TAP independently but not located in the signal sequence were digested in
vitro with constitutive proteasomes (c20s) and immunoproteasomes (i20s). The HLA ligand sequence is highlighted in bold.
Proteasomal cleavage efficiency was scored from 0 to 3. Score 0: no correct C-terminus was generated; score 1: <5% peptides
with the correct C-terminus; score 2: >=5% and <10% peptides with correct C-terminus; score3: >=10% peptides with
correct C-terminus.
Sequence GeneSymbol Gene Title HLA
HLA 2log
(721.174 /
721.45)
c20S
score
i20s
score
QRVKEVLPHVPLGVIQRDLAKTG AUP1 ancient ubiquitous protein 1 B*5101 0.30 3 3
HNNLLTYLPREILNLIHLEELSLR LOC116064 hypothetical protein LOC116064 B*5101 0.27 3 3
ETFALASSLLDRFLATVKAHPKYLS CCNI cyclin I A*0201 0.21 3 3
KASSSLPKKLALLKAPAKKKG HSPC023 HSPC023 protein A*0201 1.70 2 2
NYAYAYTLLGHEFVLTEELDKA CDC27 cell division cycle 27 A*0201 -1.29 1 1
NEASSHKYVPRAILVDLEPGTMDSV TUBB3 tubulin, beta 3 B*5101 0.14 0 2
KLKLDVGEAMAPPSHLLLPVPCK PELP1 Pro-Glu-Leu-rich protein 1 A*0201 4.19 0 1
SGFRSVKAPVTKVAASIGNAQK PDLIM1 PDZ and LIM domain 1 n.a. 0.81 0 1
QQVERHREHLINYIIFLRITPFL TMEM41B transmembrane protein 41B A*0201 0.17 0 0
RLETRTLAEIAKVELDNMPLRGK NONO non-POU domain containing, octamer-binding A*0201 0.14 0 0
DSAVKQVQIDGLVVLKIIKHYQEE EIF3S3 eukar. transl. initiation factor 3, subunit 3g B*5101 0.12 0 0
LAAVLEYLTAEILELAGNAAR HIST1H2AJ histone 1, H2aj A*0201 0.27 0 0
SGRQPAALLDVRSVPGLDGSG GDF5 growth differentiation factor 5 A*0201 1.94 0 0
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